var title_f4_51_4912="Operative management of hepatic injury";
var content_f4_51_4912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Operative management of hepatic injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 525px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for operative management of blunt liver trauma.",
"    <br>",
"     (A) Minor bleeding most often from grade I or grade II injuries.",
"     <br>",
"      (B) Manual compression, fluid therapy, correct coagulopathy, acidosis, hypothermia.",
"      <br>",
"       (C) Subset of patients who would benefit from angiography is unknown.",
"       <br>",
"        (D) Placement of clamp across the porta hepatis.",
"        <br>",
"         (E) Finger fracture as needed to ligate bleeding vessels and injured bile ducts, viable omentum used to fill deadspace.",
"         <br>",
"          (F) Risk of liver necrosis.",
"          <br>",
"           (G) Rates of survivial improved with combination of packing and/or shunting compared with direct repair alone.",
"           <br>",
"            (H) Timing of interval laparotomy not well defined, formal resection rarely required.",
"            <div class=\"footnotes\">",
"             ICU: intensive care unit; SHAL: selective hepatic artery ligation.",
"            </div>",
"            <div class=\"reference\">",
"             Reproduced with permission from: Kozar RA, Felciano DV, Moore EE, et al. Western Trauma Association/Critical Decisions in Trauma: Operative management of adult blunt hepatic trauma. J Trauma 2011; 71:1. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"            </div>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4912=[""].join("\n");
var outline_f4_51_4912=null;
var title_f4_51_4913="Zoster vaccine: Patient drug information";
var content_f4_51_4913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zoster vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     see \"Zoster vaccine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2985421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zostavax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13166772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zostavax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_shingles.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11928 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4913=[""].join("\n");
var outline_f4_51_4913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985421\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13166772\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026007\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=related_link\">",
"      Zoster vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_51_4914="Radiocapitellar x-ray";
var content_f4_51_4914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiocapitellar radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 589px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJNAUgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5z8G+F73xbqktjp0ttFNHCZyZ2ZV2hlXsDzlhXY/8KU8R/wDP7pH/AH9k/wDjdH7PP/I6Xv8A2D3/APRkdfQ1AHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHzz/wpTxH/wA/ukf9/ZP/AI3R/wAKU8R/8/ukf9/ZP/jdfQ1FAHzz/wAKU8R/8/ukf9/ZP/jdH/ClPEf/AD+6R/39k/8AjdfQ1FAHyR4y8L3vhLVIrHUZbaWaSETgwMzLtLMvcDnKmiux/aG/5HSy/wCwen/oySigA/Z5/wCR0vf+we//AKMjr6Gr55/Z5/5HS9/7B7/+jI6+hqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopk0iQwvLM6xxRqWd2OAoHUmgB9ZWs+INN0dSL24Hm9oYxvkP4duvfFcJ4l8czXpeDSGktrTBBmxiST6f3R+tca0pLFiTubkknk0Aeh3nxFAYrZaWx9GmlAz+A6fnVEfETUup06wI9A7/41xIcZGOec80qMCPYUwPRrT4j2uQNQ065hGMl4WEg/Lg11Gj6/pesAf2fexSyd4idrj22nn8q8QY8/hyaYQCwf+IdHHBH0NKwH0NRXk/hvx3d6YVg1lpL6y6ed1mj+v8AeH616nbTxXVvFPbSLLDKodHQ5DA9xQBLRRRQB88/tDf8jpZf9g9P/RklFH7Q3/I6WX/YPT/0ZJRQBQ+ClxdWviu5ms1SRks3LxNx5i70yoPY9CD6j0zX0bY3cN7bLPbtuQkg54KkdVI7EV84fBiZLfxNeSSkBRZN/wCjI6978O6fNBJPe3AML3IH7j0A6Fv9r+Q4oA3KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvL/AIheIvt9w+mWbA2cJ/fOP+WkgPQH0H6mut8d6y2jaITA2Lq5byYj/d4+ZvwH868cJwCMtjHc80AOyQ2Se1NJwQDTd24+mBSenWmA4ZIHfB6U8ng89qiOcZHrSliCc0ASfTPTn2qMnJGOMUA5IxTe49aAHDHc967n4W6u1tfSaPK3+jzhpbcH+F+rL9COfrXC59BkU+xuZLKVJ4mIntJRKjfQ5/xFAH0NRUVrOl1aw3MX+rmRZF9gRkfzqWkB88/tDf8AI6WX/YPT/wBGSUUftDf8jpZf9g9P/RklFADP2foY5fGtyZEDGOxd1z2PmRjP619E185/ARJ38Z3BtpFRlsmZgwyGXzIwR+v6V9DwTxThjC6uFYqcdiDgigCWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyv4qXhl16G1BbbbQBivYsxzn8q4tTy3oRW341uTd+KtUfOQkvkqR6KMCsPnJHOcc0wAHkdsUvHpjmmqOB6+1B+tACnke2aCckmkboSD+fegj0oAAQcEYFIBx+NA6ig5C+2etAC4ypx0BpVAFyo6iRCppueDTZWxJbYz9/8ApQB7Z4AmM/gzSWckssRQk+zEfyxXQ1zfw6jMXgrS9wwXRnx9WNdJSA+ef2hv+R0sv+wen/oySij9ob/kdLL/ALB6f+jJKKAD9nn/AJHS9/7B7/8AoyOvdbq0ljuhd2OBIeJYycCQf0PvXhf7PP8AyOl7/wBg9/8A0ZHX0Lg+hoAQHP17j0pax9QkaG+V9PRprn/ltEh4KDufQ+laNldRXtus0Byh4IPUHuD70AT0UYoxQAUUYoxQAUUYoxQAUUYoxQAUUYoxQAUUYoxQAUUYoxQAUUYooAKKKKACiiigAooooAKNwT5m6LyaKMBuCMg8EUAfPFzOHvJ2eQb5JHkwTyRuNMY5YEnPFfRPgL4beGpItQhvrWK5GqWCEGRQzphmDspP3WDY6Y6V4X4m0O58Oa9faPcq8k9rKYk+XmUH7hHruBGKYGSW+UY9cVfl0nU4o1aXTbyNGG5WaBgGHqDjkV9J/CP4aWnhvTLfUNZtorjXpQJSXUMLXjhUz3Hduueld9quqzaepMVhqF6wAYi2j3fqep9qVwPkHSvBfibVl3adoWoTxkZ8zyiifgzYBPtU2p+APF+mzgXnh6/2sAVaCPz1/FkyAfavo+f4peHLK9itdee90W4kzgajbPEv/fZG39a67S9SstVs0u9LvILu2f7ssEgdT+IouB8Z33hjX7Cye7vdA1e2tYRmSeWzkVFHqSRwKw0kV03DIXsWGM/hX3k6LIjI6q6MCGVhkEehFZMPhrQLZzNBoekwuOrrZxKR+O2i4HxEssbIXDAr/e7UQK+oahb2trl3Zgi7ecu3AH8zX2LN4Z8Cpdm6n0zQVlUlmLBNvPUlc7T1PUV4lp3hxZviJd+JoY7SLRrx55dOhgUAEIVh3hQMAZyQRRcDsLK2Sysre1iOUgjWMEd8DGf61PRRQB88/tDf8jpZf9g9P/RklFH7Q3/I6WX/AGD0/wDRklFAFr9mnTW1Tx5ewJDazbdOdyty8iLjzYhkGMg55+nWvpb/AIV7Z3RT+0ZWjjU58qxlljB9izOSR+VfP37Iv/JSdS/7BMv/AKOhr2Dxp8S47bxLaWOma1plha2Op29tqJuJoxLMGcCRVRjlY0XJaTHXgdCaAO3t/BPhy3BEOmBM9cXEuSfU/Pyaqat4WsrK2WfR9KikaNzJNb+bIDMpHODu+93FYfiLVNb0vxPfXWq3uvWXhpp7eO0ubCKxkgQMqhjLvVpgDISMgYGe1WNH1LxPJ47a3uhf/Y/td0k0L2QS1itlX9xJHNty7sduV3nG5uF2jIB0Gm6R4f1OyS6tLQNE/YySAqe6kbuCPSrX/CNaPjH2Ef8Af2T/AOKqVrKHT7m91K2jmMkiZlgiPEhH8WP72Pzq5ZXUN7ax3Fs4eKQZBH8vrQBm/wDCMaN/z4j/AL/Sf/FUf8Ixo24H7CMj/prJ/wDFVsUUAY3/AAjGjc/6COev76T/AOKoXwtoq5xYjn/ptIf/AGatmigDFHhbRQcix/8AI0n/AMVTv+EZ0fj/AEIcf9NZP/iq2KKAMf8A4RnR8/8AHiP+/sn/AMVTD4U0TOfsJ9f9fL/8VW3RQBif8Ipon/Pif+/8v/xVJ/wimi9rMj/tvJ/8VW5RQBhDwnow6Wrj/tvJ/jQfCWjHrbSf9/3/AMa3aKAMCTwfo8kTRJHPCXBXzEnfcme4yTyOtcDpUsslkoul23UTNDMp/hkQlWH5ivXa801+3Fj4v1KFQBHdIl9GAOBuyr/iXVm/EUAQUUUUAFFFFABRRRQAUUUUAaXhdpFu2srTatyGe+sz/wBNOPOQ/wCy64/HFZnjHQI9d+PHhrEJC/Ylv7xHHKrGxCg++duPpUlrPJaX9teW5AmgfcuehHQqfYius+HF1caxP4g1zUIoYria8NnGIzkJFD8oXJ5OTk/U0gO2Jyc0jDKsASMjGR1FLRQB4Dr/AIB8W6ZeyNYTRalFncJZtLhmEg3dGCgvnbjr1IPtXZfCrQZrC/vLyTTJdJaRF8xFtmt47gkt1jY4DqFHzLwQ+O1emUUXAZK6xRvI5ARQWJPYCvn74jXGtatBHd3ZvLhblUmg02O6NtbxxSbvKVtvzSSMFOR0UkCvZvH24eB/EGzO77BPjBxzsNbLQQSIgkhikVRhQ6BsD2zQB89/BLwekniFbu68K6fBYrExnLgTKr7flXEi8N83Y8YOa6FVg+xaItqIgkFvdxlY8AR5u2IXA4HA6e1es6/eJpugX925CRW9u78cBcKa8d0e2NppVpDIoWZYl83AxmTHzH8Tk0wLlFFFAHzz+0N/yOll/wBg9P8A0ZJRR+0N/wAjpZf9g9P/AEZJRQBv/si/8lJ1L/sEy/8Ao6GvqfXdGt9ajs0unlQWt3DeJ5ZAy8bblByDxkc/zFfLH7Iv/JSdS/7BMv8A6Ohr65oA5jVvB8WrXrvfaxq8unyTx3L6aZY/s7MhBUfc3hcqDtD4z2rp6KKACs37ELG9kvLaTyrV1Z7mDGQxx99fQ+vrWlT/AC3/ALjflQBWs7mG8to7i2kEkMgyrDvU1YV5ZXei3bX+mwSS2Uzj7VZopJ3E48yP0PPIroPKk/55v/3zQAyipPKk/wCeb/8AfJo8qT/nm/5GgCOin+VJ/wA83/KjypP+eb/lQAyin+VJ/wA83/Kl8qT/AJ5v+RoAjoqTypP+eb/kaYQQcEYNACUUUUAFcb8R4PLXSdRCk+TO1tIR/Cko+8foyKP+B12VZ3iOwfVNB1Cyhx58sLCHPQSDlCf+BBaAPPqKq2V3HcaZBelwsMkauXc4AyO5NWLQTXzbdOtbm8P/AEwjJGPXccAj6E0AOorctPCOtXAVphaWa9xIxkbH/AcYrSt/AK4f7brF1Ju6CGNYtv0I5/OgDkcUu1v7p/Kuj1D4eaDBCHu7/wARS5O1VS+csxPYACsaD4Q2d7q8d5Pfa1Z6ao5sXvWeSY+rt/CPYfnQBmyXUSTCHLSXBOBFEpd8+mB0/HFW4NI8TX3/AB46C8Kf89NQmWHH/AOSa9U0jSrDR7ZbfS7SK1jAx8g5P1PU/jV2kB5JJ4B8aXO0prehWRPVFtpJf1NdJ4E0240vwDPBfzLdXSTzzyzRrtErB9xIHviu5j/1i/Wsfwnn/hHrJyu1nUsQfUsaANOCVZ4I5UOVkUMPxp9ZWlP9ju5dKlIGwGW15+/CT0HupOD+B71q0AFV729trGJZLyZYkZgqlsnJPYAcmrFZ9/ZTS39re20kSzW6SIFlUlSH25PHII24yOxNAEms2qXukXtrKMxzQvGw9QQRRo0/2rRtPuM5863jkz65UH+tVJNTuI4JI7jS7trkDbtgAdHJ7qxI49c9Pejwrp1zpeiW1teyI86RxqwQkqm2NUwCev3c/UmgDJ+Jd2segJYYVn1GYW5Rv4ox80n/AI4rVw5OSSetb/ivwovj3xTKtxqN7ZWeiII4HtHCsbpxuYn/AHU28f7dZU3gnxXpTH7PeWeu2owAJR9nuMe5HysaYFWioGuBFdC0vIprO8PSC5TYx+nZvwJqfoaAPnn9ob/kdLL/ALB6f+jJKKP2hv8AkdLL/sHp/wCjJKKAN/8AZF/5KTqX/YJl/wDR0NfXNfI37Iv/ACUnUv8AsEy/+joa+uaACiiigAaRYVaV/uoC5+g5r5oIW4DTOWdpJHfcZG5Bckd/TFfROvuI9B1N2OALWUfmhH9a+cbZTHYW8fI2xIDx3AFCAc0MZ4w3/fxv8az7mFrKbz4zI8R++pkbj6c1oq+eufShwflBw3Y0xEUKQTxq6BipHXzG/wAalMcYUfKw/wC2jf41RuZZ7OYPGoa2wAVA6VdhmWaMMh3KehFABsXfkmQZI/5aN/jQ0SHOGf2/eN/jQZ4vO8ospnPSJfmc/RRk/pWlZaBrl+N1joeqTrnkmHyv/RhWgDMZAf8Anoef+ejf400W69MPjp/rG/xrqLbwL4rlxnRHiJP/AC2uIx/Imro+G/isjP2Swz6G8P8A8RQBxi20R4YPyMH943H617d8Kb577wLp4nlaa4tS9rK7HJLIxxn/AICVriovhp4odgJIdMjXByftbNj8Nldd4K8J+JfDlle2yXWjlbi4+0KHjkcRkqAwwGXOcCkxnaUoBJwASfas46Rrc64m1uK1b/pzs0/9q76avhG3kDf2nqGp6kWHzR3Fywhb6xLhf0oAZrXiLR9EdY9V1G3t53IVYM75WJ6ARrlj+VMguNa1aNH02z/sqAn/AF+oJmXHqsQOAf8AeJ+lWPDngvQfD9y93Yafbi+kADXJQb8DoB/dHsK6M8KWPCjqT0pAcl4b8AaFoaArDJe3AZn868fzCCxydq9FBPOAMV1iAIgRAFQcBVGAPwqo+p2avtWcStnGIQZSPrtBx+NKlxdzMRBp0ygdHnZUU/TG4/mBQBbqteX9pYlBeXMMLP8AcR3AZ/8AdXqfwFIdPvblMXV75C55S0XaSPQsckH3XFWbLS7KyDG3tow7NuZ2G52b+8WPJPvQBkL4m0gvj7TKh9XtJkA/4EUA/WtWKWOaJJYZEkjcbldGBVh6gjrV9vmGG5HoeawNPQ22t6taRgLaqIZ41AxtZw+8D2+QHHqTQBp0UUUAI2SrBThsHB9DUNjbi1s4YAciNdufWp6KAKWq2RvIEMLiK7hbzLeUjIV8YwfVT0I9PcCnaZei9tyzJ5U8beXNETzG46j+oPcEGrdZWqA2N0mqRhzGq+XdIozmPs+O5U+n8JPXAFAGrXIa/wCKbyxvVsodPkjncsFYr5hdR0ZFyA3J6ZJHp3rrlZXUMhDKRkEdCKgvbK2voPJvYI54sg7ZFyMg5B/SgDh4vFWvKjKbUTiMZ3CwkR3+oLhRWzp3ikt4MuPEOr2ZsYYInmIDbhIijO5R1wew5/Gry+GdKDfNbGRO0ckjMg+ik4rP8QxJrmvadoWFaztit/fJxgqp/cxkf7TjdjusbCgCn8HnmuvA1vqd5GY73U7m4vLhD1VzIy7f+AhFX8K7WsrwvZmw0SK2ZNhSWdtuMcNM7D9DWrQBU1TTbLVrRrXU7WK6t2GCki5x9PT8K8/8QeDLvSIjc+HjNfWaDL6fI26VR6xOeuP7rfhivS6KAPg/4+XMN14vspYH3J9gQHjBUiWUEEHkEdwaK6b9r62gt/ihZvBEkbT6XFLKVGN7+bKNx98KPyopgN/ZF/5KTqX/AGCZf/R0NfXNfI37Iv8AyUnUv+wTL/6Ohr65oAKKKKAOc+JEjR+A9caM4f7PhfruFeIT8E4B25xXsPxZnMHg5lAz511DCfoWrxyU54zkk5xQhDMgDJBxSckcHnPQUAc4zw1ID8wA4pgLtDDY2CrdjXVeCPAK3Fgmu6w11/Ycp3LaQgpI6f8APRz12ew5I5PHFYGj6ada1nTdKBKre3AikZeoQAs/0yqkf8Cr6Su5Vsbe3trSJGlkIgt4jwvAPJx0UAEn8u4pMDP0/SdOsYYLHw1a2NjHOrS+bbxJhV4yyjGCxyMZ47nPQ6Y0C18sCSe+kk7ytdyb/wACDx9BXnuiWOo+GPG2pXUeopfaWVaL7HJcSSTQyMQ5McEUbeXGSDj2wc133h/xBDq891beU8N1bKjyIyuAVfOCN6qf4SDlRQMeukT2ob7BqNwfSO7Yzrn6k7//AB6lWS+jYJPYs/H37eRWBP0Ygj9a16bI6Rxs8jKiKMszHAA9SaAMn7XPkj+y7/j2i5/8fpzT3XATTrkk/wB5kA/RjUg1m2d9tqlxcnGd0UR2EeznCn8CaZ9uv5H/AHenxxx+s1xhv++VUj/x6kAsf9oOuWtII/TdcEn9F/rUX2bWmcE3OmomeVFvIzY+vmAfpUgOpOxEl1bIh/54wEMPxZiP0qFtPlmBF1qWoSjtsl8nH/fsLQBM+jzThhPqV60Z6rFtix9GQBh+dUZrXwykiJfTWE9xCRtN5crLKp7csSc1LPomnXKqLy0juypyrXX74j8Wyauw28MMaxwxRoi8BVUACgCJtc06F9ifaCfWKzlYH/gQTH608axEwzHa3rj/AK47f5kVPRQBWbXLaP8A10F9GP8Ar2d//QQaemuaWRl72GHPQXBMJ/J8GpqRlVvvKD9RQBdQiRA8ZDIRkMpyD+Nc/pzLc61qt9Awe2lEMCODkMY9+4jsRlwMjuD6U2Xw3oc0xll0jT3lPJdrdST+OK1EVURUQBVUYAAwAKAHUUUUAFFFFABRRRQBkRwzaQSLdGn03qIVHz2/sn95P9nqO2RgC7a6hZ3blLa6hklUZaMON6/7y9R+Iq1VW906zvl23tpBcKO0sYb+dAEGpaxZWAKSSiW6wNlrDh5nJOBhBz17nAHUkDmovDunS2cVzc3xVtQvZTPOV5C9kjB9FUAe53HvV+0s7azTZaW8UKekaBR+lT0AFFFFABRRRQB8dftjf8lN0z/sDxf+jp6KP2xv+Sm6Z/2B4v8A0dPRTAg/ZF/5KTqX/YJl/wDR0NfXNfI37Iv/ACUnUv8AsEy/+joa+uaACiiigDz34zTMul6RAD8st2WI9diFhXlWSGwMYFej/GS4BvdHte6JLcfyT+tecEEPx600IdghsE/TFIw3Y/nTVJGD3PrRuOOgwO9AHX/CKAy/EO3bGY4bGeQ57MWQA/lur3C3TzPETM2cQWq7PTLu27/0Ba8Z+C8ijxvOhB3PYMVP0cZ/mK9mkcW2s2cjEhblWtj7sAXX9BJSYyawVYtW1SPI8yV47jGOimMRj9YmqGITR+KpBPKHiltd1uoXGwKyiQMe/JQj/gVZ0J8v4n3YMhzcaRDiPI5Ec0vI7/8ALT+VWDLez65d3NmbVreNRaKZGbKMCTIwAHzclVxkcoeaANXULz7MFjhTzrqTPlxZxn3J7KO5/meKyLK0TUYludSc3j722pIuIoyrEfKnTgrkMct7joKfiTUIfCvhzUtWuZDcXezG98BpZDxHGAOgycBR69yST8/+GvFHjzw47eTrdrqNsztI9tfIzDcxy21h8wGc45x7UAfUdFeT6R8YVdVXWPD93BJnl7OZJ4wPXkq3/jtdAnxS8LHaJLq7iJ7PZTDH1O3FKwHcUVytn8QPDN5EZbfU1eMNsLCJ8BvTp19quDxZpTKWhN5MB/zys5X/AJLQBvUVzp8VQuv+jaXrUzdlNhJFn8ZAo/Wojrmt3Cn7H4dNuwPXUbyONSPbyvMP5gUAdHPNHbxNLO6xxr1ZjgD6ntTwQRkHIPeuRuIPFF8mJNZstMU/w2Vp5rj/ALaSHB/74rznX/C3ijwjcLrGj+MtTk097lBeW7RIfKV3Cl0TBTgsMgKuBQB7rRXmmleOb7SysfiRUu7IHB1C3j2NGP70seTx6sp47gDmvR4JoriCOaCRJIpFDI6HIYHoQaAJKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD46/bG/wCSm6Z/2B4v/R09FH7Y3/JTdM/7A8X/AKOnopgQfsi/8lJ1L/sEy/8Ao6Gvrmvkb9kX/kpOpf8AYJl/9HQ19c0AFFFFAHkHxbcSeLLdTg+VZhMf7z5/pXEkLz+VdF8RLkXPjnVNpGIRFAfqqkkf+PVzhI3ZPQUxAoyeDx1oxgetCr6Yx705ufYDrxQB0/wqmEPxDsGzhZbaeDGe52MP/QDXumrW8t1p8qWzKtyMSQs3QSKdy59sgA+xNfOPhy8/s/xPod1n/V3sQ6/38x/+1K+mu+KTGcxO/n+O/DGqQg+ReWFzbkkchv3cij64D/lWzosey1mC8g3dyfxM7mufjsF1qWW5mvHj0W1upJ7Zbc+W7PhllZnHOwlpMAYJznPStSLw7pgjzB9qRWy4KXkvU8k8t3PP40gPIPiv4jOt+J/7Ntmzp2kPh8HiS5I5/wC+AfzPtXIrgA5IxnpW14y8NR+G9eYWk011pup7r63nlfexYkeYpbv1DA+h9qwyOeelUhAScZAwOmDTs4xnI/GkHIGT9KcAdpwM+1AHo/wSuWRdesjIcCaO5jXPZlwx/MCvTSSepNeK/Cm6Ft44EZzi9s3iz2yhD17TSGFFFFABUN/ax3tlcWs2fKnjaJsejDB/nU1FAHkmnmb7HGt0wN1FmKcjp5iHa/8A48DUmg+JD4J1u1iupCPDOoy+U6npZTt0dfRGPDDoDyOpq/r1r9i8S6hGoPlXGy7Tj5V3DawHvuRmP+/WLr2mxaxo15YT/cnjK59D2I9wcGgD3WivKf2ePFk+ueE5NI1V3OraM3kOX6vFkhWz3wQVP0FerUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigD46/bG/5Kbpn/YHi/wDR09FH7Y3/ACU3TP8AsDxf+jp6KYEH7Iv/ACUnUv8AsEy/+joa+ua+Rv2Rf+Sk6l/2CZf/AEdDX1zQAUo5NJSqQpDHoOTQB88+KmEvivXJ15SS9dlI9lUf0NZZzgkKc9qnkZnkndmyzzTH85Gx+mKYOcCmIiywIOaflimNxyeDSsCOg+U+lIMHoCPf1oAq3ryx20ssIzLEplQDj5l+YfqBX03f38kmh250+ULe30ax2rkZ2sy5347hRlvfGO9fN3BGMZB4PFe0/DCbUrvRfDNxqcUEcR0oC3CMWc8R5ZuwzwQB0HXmkxncW9tBY6dHbQqFt4Igir6KBiqWlRTSeErON2YTmyRWYdQ3ljn861JApRt5AXBzk9q8f0bxJealoVrd2a6t/aFtYwJBsTEAlVPnMoOOGbg5/hwRSAzvH0yS/DrwBPGNsq7LZ0I+6VtnWRT9GTH4VxPuTnipLnXp9dmuIFUDSrHUr2a2kDZMxlkY7sf3QGbH+9UX3l447VSEGSBwM4p6scHP5U3nOP0pQTgjFAF7QdQTS/EWj3sp2xxXSK5/2W+U/wAxX0QwKsQeoOK+ZLlA9tLgfNGPMX6r8w/UV9IaVdrf6XZ3isHFxCku4dCSoJ/XNJjLVFFFABRRRQBx/wAQLQ+bpmoJ0id7aTnACyAEE+p3oij/AHzXO16B4jsf7S0O8tlAMjJujz2kU7kP4MAa87t5VuLeKZM7JFDjPBwRmgCz4Os4tHnfXIyYzZXzwXQHQ2c4U7m9kl3Pn0DetewEEEg9RXnHgNYJtX1XT7hRIl9Zq0iNyCsbbenv536V1nhuWaBJNIvnZ7uyAEcrf8t4OiP7kcK3uM/xUgNuijBHJFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc7428W6f4S01Z73fPdzny7Szh5luH7BR6ep7UAfLn7Y3/JTdM/7A8X/o6eiuU+P+qa9q/jeG68TQWltcGzQQQWzbhHDvkIUnuwJbJopgdJ+yL/AMlJ1L/sEy/+joa+ua+Rv2Rf+Sk6l/2CZf8A0dDX1zQAVV1aYW+k30xO0RwSNn0+U1aqlrlm+o6Ne2UTpHJPE0au4yoJHUgdaAPmuzvbZ7S3JuYy3lKSd3cgE/qTUi3VsW/18ec+terw+CNbijjUXPh75ECj/RJR0GP71B8E66f+XvQOf+nWX/4uncR5Ubu2C/69OKQXlsOsyYx616v/AMIVrp+9d6AR1/49Zf8A4qkPgnXCMfa9Ax/16y//ABVFwPKEvrXcv+kIDnue1e5eCJo7f4W+HdRZiI9PtkkLKePKA2uT6gJlsf7IrDXwRru5f9L8P4B72sv/AMVXZeCNPjPgGy0u8CSKLdrS5ROF3DKSKPTnIpMZs65ZHVNFu7OOUxmeMqG7fQ/7J6H2Jrgvivb2GtfDGfVpLbypRHC+QxRkXzE3RkjrxlSPauw8KtPaaRFp+q3Uct9ZsLR5idvnEAFGGepZSpI9cjtXD3UWr63p2qeGLWFYJLfVZZrq5vVLRGJrhp4kQKctuUoCeMDI5NIDyFLqxhVYopYUjUbVVeAB7UC8tef3yDv3r1keCNc3Etd+HyT/ANOkv/xVO/4QrXOP9L0E/wDbrL/8VVXEeTre2mT/AKSnP1oN5a4x56Z/GvWP+EK1sdLnQP8AwFl/+Lo/4QrW+91oP4Wsv/xVFwPKReWhxmePB4PWvavhHdJc/D3SljORbB7YnOclWPP61mHwXreci50Af9usv/xVdV4S0iXRNH+y3EsEszTSTu0CFUyxzgAkmkxmzRRRQAUUUUAFeXXMX2XVtSsyCPIuGK57o/zqR7DcV/4Aa9RrhvHNv9n1yyuwoC3cRtnbuXTLoP8Avkyn8BQBT8LyND400ZlGBL50Mjf7JiZgP++lWvSNW077YIZoJfs99bndBOBnae6sO6noRXllpP8AZtY0eQZydQt48j0aQKf0Nex0gPMNLj8Q2Him9W0td08twJ3iluSN8bYBU7uGQclWXBXoRXp5xk4PHaq97Z297GqXUSyBTuUngqfUHsaofYtVti32LU0nQniO+j37R3+dcMT9TQBr0Vkm+1SKUibRg8IH+sgulZm+iED+dLHq00hwNG1ND/00RAPz3GgDVorMWfVplYLZWto2flaaYygj6KAQfxrSXOBuOTjk0ALRVG/vJrORHNq81oR87xcvEfUr3XHpyMdDniS0v7S8C/ZriN2IyEztfH+6cEflQBaopSrDqCPwpACTgCgAornNQ8Z6LZSTIZ5bhoH8uUW0fmFGzgjHUkH+6DVxry+v8rptubaE/wDL3dLjI/2I+p+rY56igCTWtSktNltYQi61ScfuICcKP9tz/Cg9e/QV4fo2n3V/8Q/EGtavfPqM1lMbG2lYYRWwC5jX+FRnAr28ww6Hpd9dozPNHC80txKcvIVUnLH8OnSvI/AiOnhHTp5QfOug13KW6lpGLH+YpoDwf9opdvjezB5P9np/6Nlop/7SAx45ss/9A9P/AEbLRQBs/si/8lJ1L/sEy/8Ao6Gvrmvkb9kX/kpOpf8AYJl/9HQ19c0AFFFFABRRRQAUUUUAFc94WjWS31iXRJUj1CLVLoXET58uVvNbhx2JXGGHT35FdEKy9Gtt1tPbwzG11S3mlbdj7ys5ZWZf41OfwORkEcAEWr6LbeJlW9hVbXU4VNvItxHvG08mN1z+IZTnuDWZoVrqWhawY/EUyXdzqEcMMd/CCqOYoyPLZWJIc/O+7PzbiOMAHc1No5fOm+1w6TrNvEQJZGDJtPALA4Dpkj6H0NcPb6te6rK2hxWl9PPiK4N0bxbm2QiZSk8cpbcV+RztAzkAHHWgD0eilNJQAUUUUAFFFFABRRRQAUUUUAFYPje1Nx4enkjXMtqVuVx1+U5YD6ruX8a3qR0DoyMMqwINAHk85xPp7AjC3tu2c+ki17a3U14hZW0kN9punzAtJb6rBbMBydomXaT/AMAKk/Wvbj1pAFFFFABRRRQAUUUUAFVb3T7O+QreW0Uynk71q1RQBmJoWnQgi2gNsT1MDlD+YNCaNbgnfcX8yHqkt07r+RNadFAFDTNG03SlYabYW1sGYufLQDLE5J+ueavmiigDkfi3cm0+G3iBlOHktvJT/echf61ylnb/AGTT7a3TASFEjAHsAK2vjerS+B4oF6TalaRn6eYM/wAqzZiC0m3ON5/KmhHzZ+0jn/hO7POP+Qen/oyWij9pHnxzZH/qHR/+jJaKBmx+yL/yUnUv+wTL/wCjoa+ua+HfgX4403wD4tu9U1iC8nt5rF7ZVtUVmDGSNgSGZRjCHv6V7n/w0r4P/wCgb4g/78Q//HaAPb6K8Q/4aV8H/wDQN8Qf9+If/jtH/DSvg/8A6BviD/vxD/8AHaAPb6K8Q/4aV8H/APQN8Qf9+If/AI7R/wANK+D/APoG+IP+/EP/AMdoA9vorxD/AIaV8H/9A3xB/wB+If8A47R/w0r4P/6BviD/AL8Q/wDx2gD2+q17ZpdBG3yQzxndFNEcPGcdR2P0OQe4NeM/8NK+D/8AoG+IP+/EP/x2j/hpXwf/ANA3xB/34h/+O0Add42l8Q3EkNjLpj3zM2La7tECeW4QlZN+7MbBwu4EFSp454rZ8F+FptBa5uNQ1JtRv7jO6QQrCiguznag6ZZyTz6YxXnH/DSvg/8A6BviD/vxD/8AHaP+GlfB/wD0DfEH/fiH/wCO0Ae30V4h/wANK+D/APoG+IP+/EP/AMdo/wCGlfB//QN8Qf8AfiH/AOO0Ae30V4h/w0r4P/6BviD/AL8Q/wDx2j/hpXwf/wBA3xB/34h/+O0Ae30V4h/w0r4P/wCgb4g/78Q//HaP+GlfB/8A0DfEH/fiH/47QB7fRXiH/DSvg/8A6BviD/vxD/8AHaP+GlfB/wD0DfEH/fiH/wCO0Ae30V4h/wANK+D/APoG+IP+/EP/AMdo/wCGlfB//QN8Qf8AfiH/AOO0Ae30V4h/w0r4P/6BviD/AL8Q/wDx2j/hpXwf/wBA3xB/34h/+O0AdZfWhg+NGhQlP9G1DffAjtLBC6tn67ov++K9Wr5t1D9obwjPqmkX8Wm6551jOX+aCEZjdGRx/reu1iQPUCtz/hp7wZ/0DPEX/gPD/wDHaQHu1FeE/wDDT3gz/oGeIv8AwHh/+O0f8NPeDP8AoGeIv/AeH/47QB7tRXhP/DT3gz/oGeIv/AeH/wCO0f8ADT3gz/oGeIv/AAHh/wDjtAHu1FeE/wDDT3gz/oGeIv8AwHh/+O0f8NPeDP8AoGeIv/AeH/47QB7tRXhP/DT3gz/oGeIv/AeH/wCO0f8ADT3gz/oGeIv/AAHh/wDjtAHu1FeE/wDDT3gz/oGeIv8AwHh/+O0f8NPeDP8AoGeIv/AeH/47QB7tRXhP/DT3gz/oGeIv/AeH/wCO0f8ADT3gz/oGeIv/AAHh/wDjtAHoHxbQS+H9NjOfm1a1/RiawWP38g9a898Z/tCeFNcsbGG10/XEaC+iuWMkMQBVCcgYlPNZb/HTw0c4sdZGf+mUf/xymgOF/aQyPHVln/oHR/8AoyWiuf8Ai54ssvGXiS21HTYrmKGO0WBhcKqsWDu2eGPGGHeigDF8H6RBrWpyW108qIsRkBjIBzuUdwfWuyb4f6WP+Xi9/wC+0/8Aia5/4Zf8h6f/AK9m/wDQ0r0x85NMDkx4B0rP+vvj/wADT/4mg+ANLH/Lxe/99p/8TXWg8A0E8CgRyH/CA6XjPn3v/faf/E1Lb/D7SpJMNcX2PZ0/+JrqTmp7Vv3o9fegDCtvhdosv3rnUfwkT/4ir8Pwi0B2Aa71THqJI/8A4iursPXvmtmBM8k8Y6U7AcH/AMKc8P5/4+9Wx6iWP/4ikb4OaBztvNV9syx//EV6UhYYwMUSHnFFgPMT8H9A/wCfzVB9ZY//AIir+j/BPw7eyust7qyqo/hljz/6LrvW6ZxmtzwugImbb3AzRYDgR+z94WK5/tDW/wDv9F/8bqGT4BeF1A/0/Wv+/wBF/wDG69pAAX2NVp1+UnjIpAeIy/A7w2jhRfax/wB/Y/8A43UL/BLw6px9t1f8ZY//AI3Xr0qcFj25qrJluevFOwHlI+Cnh3cB9s1fB/6ax/8AxupY/gj4bZ8G+1cf9tY//jdeoQjPAGAKfDxJ+nNFgPM4/gV4aY/8f2ske0sf/wAbqtffBHw5bxM6XurnA7yx/wDxuvY7ZTluenNZ2tZNrLkcYNFgPCz8LtE4/wBK1Ln/AKaJ/wDEUv8Awq3RMnF1qX/fxP8A4iu96EetOC/N0PFFgOBX4W6IWwbrUsf9dI//AIinr8KdDZsfa9S/7+R//EV3qj5umPwqVRg8jBosBwA+E+hEkfa9T/7+J/8AEU//AIVLoX/P3qeP+ukf/wARXoKdQAOD1qXoDwOlFgPOj8JNBAP+l6oTjP8ArI//AIimn4S6FtBF1qnP/TSP/wCIr0hR8oz+dIQQfX3osB5nL8KdDX7t1qX4yJ/8RVeT4X6Mp/4+dR/7+J/8RXp8iBhjJyKoyoAx/lRYDzCX4d6SjcXF9j/fT/4mqjeA9MBI8+9/77X/AOJr0e5jXPTBNZdzGyHkDH0pAcX/AMIJpn/Pe9/77X/4mj/hBdM/573n/fa//E11mcZ460fSgZyf/CC6Z/z3vP8Avtf/AIml/wCEE0z/AJ73n/fa/wDxNdUeKM84oEcp/wAILpn/AD3vP++1/wDiaB4F0z/nvef99r/8TXVkflSg4oGcqvgPSzn9/e/99r/8TR/wgel5x597/wB9r/8AE11o6UAY70AeSeMNIt9G1OK3tXldGhEhMhBOSWHYD0orR+Jv/Iet/wDr2X/0N6KQC/DH/kPz/wDXs3/oaV6e3JOOleYfDD/kP3H/AF7N/wChpXpx6nNMQnbpS9+aBjFHf+lACHAFPtiBKOvtUZp8BxIKAOgsj8ua2LdxklRzWPYZKDJwM8elbNqCAGA4PFMC6CWYAZA705ucggfWkGFcGnMTyyj60ARseme/Tiuk8Mp/o8hOfvVzRB688/pXXeGo9unKSPvMe/vQBsYxGAapzLlGIPB7VcYHZ2/Oqki5OKQGXMNowSSD1qlNxkAnnmtCcAyHJFUJ0wCeOvFMBNu0qoNSqu1x6UyMfvyuOBirKoM5X7vpQBNagAHA46Vma4MWcuCMYNa9uo2seMn3rK10j7FJx2NAHDkfNxzzUiLl8D60p+8CKeh+Zf5CgARsMVHccmpAeevbpSJH3zyTk05UPzZPegCRCAuAO+aeGJHtmmRrkDJGRT1AAGDnFACkYweo7UdD7Y9KUDeM9BTyoI460AQOuevFUrhTgkfyrRZePf0qpKpJbP0oAyplG0mqlwqkkAe1XZkOzAP45qnMuxV+bJpAZV1EYzkdKrg+hrUuvnjxiszGGxQAUYpe9DHoMDjuKBgaMdaM+lO6daAEzwKcKQ/rRzigDzb4mf8AIdt/+vZf/Q3oo+Jn/Idt/wDr2X/0J6KQDvhh/wAh+4/69m/9DSvTW5PSvMvhh/yH7j/r2b/0NK9LzknNMQ79aUdKaD2NB9c0AKTnrS25xJ/9amdTx+dLEfmOSc0Ab1kRszW1a5LKF6elYdkcAe9dBZkLjjr0FMC6oJIyOnQelSOMAlenfNIo5PTB7VIyjkqc+1AFbucDnHFdtoqbNOt8/wB3Oa40oSygev6V3VpGIreJSew/CgC04yoAqGZeeOuMVY2jIqCcHJJNIDHuWCSjOeT0qrIv70MQSqjP41avI904zjg5qCZf3IJBJ70wILYFpGbHfNWo87iR0zUUQEaYA+ZutTQqSmWFAFm2GA+ayPEPFjIRW5bLiI+9Y3iMBbN8de9AHFMuQew6ZpY8/jUhXOD2pUU4JHJ70AJEMEYH41KAOc9PShYwpxnFOVRtwMHNACgYUKOnrTsEYNPXOAMc9KeFDcGgBFHQ+/pTyBnjp6UKmAeT7UDAYAjigCF+QeeKgZTsJHXFXCuTkgce9RsgKYoAyp4t0eSD/jWVeISQfSt+4gzx61nyxnOCAccYoAwrjpjnFUJOpHFbFxHyRtrKmQK5pARj9aO5oPWjqM0DF6CkoXjrzS0AJz60q9aSnL70AebfEz/kO2//AF7L/wChPRR8TP8AkPQf9ey/+hPRSAX4Y/8AIeuP+vZv/Q0r0ts15p8Mf+Q9cf8AXs3/AKGleksecdqYC54xS/hzTc0ZzQA7+VLGfnAxTBnpT0PzAjrQBt2BztGccVvWr7WAI49a5yxb7ufpXQ2RwQONvfIpiNaHG3JHXmpAQAcHr2qJCNp9e3apA5x24oAdbLvvIQvdwK7p15XA7VyGiIZNSg4wAc/lXaLxL1oAcp4HHaoJ+SRjoKsR5JJIJ9Kr3ABjJGcjrSAzZxuPPaq86howKmdiJDhSVPWmTx7oyR37ZpgVY/us7djxVqP/AFYPeoZF2qqjp1NTrkoOMGgCzCf3ZxWN4kANmSDituIYi2nqax/Eo22bY6HHFAHGqo5GP1pQNpyvX1pzKASQPzpAvyHggntQAqkdSPrTwRn9aaueR2qaPaQc5DdhigBVPQnPvUqnDYB/GjHA44zjFKqjJ9KAFbnPGPXmkIBWlXO0n1o3ZGMDHtQAuCwxjimOD3GCKdIeBtpuc8nOfWgCvKDjH41SuVDYPrV+Zt3aq0i9Sw4NAGTcpnOMVjXEWWPrW9KuGYdayplILY/ChgZRjOeOtIFPerbJ3IpoXjpSAgxxnHHrTRVkp8hz1z0pGjBX5uTQBXxxQMVOY/lztpPLGBQM8x+Jv/Iet/8Ar2X/ANDein/FJQuv2wH/AD6r/wChvRSAj+GZ/wCJ9P8A9ezf+hJXpRwOnWvNPhoca9P/ANezf+hJXpTNzTAM0hPNKWJ5NJxQA7PehScg0gPrQPYUAa1mxXb/AFrorL5nBP8AOuatDkLjmuismxICfWmhGunXk59RmpF4PBBBpi4JGO/PSpBjg5xx0oA1fDsfmahuOfkGRkZrsEHPOM49K5nwuQ0k3Azkc10yDr/OkBJGflPriq06kIeB0qwgOw9fWmzY8k5/WgDHZMAnHP0prKxhIxnnrTr3KD5agebYgwwHHQ0wHuuOQKSQkbegqaIeamTnmoZYzvAyOtAFuA44xn8KyfExxZvzx0rTtmIYgnoKxvFP/Hi/bp+NAHLvwgP5U05EXvTQ4MYGTUgbKgd/SgBFPANTr97I69ahYZwOgzT41PTGKAJgfnUnpUuPlPHFRKMk56jmnBjuoAcQeMAUSJhecUoIA470OCRg896AIxxS8bScU1ySRz2pGcACgBmBzxUcoyvXpTy+QepGajkwVIzQBnTZy3Ssy7QA5FasoKg9eR0rOulO1TQBRK/L2/KmhOBmpyPlwfWgoM9aQEJXbxmh0yRgde9SvwwzQDucZHAoAhKdB0pNnI/lU2zJ5p4A3e49qAPJfiyMeIrYY/5dF/8AQ3op/wAXhjxJa5/581/9DeikMp/DX/kOz/8AXs3/AKEtek9K82+Gn/Idn/69m/8AQkr0j8aYCZ70tJ9TQaAFycnNLnim0DrQBo2ZYbegFdDZ53L6Vzlk2SuOBXQWYwwycj60xG6jAnp+IqUdOnA6DNVYHVhn7v0qzvAyc54oA6TwmB+8J9etdLGdxbniuY8KPlZO3NdIhA3HqM0gLKf6rI70y4H7rAAzUkJHl7RnFMuUwgPPHpQBz162xxuPy9/eqkxjdgR06jPeruorvbA/Ks8RgMA3HamBpWkv7zaTnFLIczNk8duaitFAIbHA5471McfMcZoALLIlbnOKxvFpJsWPB5H863NP5aTrxzWN4ri/0Tv94UAcgmNoB45qbpg9VxSRqpONtObKEdPqaAFXr1zzT0wGPNNTlh0H0FSbc8j+VAEiEtz2x2p/GT69KYMbeBgilOV6nn2oAVmzjb+tOXKjrk461EzE8enNKWx360AJKcY4yDUbYAH+FPkb5QKjbG0Y6d6AI2LZ4qLs2evQ5qRwByOlQbs5Oc+1AEU/C9Ones28Jwo5wa0psKmPvGqFyCeelAFZgMjHJ96QgFsngmnOTvHIpRyx4/GkBHtyxoCjPIp4I5znFInDHBoARByTninInzZH604LnnPPWljXJPPSgDyL4wjHiW1/681/9DeinfGM58T2v/Xmv/ob0UmMz/hr/wAh2f8A69m/9CWvSCRz615v8Nv+Q7P/ANezf+hLXo7HmmAHoKD1xRRigQLyQM4pRgHkZpMcUA89KALVq21hXR2b52j5sYrmbY/N6V0Vkc7R1460wNeM4Xkn6VZUhUJJx9KqW6kg45Hr6VaRcDaceo9qAOi8LS7HdevQiuoidfJLADBPNch4bfbespBYEZrrekRx+lAF+2dSuN3J7VJMPXGPpVS0IDemRkVeZd2CTnikBz96AJyScHPQVmvtM20nkda1b6OSO5ZwOP5Vi3Ehdm2YBDZ3etMC9bSDBODj3pQxJfiqdg37ghgc5q1sbYc8gjPWgCxpxCls579ay/FfMEfHGcnArUssduh9+azfFoIjhAwOf6UAcrtC8jPpj3oIJGCDj2p3luWXuSeoNSbCnD88cYoAgA2fd6GpA+TgDmkfOxj3Haq4k9RyfSgC2pIIxnBq19nLpuY4qPTo/Ol5HygZ5rTYEMFAznt7UAZcsLLyPmHqKhbOODmtWSNeRyGHc1QlhC7trcjt60AVH+8AMnPrRnGR26cUrNuIxyRUW9ieelADJTwcngdKrM/lg+mcYzUsx9vpVaUkhaAEZiTyeMdKgl5FPdjmo35bvQBBx5o5GaQZyQD1p+0eYTjJpoAy3p7UgEXkdRmlVcJnHHvSIpA55/GpDgIAfyoAYo+Xr9BT1D7Txx60mQI+vFSKeM9z6UwPH/jH/wAjLaf9ea/+hvRS/GUY8TWn/Xkn/ob0VLGZ3w2/5Dk//Xs3/oS16Oeteb/Df/kOT/8AXu3/AKEtejvwxzmmIKUHB9RTeCOKOcUAOzSds0nHFBPNAE0B+cD1robJgMBa5uI4YHpW7YMBsyfagGb9ucjjjPpWgq5jIccn0rNtMDGfStOEgJjGfTNMC3oj+XfoSeCCvFdgHbyEYHPPIriYHC3cLH+8PyzXUxSs1uOcEE0AbVmyAqARnH6VfLYxgjj1rG01yX+bG6tWU4BAxmkBFOqsxJ5zWNdWKsdwP/160C+S+TzUB2bOCc0AY4ja2J3kkHv2qyoMkIOMZqxOizJt9D0xUcaFdqgd/wA6YE1mhLAEdB6Vj+LVLNEuK6K2Qh+SMfSud8St/pAG71HSgDm+VTaeg6AdaeozjdxxSBecD1pxyR8vIPX2oAacHIycVnnrjHQ8VfYFM8ZAqjKx84r79KAOg0NP3DMRk45NWogXkYtg7evtUejgrbkYyAoqVFHksyt1agCG527Ce5OahgAyob/exUl24OArLnHQ1FEw3BWwD0yKAIL+yMR3xqdhOT7VluVAXnnFdfEqyIFY7gRWPqelNkvb4BB6UAYcmB1I571WmIyBjg1LcrLE+JFPBx7VXMis+OhFAEchBPXn2qNSN56012y5/So0cKegIzQA8nJJBxSjAQnHPvTGJZSeKiDkAYpASt9z5R160E8ADjjmo3Y5XNNJ5HOKYE/OVHBOKkUjp6VVMhyOfxqaNgW+Y8UAeTfGbP8Awk9rk5/0Nf8A0N6KT4y/8jPa/wDXmn/ob0VIzN+HH/Icn/692/8AQlr0d8lySSx9TXnPw2Gdcn/69m/9CWvRj70wENITxQTkntRQAAfnR3ozR64oAVT0wOa3NMYkrWEOlbOmOUIA78UCOhhY4AB781qQt8oHOe1ZNr8znsMdxWnGflOMf4UwJwwBx3zW5ZTZAGTiQY/GsEfePX8K0bN9sKkD5s5x6UAb+jyHztuckL/Wt2clV69RWFo5YyMQF6c8VsXLfMBxkj0pAVN2OWJ6dKrE8mnuSNzHGc1DIwKF+/qaYEpY7V2k/jVgKrspye3SqTNh41B4NWrFlZyp6igC9EvHGQK5fxIo89ST1Jrq4+CPU1zHiaPM0XbknNAHOdQMsRz/AJFPVtsQC8n+VNdCSVJGDwT60sQMYbBP0zQA84Kc4+nesuYgXpXjkjIrQduMlcn64rOk+bUFOOB6mgDqtIX/AEaXGelK+PKAIII/KmaKCYzznjt2p9zkI65+VemaAM+5GdueVHHHBpECkcnA6jd2qGc9S2Vx0wcGmLICPv8AbvQBeiZwy/N9OauQ3HUSfTNZCTjcQDk+/apluGWM8j86ALk0MMyksox71k3OgxSLuTKMeeDV+OdlBJIP1qwLx8dyB7UAchcaJcRE7WDfhis+axuIid0TH3616As0cjAMnXoRQYYZXO7sKAPOTDKByrg/So5FZcAq2a9Dk063ZSAefyqJtIQrnAPagDgjncBimtkuPau4bSVJzsGenSoX0eM4JjHP+zRYDjCMtjvUked/FdcuiR55hUn6VKmhwZGYvrQB86/GPH/CTWuOn2Nf/Q3orS+P9otn4xskQYDaejf+RJB/SipGc98Nf+Q7P/17N/6EteiHnivO/hr/AMhy4/69m/8AQlr0Un5qYCdulJS9RQfSgBO/pRjNLSCgBw4rT03qCT3rNB+UjBzVzTmw4B5HpQB1duNuCMEitCPntwetZlsRkdQDWpEflIzkHpTETIRjK9KsQt8oJJGDVZepIOfQVPEwUHnrQB0ugnMj854FbdyfnQ1z3h5txcg9cdK37hlJGRjA9KAKs+CMjn8apEExkHnHIq/H+8U9cd81QlwgHHfrmgBwxtQDp61Zs8NNjPAqsoKgKAat2i/vAcE+tAFxTl2weh9awdeb5hnHQ9a2WO1yB+VYWvuMJuJP9aAMpUAyVAdug4qCcKOVGD9cVLE2CyhuD09aScFjg5HGcmgCnI2CRkEVST5747TjA71dlX06Cs6zIe8Y45yfegDsdFA+znI+bjJFRXD5jYls8mpNODJYk9ytQS7Bbctg4zzQBmTHcGGcjqc01HRcYTcD+FMlKpnvuPfpimKIy2CxBzxmgC5577f3UeFx7VUkuArZdTSSI6DOTtx2PBqCWRSuRI3I4yOlAEyXik5KEjtzUwvAxByVBqgHGSoO/wBqiOcgBCAemaANbz5CMhiecU9Ll149etZ4Yhfl+9T1lJIB5X60AaUdwSrZzyKVrorEQd/8qzHmcfdONtTpI0sLhh8y4OfagCyt4oZVLSfnV5bqLbzKvHtXOlnYjBKnHWmhmjUgsCT1NAHUC5iHIbd7ipo7uIsATkVysTtgktyPU1NDO24ZORQB41+0q6v4508p0GmRj/yLLRVL4/Pv8YWRP/QPT/0ZJRUjOf8Aht/yHLj/AK9m/wDQlr0VgRXnXw2ONcuP+vZv/Qlr0SmAnbig9KOSaMUAA+lLjqKTijNAC5q1ZtiQZqr25qWA4kHpQB1Ns+SOa17fBGMk4rBs3O5cdK14ZRt2gYHc+tMRoIcd8Uu4Ag8/4VDGcqSMDNPycYOM0AdF4YOTITgZNdBM3PUHiuZ8NuURzjHzcGt5ZA1wBnJ9PSgB0B3K2CPn6EVDJFuTJ6LUsI2syjIPansrbCfb0oAhCbNucZOMVbtl2zHGeaiZDhcnBHcjrU1sCH3ck889KQBIcswwN30rmdXbzJ9vYDrnpXRTHYWYk9K5W7O+7kYHjPAx0pgVnfY6KucHocfzqaUHylKkkHtVeR/m+9kHqT2q5B80ZGcggn8aAMbUZDGjepGOuKq6SN8+AAc1W1KUzyZU/KO9aPheHN7nIKDmgDq5MR2ioSQxHas+6kKQcEegqxcXHmXOxCcYIA61RvSfIBypByTzzQBmzMXXJ5I96ashZDuUBQeCvNQNIxBUMGB9RjFACABGVlcdWoAeZEYkKzK3v3qKRCOhBH0qR2ZV2t8/YHHWgoCQFyG9M4oApSHkECpgrZDAEgVI0bE87ulKqEv3PHSgBgcEHqMcn3p0QJz05/CrCwqBl8+1MdcH5cgGgARCCdxBFTxSFY3QcbgKrEAE7STjqegpVcKMsDnHrwaAHzSEDBByRziqh3HAIyc0/cTyxI3c9acvfdkZOTg/yoATnnIwKYpw3yn6ZqQkjGCWA9qI4t2cnn0zQB4h8b2LeK7Qk5/0JP8A0ZJRS/HFSniy0BB/48U6/wDXSSipYzH+G3/IcuP+vZv/AEJa9EPXrXnXw3/5Ddx/17N/6EteiE0wA9TRnpS96aRQAHrR+NBGRxRQAoqSI/MKjA49qcvWgDorM9geMVowMBz1rI05x8v5VqW7AHB5I7UxGlCxIwM574p7OAcdz3qssmcN0GaJG+XOQCaAOm8OOBEwLAkE1qPL5V2z5GMZx61ieHTi3BXg+prVuWAZz3xg0AadvIkwaReB3FXl2mHC4B7Vzej3Swzt5n+rkwPx7V1EYQxkjtSAa4+4DzU0CDPHBxVV2ZWBySM9KtRnaQTnkUAVL2MhWIGeOlcfOzNLKcgYYV297hoiwPI9K4u7jcSNlSQDxz15pgQSqHGMdznmiaXybNhGfvjI57U2XauG5wOPxqnfy5U4wR2GcUAc9LlJNuD1710Pho+XHcyj0AzXOXJJmJPPPArd0SUfY5Vzhs5xQBoW7D7ST83OeKLtiIxtA44A9aqRSjzGHzbsEg9vekviTHjccDqR24oArgghvk+Y9/Sm+VIFXI3EnrUMZfIUHBPpzWlbmdivmICM9e4oAiSPk/MVOc/SlZGDAMM5745rWht0bJY496kFtAOQ7c9jQBjIjnjp9akjhZXD8CthreJgMNigwR7/ALoI9c9KAMsgkkE471XniYjIHetme325KqG4zVdnRDhlwcdKAMloyCQo+op8WAp8wDHTkVfLRZywxzkHNKqRPGQSRQBmykNgLD0469aailMHZ17GtDy1YjDcdhTxAW5wPl9TQBQBRjtGB7UgUqQuPxq8bJuqx9ffimi3mU4MZxjoKAPBfjz/AMjfZ5Of9AT/ANGSUU74+qyeMLIMpU/2enH/AG0koqWMwPhv/wAhu4/69m/9CWvRD2rzr4b/APIbuP8Ar2b/ANCWvReaYAOtJ3oPekoAMigfSlPtScUAO+lKDikFH4UAa2ntwuexrWjOG4HFYVg3OD1rZt5OSD3GKYi4jfL2q5aw+Z8zHIFZgfA6ZGcVtaMQ8UmTkjkUAdRpMK/Yc7evpTNUBhmKgDnDZq1p6Mtkp555xmrOoW4ukjZTjKcHNAGDAA8nzHPI4Heuo06RjCFIzx1rA06xmOoBCnc11dtaCNCSMcc80AMuT+7UqcZNMnuPKRQ3U9OKknkjjQ5OSOgzWHe3JdgM4Az170AaNpdbt6Njb61jXEYjncPypOQartdNCwGOGPUGpvMBSQSEgHofSgDOulVVySDgnisS9KsdxPT34rfvl/0deBuJPJ6/lXKatIYwV4LE9qAKDsrSEg96mtbloHJU4VuCKpKckDtV22spbh/kGF75oA0UuVJ34z14B60+eVZFHvjPPeqq6e8bHDEeoqGaGZwFQ4/rQBYiZTKpdyqgjParb6xFBlYMn9f1rGeKZgobdgHnJoa2ct2zQBck1qX+AYB96jXW7gP8+GqjJbybgD1+tQurKxBGCPekBuR6+4bBj+X2NW7fX0I5yB7jNcvG2VPY/WnZ/dkD+dMDtLXWYmwS/GcVNJNFcYO7HfOa4UZC8H8jTluJY0G1jx70Adg6q5xuBFPi2DIcZUdM1yyanMmNx4NWRqx7kjnNAHRsyR42Bc98mjczE/vBjHSsSLUkKgOQSKVtURSOBj0FAG2iv3zj3NTwMQAS3B965aTWJN2Ix+dVn1O5eQfPj8OlAHmf7QziTxnYkHONOQH/AL+S0Vk/GOR5fE9qZG3EWajP/A3oqRlD4bf8hy4/69m/9CWvRSTk9K86+G3/ACHLj/r2b/0JK9FYnimAntSY680c5oxQAh4FKPrR070maAH8c+9ID15pCaWgC3ZudwGM1qxPtP8ASsa2bDjP51qRkbsnmgC8CWTjH51taG/7twMHPBrBiYlO3HrXReGkDq/TBOORTEdpYr/o0a5AGK07a1cxxK3C9ye9R6bbDYCwAUDAq1cXI2KqnjOOPQUAXEWKH7oBf+tZt080iybWKj2p8UgV855PPJp4G8ZGMH0pAYbyuMnHVu9U7jJwpyV7e1b0kC/xAc+9Z97boCrgMOcHFMDnL0PkHdtCt1NLFcnlC4yemTn8quX1uViITLOTzz2rKKtHubjAx1oA0BOrwbX4I+XdXB3MjSSMz9ckAeldJPK7YHIzyGz0rInsn87cRw3NAEWnWrXFxGOg6121rpot7XdgMzdgay/D9mElMrhiqDGPetW6l3ddyMOijvQBWuLUs+VB5zyBSR2AyNw96es5YZMYFP35bKnPG4AmgCNrKMnDbeDj1qF9MjdMh2U4OCBwfatDdh0KkYc96ruzqrSFuB1X/wCtQBgy27wvh1Jzx0qGayDAqBggVtqQ+0DBx2btURt1UllyG7AmgDl5bVkPyjrVXoCDxXWNarKCNpDe9ULzTt44XOBjgYoAxc4QAcUxz09fpVuWzkjGMH1qu6suAV+uaQDGHIxn8qVic8HNDZ3Cm9H4NADudwHNOH3xx0ppPzcilHXjnFAD24Y9aVc7jUe75uRTk5egDyj4v/8AIy2v/Xov/ob0UfF458S2x/6dF/8AQ3opDKfw1/5Dlx/17N/6GleiN7V538Nf+Q5cf9ezf+hJXoZ6+1MBCeKB16UpH5UlACYyevFH0px4H1pDQAUoxjmj2oFAEsI+YCtWJeRWVEcHIxWlCw3DrQItpwDg5zXTeHVxACSATzknA61y0Z5PPFdfoMRMShRxtHX1pgd5aTB4fKGdyqDzTWyqrnnb1+lR2qNHcfMNoYcZ+lTuCI87QQck0gI43KtjAIIJyfSprckBdpwmMY9KYoBdSqnG3AzT1RQ5APyjgfWmA6VNyDnmobqHeAexHPNSJkp83Q+o6Ur/ADIo2gqeppAZV7Dg52gjbzjsayLuMmDIVcDr7VtX0jq+1cg4rOYs5KygHPUgUwMoWwYcHcPeiW13Ku1Rwa1li2ICIyQenHSmzRsUOMgMMZzQBXjZLe3KoQMnr61XkkcKd5Gc5XnpUIyHKsCD0OaXIC7ieP8AZGaAHxkg/fBYnFIgInCqWYA8nHSmW+SrnaoGOueSaYElacEy7MdiaALD/MSBvUZxz0zTWiI2lnJbGOOaJUIXBcht2eOhqu8yB8HOfbpQBaVE24dAG/vZ5NOSF1GCMj86qeY0hUBm3dMEZqytw0S4Ljd/L60AWEhSRsAEHHepRp5JOVyByCD3qOK6LNyyE46CporuVXONwPqO1AEE2nBzygPHGazrjSNzMNoxXRwzuzcgMp7mpFkgKnecNmgDiZ9ALHIBXHpVKTQZQ2VY4+leilIWQ4IOKYYoRGM+vXFAHm0mkXKt93I9RUBsLmMkbGOK9Mkto2AKlagksFwCvrQB5qLebd/q3/KlWGXcMIfyr0CawQDhcGmDTlUBgBg8nIoA+afi+jp4ltg4IP2Rf/Q3orW/aDh8nxlZL2Onof8AyJJRUjOd+Gv/ACHbj/r2b/0JK9EwK87+Gv8AyHLj/r2b/wBCWvRD1piEPvRxml/CkI5oGIRkdqAOlA9c0UAKBzSgflTehpaAHr94elX4zhlrPB98VbjbkY/OgRoxgFq9A8IL8nzZ4wBzXndu+X9a9I8IBVyWwcYwAe1MDtRCHjBI5XkU3y8RgZ+Uc+tSWjcFcggmpJQ0eNoJTPIpAUJAN+45HYc9KRsBSMEY6+9W5YVYKVzt7VG67mYoAWHrQBWEnrwD3zyaguJCH2qRjHOT0pWO2Ni6lQCcNmsy4m81k5ZGyQfemA+e4LkgYJqoSVJD5z1IB6U8SKCPVR39KUhgC24fNwaAIpXyhABxnH3qGk2oN5C9hio5D8jsMHaef8arEsqKGI9TzkY9KAI5Gh8wmSZvmPRRQREsZCu3X1pjAIxZVTPfJ/nTtxBKyRxEHn8KACMgRKcq2fXv9aguC7lRC0anocnGacijzT0UDqBzUNwsbkncV98f0oAmBkijVJk8zHo3Wmm5iGcxKg9M1CXXcFKyMB/skdKVxOc7EUoMEbutAEiyqRkqY0H8Q4NQxFCHKzO7HnBpJWm5ZCpJ/hUdDUcM06oVKnd05XrQBYYsgG2Pkiprd5gw5KjpjIwazWeZVOVPuMVJFNwBIcE84oA1knmclC+0dBircSDAzN83fislZlBOVYKenvU8codiFP4igDSwMk+ZkelNd2WPg7s9OaqGZhtVTnGRwKk+0bIz5g/EigCUyMq5c49aQXjgY3AemaYs0bRglM56Co5BAV4ZQfxoAtNesBj7/HtUkd2u0blzWWXgXC+Yc/TpU3nRgYjfPp70AeE/tHSCTxtYMBgf2bH/AOjZaKg/aELHxlY7+v8AZ6Y/7+SUVLGc78NDjXLg/wDTs3/oaV6J1rzv4a/8hy4/69m/9DSvRe5zTEIO1Ic5+tLmgHn2oAQcDp/9ak6CnHikPoOlAxOhFLnik6mloAUdPap4sbl44qDjFSxN0zQBo2x+fA6V6T4PG5Bz1I6D0NeaWrL5y816H4QnAXbyPQ+tMR30OFzwcdatpIM4PNZluxYkFueoye1XoGXYcnn3PSkA518ogY+Q8j2qOaNW3fNweetWCd0ahsFapzmOEHYN3tQBl3TkM64z74rJupRhX529eBwa0pjEzyN90gc5NZU6gsnPBGGVTxTAieXK5fknJGRwPam7jIuzf8p4yB/Kom2NLgOVXqR0pPNKkBgSMnnHegBZvkUqsisQOQRxVd5MqMYRuMipXYMFIO0HPsPpVNyqKx4YAZPBoAY9x+9ZTGjbcZPepmEW8MshDE/dzVW2MbybgTtYnjFTXEkJXLoF7cd6AEGRIvllDnnOcZpZnuM/OUjx3Jz0qqDvP7oImB1z/jVhZJFjHm+SQRgFucUANmaaVObyFR/stio3kkA5mLMv8bHPFOeASLwFLZ5K9KjfdEAPLwM+mc0AIssivxc4XgnacUeZcDLGUEYzy1RmNxlh909AetNXcQUCrluuaAHZunBO8nPXntS+SvDCQsfQ1GchQo3EjrjpTiHdQGXaQOtAExlJkwy8d2z1p4k2sWC9f5VW2kMDsY56nPFSIUbAx+8AxyetAEsczEYROmcMT2qU3B4UruxwSaqOkycBlIx0BpqyOudxGehoAviVyG3rgY4x6VCsvzYKEj160yG6ydu0Y+tSIgOWJzxjigCVsMPmz04yOlELIRjjIpsCqgPz5+veplhgOSuMmgDwn4+tu8X2Ptp6D/yJJRR8fU2eMbMdjYIR/wB/JKKkZgfDX/kOz/8AXs3/AKEtejAc15z8Nf8AkOXH/Xs3/oS16Me4NMBCDRS9smk4NAhM0lOwMUnTqKBiUD9KOKU/SgBMYNSRkA81GOvNKODQBegYLIp7etdt4buAqq3QbuvvXCxEZ4PPpXRaDdBHILbSeB2xQI9Qtb0SYMY4xj3960Ibobc7SSR1IxXDw3MtsvmK2SOoHcVp22qwvks7KcYAJpgdR9sBQHkZ6Csi71Am5KrjFZF9qzyhY4MlF+8cc1RkbK5yePwoA05pPmyG4/vds+4qIMB97gjr3/Cs+ORi2FYDJ6g9akaYq+SORwTmgCxcMNqHcOnIIzUDsTluFXBJIPSo2nTdw+c8H1zUMzCQEjYGwcENgUAOkvNsY3kEkAY4/SqdxdeXxtyfXtUcp3YXaR/F+NQbHC7ioY+ooAuWbJJHuysZB644+tPvHJXA2Oo6EdD9fSoI0ZUOxAMLgZJxVdt6R/KdoJxx0oARm+Y/ugT9anjkfaS0IVe+f8KWC3edw4IU45ycCtAWLJb/AL5Nx7Y5oAoyBWfcHWM56dDTDNLvHOMDgitI2URCs0Wcc/MDxSSxSOmYjEoAweB1oAyjNKCCDx9KcJfky4JY+2OKtqsmQrDf7pyaVoNyljBI2e8rECgDPLE8phVPpUmTIAPMwD1yOtWoxIqhVRShGcKP60rB2xvgRSOrE9aAIYYjuPOQBTj/AKzA+U1bjgeTkMgUcEYNTfZhgbwjDtxQBmMz7gEU59akEfA3oBzzu71fe1bGY0x9elMGnzMPmjyCcjjNAFYQuc+UEyO1NW3uUOXHBrTW0eIKMcd/l5p4tg+Mb89xigDOFvJtAIq1DbShcAZX2q+tlJkhUwPpV2GymVRnPPYDFAHzZ+0ArL4xsg55/s9P/RklFW/2k4TD4409SMZ02M/+RZaKkZynw1/5Dlx/17N/6Elei45rzr4a/wDIcuP+vZv/AEJK9GPBpgIOnqaXg+xo9/ek96AGnrRznnrSn3oFAgwMf0oycYzxR+FL34oGJ9KQ4FLxSY4zQIlRguPXNX7GYwyhugPBrNAGRU8TE5BJwaAO0huy8IAIz7d6fuYsWwuAOh71zthd+WNjc/Wr7XHT35pgaUT/ADZLdO45p73MgfdwT0PYVnLJyCMfnSNLncw57YoAueevl4UbCe4PekS83Ehifl46ZrPeYoV4GfQihp+QGQAnvmgDSW5wvzR7vXsTTWkDqREGXvtIziqUcqlj646g1agvhEvIDfWgC8lt52A2A4XhgcZqxHpzMuCWYDoM1nvfbgdsgGe3pUX2iVVGxhn13GgDoINIaLB3hA39/mnfY7eA4mj+0IemFrDt7q4dSJJAcdN71bgmO4AzIOP4ctQBfDwREKbJiD044FK90GG2OzkXnqB1FRR3KKuHct9cCrH222Vc71yPQ0AMeHzlJEE+D23UkemOVw1syrnOS9TNrttEvDjgcZPSom8TWqHc0ke4j1zQBI1hcHCwERqOgAqUaVcHAkkD/wC8azJPGFvtwsvPsKrP43hGMByR3oA6RdHOfv7QB2qVNL25ImP4gVx7+OME7YnI+vWo5PG0zZCQAHsS1AHbmxXaMuuc5ORnNSfZYUXJIP0FedS+Mr9mwiRqPzqrL4o1N+DKqj2WgD1DZCozjI460+SSJVxlRzXkh1zUWz/pcn4VWe/un3eZcSkn1Y0AewyXVuCN0iDjoT0qGTUbVSP30Pr1614+ZpCOXZj7mkQnBz1oA9dfW7JW/wCPmIHH96kbxFYfw3MW0e/WvJAOCD1FCknPSkByX7Rt9DqHjexlt3V0GnIuVOefNlP9aK5z4p/8jBb/APXqv/ob0UhkfwzONduPe2b/ANCSvRW615z8NeNdn/69m/8AQlr0fimAmSFKg0h6ClI96MY75oAQkik79acBmk9aBCGlPtR2oHWgA6c+lHI/HmgY5o7c0AHce1OUnnmm5x0pKAJfNO3rVqK9Kqob5h2qjj1707gAEHNAGrFfqrY5GaeL5CcN/jWRu55o3HHWgDX+1o2MsfUcUv22NW+bLe2KyQ3fJ49KTdyOelAGqL+IFsIcU1b4Y6Gs0PjJpNwC8Hk0Aay6gMYKg/QU4aoFJ+XiscMc47UBu2Bz70Aao1TAbavJ9qYdWl2gLkEcdazM44OM0qlS3agC82oXLMPnNR/apWJ3SN69agU5bg89BTgSG7Y96AHGVih3Mx+pppYYBPp2pquSCO1LkbevSgY0cdB155qM43dakJJAB60zOcngH0oAVen9ak9COtRKWGKkyDz0NACj73Bx9acuC3NNBwxwM05TyeufpQA4MBn1pvfnpQOTxSjDA460AAOMjNCk/U/WkXGOefegHCkCgQ5WyCAaFPGT+NRhxyDinAn04oA81+KX/Iftv+vVf/Q3opvxPGNet/8Ar1X/ANDeikMZ8NP+Q5cf9ezf+hpXo9ecfDT/AJDlx/17N/6Elejn6UwDJpP0oFHSgAxTcY4pxHy8UmcUCDtR2o9xR1PXigAOetJj1p3Sk+lABilAPam46c0vTpQAH+VIDQc5o59eKADjrS+1GRx60lACjpR1FIDg8HBpSAKAAZHelzxgd6T6mgZ60ALyKQHmgmkDfWgBevFOyAp459c03k9KKAHK20g96XOTmmelAJ6UAOz2zxRkEYNA6dqTH50DFY4YetM5OaV/c0g9KAHK2cA/rSE4PrTfanAnjtQBIJAT705TjPNQ5yxpVPtQBMHA69+1BfJOKg4zmlBxQIlLjaBTdw5xjPtTeKB9OaBiqeBkc0/jdkHNRj9aBQB518Tv+Q9b/wDXqv8A6G9FN+Jf/Idt/wDr2X/0J6KQC/DQga7cZ/59m/8AQlr0csCcnFeFUUAe6Eig4xXhdFO4HuYFGMHNeGUUXEe5Gk5yBXh1FFxnuQPJ703NeH0UXA9wpSeOK8OoouB7hn8aP5V4fRRcD3DPpRntXh9FFwPcD1oP1rw+ii4HuA9qCRjGfpXh9FFwPcNwAo+teH0UXA9wB6g0Z4rw+ii4HuOfWjPOc14dRRcD3EtSg5xXhtFFwPcX5PvTRXiFFFwPbxjnPBozXiFFFwPb/wCLJpVJ69q8PoouB7iCaWvDaKLge5Dr7UteGUUXA91XgGkArwuii4HW/Er/AJDtv/17L/6E1FclRSA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic and radiograph demonstrating the radial head-capitellum view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Greenspan, A. Orthopedic Imaging. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4914=[""].join("\n");
var outline_f4_51_4914=null;
var title_f4_51_4915="Technetium Tc-99m tetrofosmin: Patient drug information";
var content_f4_51_4915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m tetrofosmin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/47/37618?source=see_link\">",
"     see \"Technetium Tc-99m tetrofosmin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15516542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myoview&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15245357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a heart imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15245349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3988902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have and allergy to technetium Tc 99m tetrofosmin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15245351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15245360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15245352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15245359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15245353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86874 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4915=[""].join("\n");
var outline_f4_51_4915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245357\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245349\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245351\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245360\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245352\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245359\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245353\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/47/37618?source=related_link\">",
"      Technetium Tc-99m tetrofosmin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_51_4916="B cell anal";
var content_f4_51_4916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    B lymphocyte analysis by flow cytometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 457px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top: Patterns of normal B cell differentiation in peripheral blood based on IgD and CD27. Bottom: Patterns of B cell differentiation in peripheral blood of a patient with CVID.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4916=[""].join("\n");
var outline_f4_51_4916=null;
var title_f4_51_4917="Back anatomy PI";
var content_f4_51_4917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Anatomy of the back",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 572px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI8Ah8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKxfEfijR/DkaNrF9Hbs4yicl2+gHP41yEvxi8OZItor+4x3WEAfqalzit2Uot7I9JorxnUfjaoYpp2iyM/XM0oGPqBWDqfxt1xYGSGwsYZSMbxufb9ATio9tAr2Uj6Eor4z1j4heIdSuCbzV712PSKF9oH4DArX8D/FLX9Bvdkkn2izZh5kVy5bH0PY0vbLsP2XmfWtFeQad8ddFlufL1CxuraM9JFw4/KvRPDnirRvEUW/Sb6KY90zhx+B5q41Iy2ZDg1ubdFFFWSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXm/xL+Ip0CR9M0SOO41XAEjv9y33fdyO7HrjsOTXXeMNeh8OaDc6hKN7qNsUfeSQ/dX8/0zXynrl7cXM8vmSl7qZj5kx6l3PzN+WawrVOX3VubUqfNq9iOee41m8n1LVbmS7kmc7XkP8ArMcZPoo7CmXF0Xk+x2uIo0GZHxgk/wBKR7hLeB51XagGyFfQDp/j9fpVG3jKwpEOZGy8me59PoOtcb11OpK2hP5yxMI7dTuPQn7zH1NY2sTln8qKTcAcPIBxn0X/ABonuWw7p99/lXnoKzr2TZEoQ5CjC/1P4n+VaxjYzkyaB4oQwRfujLN3J9KgtZszxs3R2P5VEoK2zn+71/AZ/nVeNiTFt7KcfgKuxDZrmXaxRxlCeParmmatdaTqMM1pM8NzG2+OVDjNZMpLRxsO68/ypNxmtd38cTcn29aixVz7G+Fnjy38X6YIpyseqwKPOj/vj++v9R2ru6+IvC2t3Oi6pa6jZOUmicMuOmR1B9iMj8a+1NNu49Q061vITmK4iWVfowBH866KU3LR7owqRtqizRRRWxmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHczJb28s0p2xxqXY+gAyaAPCPjJrp1LxJLYQkmDTAIwAeGmcAsfwBUfia8okUSGYYyryFA/sCNx/HAFbT351GS9v5jiS5u5LhvzZv6CsK0YtawluFZvyG7/AD+VeXKfNJyPRjG0UiK6ZXuooz/q4wZCP5frUfmH7DcSg/vZSIkPpk4P6ZqGaTD3TjuwUfRR/jUU7fLbQ5xsUsfqeP61SRLZSlBfG0cDp+PT9MVWnAkuAFHDEAf7o/8A1frV1yBbJIOruxH4cCs6J911kdFUn8hWyM2SSrt0WZ+5cj/x3P8AWqNsMGEn+8R+Y/8Ar1oTHfol0o6q6t+gFUQv+jEg/dINUiGW4hkrGfUrTLU4ujEejgoakxtkVh/fB/OoiNt7Kf7hz+tSMtxkpAQ2Qd+K+sfgBrX9rfDu1hd91xYSPbPk84zuX8NrAfhXyzGofUIoiAUKZ/4EQcH9K9a/Ziv5IfFmqafk+VPamQj/AGkYAH8nNOlL3hVF7p9KUUUV1nOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVjeNCw8Ia3sBLfYpsAdfuGtms7xJGZfDuqRjq1rKo/74NJ7DW58gwyj7JKiH7qSEfkf8ahtnB06zXpukVfyJ/+vUMBzCSv8UTH6goD/Q1nC4aO2WLr5cwdT+J/xrzIxueg5WHON0GR1LPkf8C/+vVWWTN1cOP4UGPwpq3OTITwu5jj2b/AgVDvEdxcR9Q2Uz/wIH+VbJGTZav8Q29oo/uZ/Mn/AArJsv8Aj7kU9fLArT1Zt8QYf8szt/IVj7wmoMQeWBA+uKqOxMtzQtfmtryI/wAUYP5VDBFn5P7wK/4U+ycNdJ2DYB/EUwkgK/Qqw/Uf4igCRT+4XPZwKSfH2mcg8swFIcFJ8kgnawH4kVDndKT2zmgRtJhbyCQdNgz+Ar039mhGb4gXTqCUWylJPp88YryyZtkcIP3tp3fpXtP7LcJOta5IMbY7WJD9Wdj/AOy0Ul7yHU2Z9FUUUV2HKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDeRmW0njHV0ZfzFTUj/AHG+lAHxK8Mmnmexul23dnK8Mi+mOvP51iOhVZ0fko20kev+f5V6B8bvD39ha5HqltK8sWpOZ33dY2PVT6j09K8yaVo4Z1JJdzn685Jrz4I7JMsR2/nnG7DEEg+vNM8v/SNrNlmHX3xU9scXNovTI5H1OaoGQvMjJnJOR7VauJ2JUm3wyrIc7Tk/oKoCNi24dQev0zT4n3tMD7n9BSh8eYB35FUtCdyW3IVo37BQf0NLcHa8q+pDf1qqkmLPIPU7R+tSE+dPJtP8QFFtQvoWeTcNk/KvP4ZJFPtov3m5/uR/M3uT0FQRPnzW+gFTs5+xv9ePck1LKQ+Zi9wjk8O2B+Br3X9l6TZrevQY+/bxOT9GP/xVeITR7fs6r/Dk/l1r6M/Zo0doNM1XVZFwbmRYoye6rz/M/pTpv3kTU2Z7XRRRXYcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQelFFAHzz+0IQdGiVxnynVG9sNivA2g8xJZScBUPHvX038aNOjuL97WfiG9gzkfwnpkfQgGvmXZLaxzW9wMToxjYfQ9a86PuycfM7XqkyxcL+881Mqx5HsMf4VXRCJwSAPm+X86mS5DFdwHU4H1yKsRxKTA2Mk5J9hiqvbcW5jxwlZnGcjcP1xn+dWZIMNIOhVAV+p4/pUgh3SypnDDnPrwKuTxqWQbv3qcY/vA9PyNU5CSMNkAtPlHCOxz6nAAqa1t2AcE4CLuY+pNPht2NjL/dVufxPFXFj8tnRDuctk/XsP8+lNy6CSKY/dJz/AKzsPfpTkjMjLH0VSMn3p5jD3ZCc7e/v0H+NSqAsrqeQPlGPU8fyzSuM2PDlrFqviSwtZMiGWdIDj+6x/wDrV9meGLG20/TvIsYlitlcrGg7Acf0r5R+GlkT4mtrorlLR/Ob3fGFWvr3TYTBYW8TfeVBu+vf9aqgrz9CaukSxRRRXWcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB518ZNKuLmx0/UrSKSY2kjJMkalm8t8fNgehA/OvmPxrplzba3dk2s5nRgrw7cMAQGVsemDX3DXgPx8tBZ+M9NvUAAvbQoxA6tG3+Dj8q5K9PlvVR00p3tTZ82mdWvAVPyjgVri4VJcBgCOnP0/wP517T4X8F6J4gsYzPYR7skl4xtOay08G+HTe3Vu9k5WKR03eZg4BIB/SsFVU+h008NOV+XoeZRQFoUc9DxkflVuOOPzwxPKAcmvTdH+HGn3dz5K3FxHGRuCsQSKXVfhVaRtuXUGRD6inJO3N0E4OMuTqeR3V1bRQzwJjO9WGO+DSW0qPfRNwVYljnudvFevaf8J9BZt91qEs2RyqELVLW/g1Ih87w9fr5eciOfqB7EVKqRegnTkt0eUeciGR04Y1Lo1vNdXUMUCsXd+MdSa6+X4X6hB5YuriNW8z5wOyeo9+ld18H/C0EHjSIfLL9n3SFiOgA4/HJFPnTfLHdk8rSu+ho/CHw4J9QtVg+a1s38+4k2nDP/Cn1zzj0Fe+U2ONIwRGioCckKMZNOrtpUlTVjlqVOd3CiiitTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8e/aStP8AiRaPqQXJs7oqxx/C64P8v0r2GuM+MGkPrPw+1SGCMyTxKJ41HUlDkj/vncKzqx5oNFwdpJnF/CBT/Zjsem44/Wub0sid553B2O5dv9ok9K3PB8jaP8NmuCT5zQbUPcs3AP65qhptq8duuAN4H4J9fevOprQ97C6RlLvY3vDQJ1I7iAwQlyOij0ql4/tZDGroQM8ECQrWt4SgB86ZQSvAUn+M+tZ3xKF0umR+WkfkiTDOeu41rWX7g54yvjLHPeH9Jv0imntGUuuGCv8AvAR6D36163penW0FmkkE73QkG4Su2c/QdBXlvh+41GK2gWAQKXdIhJISFQMwGT7DNev6ZYvY6bFbSusjrnLKu0ZJzwK48Mm7tovMJcrSv8jifFsHluWA4qf4OWJ+06rfMP4hCp/HJ/pWr4pszLaMwHIqf4VhV0O6QABhcsW/ECujDx/fanFVl+60O0ooor1DgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikZgoJYgAdzQAtVNWuRZ6ZczkZ2Rkgep7D86oaz4jsNLi3TTLk/dH94+w6n8K8z8QeI9Q8RyGBc21l3jHLv8AUDt7f/qrCdZLSO514fBzqu70RQuZhqAtbKE7bC2OS4/5auR2HoOg/H2q3cAJCIym1QPlhGPzb/P5060gjtEHVZMdOGk/AdFFRYN1drBGCNxAKqcn/gR/z9a5ox5VY9nRaLZHWeG4CumR/wB5yWY/j/hiuf8AiYl3/ZhjjkAgLAsuOuD+hrtrSFIIEROEUYGK5H4kuqaDPI3DKyFUzy3zdBWuKTVGyPKwk+bE8z6s5e0juZNO8ry0WNl2ls5617dDGUt4kOSVRVOTk8CvHNJklvbIQW8EkcsmFQvwFJ4BJ+tewWccsVnBHcy+bOiKskmMbmA5Nebgb2lc681esV6kN5As0TIw4IxWJ4OX+ytcvbKTKx3ADx56Fh1H5H9K6ZlzVS5tUlHzLkjkHuD7V2WcZKa6HnRknFxZuUVhw3t1ZjbKpuYR3H3x/jWlZ39td8QyDeOqHhh+FdsKsZ7bmMoNFqiiitCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopsjrGuXYKPc1jar4k0/TgfPuIo2xkB2+Yj2UcmolOMd2XCEpu0Vc26hnuYYR+8cA+nU/lXm2pfECScMumW8snYO/wAi/XA5P4kVzN3qmp6kSJ7xkUdYoG2D8duSfxNYSxH8qO6nl1SWs9D1DVvF1hYb1eZFkXrH99/++RyPxri9V8ZajfnbYQNBEf8AlrPgt+C9B+tc1BZiPlYiV652/wDxTf0q0nkHkFAw9NhP6A1lKUpbs7qeEpUtUrsiitjcXDSzzieY/ed2MrH/AAq8PLhCrmRV7BmEYP4D5qrSSsvUN9SXb9AAKYJZGLEA4PXYoT88mlsdDTZNPM7ZQDYuclUGwfiep/Cul8MaWsSpdzYaU8pEo4X3NZXh7S/tcvnTgNEh6Ox5PpjpXbQrsAG5EUcBUGMVvRhf3mebjcRy/uofMsKwXqMv2HpXIfEBF/sWeWTBERDEntzXXhW7DHua434hIx8P3a5Xym2+aT1IDA4pYxJ0nc5cE7Vo2MzRby3ksNsG8sR8pCnk54x9K9L0iO+jtCmouskithZF/iXHU15x4b1OwtrJFaaIMOig8/Su/wDDD3rWe3UJYpSQGQo2Tg9iO2OK8jBaTtZ/13PQzG7Tf9fI1aTGaeVpuK9Ro8i5GyCqdxaRykFlw46MOCPxq+aawqHEuMmipDdXlqQCftEQ/hfhx9D3/Gr9tq1pMwRnMMp/glG0/wCBqs6ZqtPbJKuJEDD3FONWcPMbjGW50NFcqiXlm2bK5YJ/zzk+Zf8A61XbbXWU7L+3ZD/fjGV/Lr/Ot44mL0loS6MlqtTdoqG2uobld0EiuB1x1H1FTVumnqjFq24UUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorN1G/McwtoD+9Iyzf3B/jUzmoK7HGLk7ItXN0kHHLSHoi9a5rVPEq29wbdnzKBkpFzt9iRzn2rnvGPif7Fv0/S3zdHiacHJQn+EH+979vr04y2tpN5kYs0zHJJJ4z3J7muOpUlPROx6uGwKceeZ317dvfAebc3UMR6iOFxn/AIEDn9aoJo2kzMxWS18wnnzUcE+5561iQSXSrmKd/wDeJOPwH+fxqY6hdodvmtK3TBAOPr2FY8jW0joVKUdIv9P0NW48OW/8OWz0Mbh1/I4qhPoNwgAhmVvSNRsb6c/0qNNUkjANwka56eUSh/Tr+VaVnqvnp5YuDt/553ajn6MOn4ii81uk/wABP2kFv+pzlzBPbHbPBsxyPMUux/z9aj3SNyzMqdwzhQPy/wAa7N7iFVKXIMYPH7z54j9G7VQvNCgmJktCEkHIVju/Kqi1J2Wj7MqOJS+NfPoYa22Qrbw4PQiN3/XJqK4gVOWTP1hap9k1vKY5Q+9Tj5pCn8qmkjeVchB/3/b/AAqrG6l1uWPC+o/Z7kWzYWKQ8ZiIANd9EzbPlIP+6a8rMbQuG2vuByNshOPzIr0XRrn7Zp8UrZDEYOexrooSuuVnl5hSSaqR6lpmJPzEg+hJFcd4/ilk0Wa3UgQ3DKrnPIwc8fXFdnKMjaRuHv8A0rlPF9mbrR545LhktMh3A4bI6AHt71OMdqbZhgv40TO8Kw2FrYCa5iiWOFdzMw6V0vh6Ga0uVvJrhJxJEZHSLgR5PAJ6HiuV8GaVYMNskBdhg/OxYfka9AsIP7VsQ7AwWjNhVQYLqD1J7A4/KvEoRc5e7q0enjJ8jafXf/gG6OQCOhpCKUYAAHQUV7R4hGRTTTiaYxqWNDDSHpzRmmu2BUMtIhYZNPWEOORTFOTVlcAVNkU20VXswrb4yyOP4lODT1vry3+9tnUf3hhvzFTk0x9pBzTV4/C7BzX+LUmtNYtp38tyYJeyycZ+h6VpVyt9EkkZ3KDVTTdffTZ1gvXL2pOA55aP/EVrTxOtpilQurxO1opqMrorIwZWGQRyCKdXYc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyeVYIJJZDhI1LN9AM159f6u9nolzqLf8AHzcv+7HozdPwA5/Cul8b3LQaEyJkNcSLDx6Hk/oDXm/jiYgabYLwgUyMO3PA/IBq4sRK81HsehgaSnLX+rGNp8LTy+YxLu2TuY5+rH1J/wA962ooY/LDH/V9gf4z0yfX6d/p1zrNlRDuHynBb6dl/wA+vvWrFLsYOwzK33R6fT8+TUI9ao3cnWAFC07eWnXGcH8T2+g59x0qvNGWGI18pMnqMH8B2/H8qWWdY8PK26T+FRzg+w/r/Kqk0rynMjFF/uqefxP+FUzOKZEwRHwgMknQnqR9T2+lQSnaN0rD/dXp/wDX/wA8US3ShdkCrj1H3RVGSYK2SS8h/wA8elQdEYs1LbVLi3QjdiHHMb8gj3q2dftre381fMhORiLqM+q+n06VzFxcBMGT5m/hRajktZJInknPzlfkA6D1FKXvKzB4eDd2eieIbOK4043BjUyRgHdjdkVzln5ZOw/Zix6IUwf5/wBK6WznFx4VhmY/ethu574wf1rlLR2yc/MhOORuA+o6/jzW9W10zgwfNySg+jLVzCUQnyEX2jI/nxW14NvVR5LVmYbvmRWz269eay7gR+UpGYhgYKH5D9O35iqlvNJbXKScfI2dw7fUf5/CojLllc2q0/a03FnpoI6dj2rmfGLEeGtTljwfLX5gevWugjz5aswyrDPFc74wgLaNev5jKhUbx2bB4q8Zb2TueRg1++j6nNeFv7T1C1byligilG3dklgPpXeQXX2WTTbSCYyTPIkaorZGwfeJA6AAGuM8Hyq8kOm+d5ck+QSpwUUDk57f416N4ftdHt0P9kxRIwGGO35yPfPOK8nDUnKXNeyPSx8+V2av/XU2e9NY0FuKjZsfWvVZ46QE4qJ2xQzVEx5qGy0hGkPpUZYk0u3NKQAKgtaCp1qUn0qANineYe1MTQ5yRUbNTmJY5phpMaK919wmuV11NyMa6u5GYzXOauuUYVhUN4Gt8N9Xa5tZdOnbMlv80eepQ9vwP867SvG/DF4dN8U2Un8Ej+Q/0bgfrivZK9DCz5oWfQ5cRDlnddQooorpMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOQ+Ic2yPTIuzTFvyGP8A2avNvFFx53iB1b5hHGkePbAY/wDoRr0D4lKxuNHIzjfIP0X/AArzDWpNuvXW44zJ+PAx/n6V51X+Kz2stjdX8n+ZfiO0ByMvk7QO7dz9O30qbz9hIQh5T95j0H+fT/8AXWQ91gYT5eMf7o9B/U1E052/MTtHYcL+J70XPR9nc1GulQnaTJIerf8A1+30qncXOf8AWtnP8A6f/XpkFnf3gUWtrPIp6eWh2/8AfXT+VWtR8Oahp+k3F/dCGJYwuUL7mJLAduO/rSuHuRaTepnSzsRydi/rVVZ2lfy7VcserHp/9eorFPtcjiZixUbgvYjvXQ2tssYIjUZX51x3Hp/P8xRubSahoVdPsRHtmlyzE7WLdv8AJq5PDiN4uhX5k+n+eK0UiTcQOY5lyPTpz+Y/rVaZW2HPzSxHH1H/ANcfrTsc/O5O5UsNQuDpUVor7Y4yy7OmeSef0p9mSsu9CPcngYPTPt79jn3rPtubi4VOfm3L+IyP1UVoxZWXKEAY3D3B6/rz+OKL3KlFRvZbmiwYxnsSSCCOCfRh2Pv396oudjHaDheqHqPp/n/CtRBuTAUEkYCt/EB1U+47f/rNZlxguArc/wADHqfUH3psygz0LRrkT2MJ4KslY/jtzb+F9RVZB5rhRGCMk89vpUnhRy2mAkEAORg9jT/FYEvh+7bjEI3MT2HetMS26N0jx6MVDE8vS/6nKeDdPSKOGUJLcXMr428ZJx/KvTNL02WC8N3dSqZNnlrGgwqjOT9TXC/DW9WYS3VxGyLESkCKMls5yx9K7+x1Fbu4mhC7HjAbBIJwf5V5mFjBSvJ+8dmPnJyajsXy1RM1DHjrUZNeg2eYkBNMwWPtR1p5OBSKEPAwKiY0rGoXapbKSBm9KUP2qvI9RrL82Ki5djQjansMioVPANTZ+WrRmV5hkYrn9WXCmuhlPFYmqpujNZTNoHC3zmJ/MXhkYMPqDmvdbaUTW0Uo6SIG/MZrwnWFKrIPrXt+kADSbIA5HkJ/6CK3wT1kjPFbIt0UUV6BxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch40fz9U020ABK7pm/kP615nqug6jqXjO+gsLdnCsCZG+VEyoPJ/Hp1r0K4k+2eK71+qwkQr+HX9Sa6G3UBeB1rzZPnqNnp0K7w0bpatHF6R8PbSBEfU7iS5l6lIzsQe2ev8q3ItH0yzYNb2Nujjo+wFvzPNbcxwKzLlzk1T0MZYirVfvSI5JSelcv8AERyPDUig/fkQH88/0roHfFcb8QLkvpfljoJVz+v+FZN6nRhI/vY+pw9m32eaKfsDhvofWuntSqDOP9Ue3dD/AJ/SuchjEkexhywwOev0P9K1tInJhj3k7oz5Tg/of8+pq0e1WV1c3dpAeJcBl+eP/D+n0NQ3W0hJ0PyEYb6f/W/xojJEYABLw9Pdf/1fqKewAZkOCkg3L/Uf1/E1ZybM5+4X7PqhI+667se4Of8AGrsZ8spgZaMnAHoO35EVU1EmK4t3bJMbhST3U8VYjO0q7ckYJ+o+Vj+VQdD1SNqAcFASFOMPnof4T/7L+A9ao3oy245XJwwz9xvUf59KtRYSIq2dsXUf7Df4Y+vy1WvDhmL4ODsk46+h/wA/0qnsYR3Ok8IufsU27s+GHbp1qXxWsj6DfwIAVmRQ7HsAwP8A9aqng0t/pSE5xtOT361o+Iio8P6gzHHlRF+fSrqtqheO55ckli9drow/BQmuXWC2ZY8gszEZ2r7D1rvrGxgsi7xKTLIAHkblmx0z+deefDmS5t4Li7dY/wB+FEakcog/x613Gi6oNSjuWG0rDMYtydGwAf615+FdNO32joxyk5trY0yc1GzUjNUe7LV1tnAkTJQxpoYAUxmp3CwO1VZWqV34qlNJiobLihJZMA1WWX94OaiuJsA1nic7yc1nc1todXBIGGB6VZB+WsLRrjzJmUnnGa3E5WtYu5jJWZDOeKzb0ZjNaFxVC55Q1Ei4nFa7D973BFes+GJhceHdNlHe3QH6gYP8q8y1hcg/Wuz+Gl35+gtbsfmtpSn4HkfzNaYOVptdxYlXgmdbRRRXpHCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMwVSx6AZpagvyVsbgjqI2P6GhgcJ4ck8+W4uD1mmZ/zNdTE3GBXIeEWA0+EnqRXXQA4yeleVSZ3VUExwKyLp8E1qXB4NYl62M1pJmUFdlWeXCsc1xfiiQTaZPk8ieP+TV0t7IfLbFcPrUbTx3BB5SaMAfVHP8ASsE7yPRwq/eRKlpjGCAyHgg/54NWFCWt5ncfJmGx1bqp7VUsHyxB+UjgjH8x3FaFzCJ7bYQMkfLk8f8AAT/StT1paOzNGCZlKuxy0fyvjuPX+Rq6UypiUgFfnjPt6f0+hFYOm3JZMyf6yP5JAfTsf8+9akbsF2r9+PlMnqvp/T8qpM55xaZR1uLzrJnUEMvbuPUUWziRY3OApwceqsP8atXYVkMi4Mcg+b/H/P8ASs7TPmtxEThhujJ9CDkfzpdS46xN60LAI0h+6CGz3GcE/ntOfQ1XvAI2IJyE+Rs917H8M/zqzCy+X5pGVZRJg+mMNn2wQce1VZ8iTDkMR+7cnv8A3T+v61T2MVubfgtyJbqEkkgAgnuOa0/E6l9Fv0VQyywMjZ7A96x/B4Iu5hklkTqe4z/n8RW/rWDot+CM4iJFVVb9g7Hm1LLFr5HNeD7IagkcMhJgiJaUA4yMYC8f54rv4IYraFYreNIolHCqMAV5p8PLi/8AsTSISWvJiVhJwAozyfw/nXolissFlGly4eYD5iOmc1wYayTVvmb467ne+hO7YFRoeSaY7ZphfFdNzisWHkqNnqs0nrTTKKVx8pNI/HtWdcy9akllzxWfcsccZqWy4orXM3NRxIW5bgUmz5svTi/YVBZc0eTy9XROzRk/qK6uI5FcLaThfEVqoP8AyxfP5rXcWp3VpTZlUXUZOKoXK/Ia1Z0qjMmVIpyRMWclqw+99au/DO5aLxBdW2fkng3491P+BNU9cVomOc7ag8FOV8Y2BX+Lep+m01FF2qI1qK8Gew0UUV7B5oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQXylrK4VepjYD8qnqpq1yLTTriY/woce5PA/WlJ2TbGtXocF4JgkewgaUYwowPSuzACpgVlaDCIrVBjHFacjcV5tJWR1VpXkVLt8LXPX8uDWteydfaudvn5qajLpRKV5IWQgVy922F1JgMhDAx/Nh/WujuGHlnmuXeQOdcTP8MX/AI781Yp6nZRdpx9SI263YEkDbJx0PTd9fenw3BjYxXCmN++RkN+H9RVO0co/B47j/P6GtlXiuI/LulDLnAboQff0NdJ6stNHsZlx/olwl3GMxtw4B3KR9a00fKr5bZIG6Ns/eHpVabTJkDmzk81O6Hhv/r1Tsbk2zG2uMqufkPQofSgTSktDaSQA56xP69j/AJ/Ws22/0e/uIz0ysi59Oh/Q1cV1O4tgqeHHYe/0qpdL5V/bl8lHzGW9QR0oJit0bEMojUhhjy33f8Bbr+HJ/KmSpn5WOc/u2bvxyp/L9TTrc7xEXAIcFHGO/wDkH86ZMjcK3DMNhP8AtDkH+Z/KqMupqeFZX/tBSPvFSGA/X+VdNqrldNvdqK8ckEiHJxtyp5/rXK+F2zqsbDjep49GA/z+VbXi4sPDeqeV954QoHoSwB/maqV/Yux5teP+0pen5nOfDWaUQtcOi/ZYY/KhLHBx3b8cV6DHcJcQRzRHMcihlPqDXH+ELOC4sjbyhZbZQCQD8pPpXXxgcKoAUDAA6AVw0L28jXGW9p5j1GaR0wOlToMCmyHmtzjuVTHk9KjeIYNXKikosO5RaIDNVZ8KORV6U8VQuORUMtFCc8VVZ8Cp7oFVNZksuDjNQy0NtZf+Ktt1z/y7n9W/+tXoumyZIBryWC6/4re2Gf8Alio/8eNeo6c3zjmrpvUioro3JFDCqUseM1eBygNQzDKmt2rnLF2Oa1u1E0DccgVzng5Hi8bach6bpP8A0Bq63UDjNcpHcDTtftLwj5YpQW/3Twf0Nc+kZpnUtYNHsVFIrBlDKcqRkGlr2TzQooooAKKKKACiiigAooooAKKKKACiiigAork/if41t/AXhWTWbq1e6HnRwJGrhAXc4BZznao7nB+lZlp8S9OttIOp+IptLttPe4jtLe80q+OpwTyvu+RTHGGBG3nKgc8E0Ad/RXB3vxP0L7Fa3Gm3cEnmavFo80d6lxayQzOCdpj8lnD8cBlVTzlhip7T4o+ELvUILKDVXM09+2mRs1nOsbXS4zF5hQJu5GOee2aAO1orlJ/HuhR6sukvPd2uqTCUW0d7p9xbLO0YywR5EVX/AOAk57VU+EPi268X/DLSvEutLaW1xcpM8wgBSJAkrpkbmJAwoJyfWgDtqK5TTfH+g6nZy3mmHVbyzjXeJ7fR7ySOQbwn7tliIk5P8GeAT0BIqt8UfCCabLfS6s8cMV6unSpJZzpLHcNkrG8RTepODyVA460AdrRXLWXj3QL6xvLqwmv7pbO6NncxQabcyTwygZKtCsZkH1K4965nXPijBLe+DT4TmtL6w1jWDpl280UiyQkDLLtJUo444Yd+lAHp9FFFABRRRQAUUUUAFFFFABRRRQAVzPjO5GLSyU/NI/mN9B0/U/pXTVwWrS/bPFkoBysO2Ifhyf1Nc+KlaFu5tQjed+xu2Q2Qge1LO+FNIp2riq871zLRFvVlG9f5TXPXjbmNbN8/UVgXLZasJs6YLQp3TbYya5DT5TJqGsL/AHgo/wDHTXT6i+IiK5eHT7zTNSt7y4Cmz1VTJAynP3DtZT6Hv9DWaW7NU7NDLdxvGMAnp6fStOAn+HIIHI7gf1FYxUxTtGeNpK/ka1LVxwJMjHRu4rpR7c1dXRfjkKBWUgAfdPb8+q1NO8NwgW+gV/duP/HhUPQ/NkMR99Op+o7/AK/hSopwDEQR6xnj8jxTOfzG/wBnR5D2lzJD6K43j8xVe50+/e32I0MsYOVKtyDVrI3Z2ru74yjH8D1/OnMzKeWkHsV3D9P8aY1KSCKVmibZ/EFkUe/XH5j9almYSplDzINw+oxz+W38qqwsAxwwOx8ZHcNz/P8AlVhV2qygfd+dfpz/APZDH0oJasy54flK6pDtOA53D+v6/wA63/GaGTw3qRj4cQFkPoe9cxYt5OoQuOAjhx9D97/H8q6vU7mHUvD9zPptzBPbyo6CWMh1ODhsEehBpy/gyuefiFbEQaMrwefsWlxWlqn710OATgcCuxskkFvF52PN2jdjpnHNcf4V3XF/byIN8SIzFx0HGK7bPFcOG1jdjxqtUshXOKrs/NPkbiq0jc10tnIkSGTHeoJJqjd6rs1S2NIkeTdUDjINJnNMkfatJlFC/OAa5+7l2k81sX8uc81zeoN1NZyNImH55HjGBgf+WA/9CNexaRNvVGz1ArxbUrG90/xJpN5dxhLa+gJgOeSFbB47feFep6Hc4jQZ6VS916kvVaHdwElBUhXIqrYSb4hV4c11LU45aM5/V48Ka4rVl3A16Dq8WUauF1NMMwrnqqzOmk7o9B8C6h9v8O2+45lg/cv+HT9MV0FeafDC8MWr3dkT8k0fmr/vKcH9D+lel16WHnz00zjrR5ZtBRRRWxkFFFFABRRRQAUUUUAFFFFABWR4q1638O6Q15PG88zusNtaxf6y5mbhIkHqT+AAJOACa0L67t7CynvL2aOC1gRpJZZG2qigZJJ7ACuS8LWc/iHVl8WaxC8SBSmj2cowbeFuszL2lkGPdVwvUtkAW28M6xN4cmjv9VhbV76f7Tdi4t/tdoOMC3WJiP3S/KOCrNtJyCxry3xj8FtRtNJll8NJZ3WqX2t2N5PBZWyWNnbRQK4ykJkP9/J+ck54xzX0LRQB5DP8Gmu5JLy918Pqtx4ht9eupo7LZE/khgsKR+YSgw5+Ysx9jTbf4LeTbWcP9v5+z+Kv+Emz9j+90/cf6zjp9/8A8dr2CigDxHTPgU9p4k03V5/EUVzNZX094Z5NO/0q5EgwElnMp3BQBj5QBzxzXdeB/AcHhv4YQeC7u9a/tlgntpbhY/JLrK7scLlsEB8dT0zXaUUAeTz/AAs1mf4eL4MbxZCmkwIqW0kWmsk+1XDBZmE+2RNuVICpng54IORH8BwtlfQDXLS3F1rFrq/l2el+TDF5IceUkfmnCnfwc8Y79a9vooA8e1j4LyX9zrM8fiEINR1tNYe2lsjJbuqggwTIJF8xDn1X6ejPDnwSGipo6rrkTDT/ABBJroSKw8pG3oi+Sq+YdoGzg89cY4r2SigAooooAKKKKACiiigAooooAKKKKAEZgqlm4AGTXm2hObrUrm6b/lpIz/ma9A1YMdMulj++0bKPqRiuQ0PTntLfDDBNceKTbijpoNJNmozcVVmbrUzggGqVw+ARWMtEVFXZn3rcGsS4PJrSvZDyKxrl8A1zSZ1RRkazMRE2Op4Fdb420o2Xw90AMMSWkse723qc/qRXNaXaHVfEunWQGVaYO4/2V5P6CvT/AIl2jXfgnUhEMvEqzj/gDBj+gNdFCnzQmzGrO04o8Mv12Xz56Nhx+I/xzVq2/hGPcAfzH+FRaifMjtpR0K4z6Y5H8zT7U/LjGe+3+oqYO6Pfpy5qSZoRgiPjDR/Tv9OoP0/KpVAJDEj2LH+TD+tNjAwGVjnu2OfxHf8Az0qeMjO4YjZujA/K349PzFWQ2KQ4X5t209iu8fhjn86hAGfkVcf9Mn/p0q2R5WDJHsY9Sp25P/oJ/E/hUFwQTtkZXx0Eq4JP16fkKZKZAwInUOXKuDG25cfTkceo/Gp/PWK2+0TSLEIMszMcKB0J9sYBz6A1S1Oe3sbCe4vpPs0Ea7mlZ8qvpgdznGBisW0tZ/Ek6XerwvBpO7fDp0nWUj+KcfhkJ7ZbngCQpy6LcfAkviy6iVfMt/DocL3SS9Q9vVYsd+rY7Dr6l4gjFl4ZubezgRY0tzDHHGAiouMDA6AAVysOUljzglCFb3HY/r0/2q6vxNJ5ehXhZwCkDMM/xccVcnelKxwV42rU29TM8MvLJpcNjYubfeh3yKudqjjgepPFdgnyoq5JwAMnvXA+Dp5tM0u4vb2RZmZVCqF29Dwo9TzXeHpXn4a3Lo9R4xfvHpoDniqr81M+cVAxNbs5kRsKgYVZaq79aQyM8VVupMKatN0rMvnGDSY0Zd5JnNYtwrTSJEnLuwUD1JOK0LtutP8ACdq194s0yJRkJMJW+i8/0qUuaSRbdlc1/jnpZtvDvh2/jXjTphA+B0V1Az9MoPzrN0K63QRtnqBXrfi7Rk1/w1qOmSAf6RCyoT/C/VT+BxXhHhC4c2axTArLGSjg9Qw4I/OurFw5ZKSObDSvFo9a0S43IBmt9G4riNCuNrAV2FvJuUVNORNWOoagu6E1wusx7ZG4rvZ/mjIrkNchJJwKmqiqLtoYXhe5+xeKrCQ8K0nlH6MMf4V7LXi8NlL9qjlQHdG4cfgc17NGweNWHRgDXRg78rTIxVrpjqKKK7TlCiiigAooqpdalY2k8cN1eW0M0n3EklVWb6Amk3bcLX2LdFZGuap9hWRUeGIRRGae4n/1dvHzhiMgsTg4AI6Hn18rvviXBerdf2XazapHbDL3F7qC2SN/uxDG4cHrz0rnrYmFFXk7Lz0RrCjKex7VuGcZFLXziPiDcvZw3UWieEcSy+V5EinzlOcZbLDA96l1jxnq85l0ez0J7Y/K17qGg3bMILfgvsUHbvYZAJPy8nHArnWY072k0vn2+Ro8NJL+v8z06bHjzXTAPn8J6XP+9/u6jdIfue8UTDJ7M4A6Ic93XF+AdX06TQLGPQnjn0SEC2RlQRPa4Awki9D/ALw9uvWprrxNdyand22nx23l277C7kvuOAc4BGOvqa6niIJXZnGjOTsjrqK5JNb1jPMdiw9kdf8A2Y1P/b2pKvOnW8h9rgr/AOyGksTTfUp4eouh01FcyPE86f8AHxpMwH/TKZH/AJ7asReKLJh+9hvIf96Hd/6DmrVem+pLoVF0N6isiPxJpDnBvo4j/wBNgYv/AEICtOCeG4TfBLHKn95GDD9K0Uk9mZuLW6JKKhu50tofMkOF3Bc/U4/rVNdVgZ41Dffk2DnvkD+tMVzSooooAKKKKACiiigAooooAKKKKACiiigBrruXB6VBJbKw4GKs0Umk9xp2MyWzOOlZl1pzNnArpqayg9qzlRTLjUaOGn0aR88Vm3OgTEHC16SYl9KQwIR0rJ4WJp7eSOI8A+HjZ6ldahcL84Xyo89s9TXcXESzwSQyDKSKUYexGKdGgjQKo4p1b04KEeVGU5ubuz5surWS0tLmzlBMtlMYz/wElc1Xs5OMHoOeO1dp8QdPFp4vvAP9XfxCYfXG0/qM/jXDW+d+OjjqPevNS5ZOPY+kwFTnpWNyCQ4XeQD0V+x+v+fpWhEQrbmBVicblPB/PjP1rItGxkE4BODnpn+laVqzwnjhQOQemP6fUZH0rRGk0XwMArEdpHUKMY/4Aeg+nWsPW9RtdJtmnuSVBYRokP35HPRVjPVj2HJqxrur2um28EZikkvrg7bWyjAZp2/2eQAB1LZAUcmsyy0a5S7/ALU12RLjUdpWNVJMNqp/hjPUHpucjLew4qrdWc6k78q3KGnaZPqN5FqOtogkjO+208NtW364dscPLg9eg7ep6SFJFLJg/Od8e7Gdw6jjjv1/2qTeCvz8Kezcr+Y6D61u2lj9q8PSmJP9Ijk8yPB4JA6D6jI/EURTkxzmqKu+rMhX/eRuAGRhg+47fzP6V03igxSaBN5yg7IS4LHrgfzrm4gssqhMCOXBUj36/rz+IrqfEiCPRpTIgPlLu6fdI71M9KUjCv8Axqa8znPCmoM8UAutOdIUIYMSGyRnBA/Wu+hkSaJZI2DIwyCK4fTIGubK2WRmCPKFcodpwT2ruLaCO2tkhgQJFGNqqOwrgwrbT7BjUlLzEfpUGKnfpTBXScRA/wB2qrmrk3Q1RkpFIilbg1j3z9a05jwaxrxsk1LKRlXTda674RWJk1C/v2HyxoIUPueT/IVxd4+Aa9d+G1gbHwrblxh7gmc/j0/QCtcLHmqX7EYiXLD1OprxHxN4fk0fx1emBT9kvz9rTjgMT84/Pn8a9uqnqNhDfCMyqC0Zyp9K9CrTVSNjipz5Hc860y1kVlO0iuvsY32DIrTj06JBwoqykKp0FYxw9jSVbmKawkiqN3pYlJJFbwUUFQa09iupmptHPW+lKh+7W/bjbAi+gxShAO1PHArSMFHYmUnLcKKKoT6zplvq1tpc+oWkep3ILQ2jTKJZAASSqZyQACc+1WSX6r6hfWmm2cl3qN1BaWsYy808gjRR6ljwKsV5fP8ABzS9W1m51Txhqmp+JZzK8lrb30xFtbAk7VWJcA4GAc8HGcUAbtj4ttvGETL4Mv4p7RXMc+oIPlRh1VAwwx/2unIxns250jT7aF4oVMszcvK7FizepJ6/jWf4OWHTNDGmW1ulo1v8hhVQuwj7wwOOua0ia8itX5+n/APTp0nTdk/+Cc7cCK4trzRtdZ/7NvoVthKpO6HYxZPrgnjPbA7c8zP4J8T2NnHDYH+2o7ME6dPaXEdubc4PLoy5Y+24/rXe31nFdxMkqghhggjII96wGuJ/DtxHuZpbF2C7WOTH6YPcfWvKxSnKPvRU0tbPRr0eu/VNdWr20N3BPWGjOJ1HQvE73GItM8TqL0AapvKP5uAB8pAA6ZHPtV+38HeKrrV0ll0iAaZHEYYm1Fo7XapA++ICCe/UGvRJ9QllgV4LiQIRkYc1zV9d3Nzex2ds5kuZTgFm4Axkkn6V4NDNKFaao0cO3LVayt+KV9Fp000NY4eTjzSkkvT/AIIWun6d4K8IanplndC9v7/PmyIpC5xhUQZPTP1P8rvgPSJtO092nULJK24r6cYx+lbOh+GbSBFlmm8+7x8zv/Qdh/k5rolswqgKVwK+qoUK0v3lVpt9tkuy/wCCc0qkIXjEpIvHSnbavC0btij7K/oK6/ZSMfaIoNGD1FR+QuelaX2ZsZOKb5OOpUfjR7N9Rqp2ZR8gEY21Xl0u3kcSNEFkHIkT5WH0I5rWYRoPmkH4VXkuo1BCDd7mpaUd2NSctjI1PULq3tBYXztPDLPCIbgj5lIkU7W9eAfm/OqFlIzzaVk/8vo/9GKaZ4rvwunzqvzSYyMdiDkfrT9MwZtNHdb7B/76Q134Oq6kWn0OPF0vZuL7npdFFFdBiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABpKWigAxRRVNdU09tWfS1vrU6mkXntaCZTMsecbymdwXJAzjFAFyiiigDzv4vWf+jabqKjmGUwufZhx+oryi/Qx37kcb/nGPf8A+vmvfvHGn/2l4V1CADLiMyJ/vL8w/lXgmot5sFrKO4Kn+Y/rXn4hctW/c9nKqmvKWrVyxB7+o/w7/Sk1HWxaSQ2GnwJdapOMxW4fagXOPMdv+Wajp6noATWFPqk8tydM0ZUl1HAMsj/6u3Xsz46t6KOT7Dmui8OaXBpcMu13luJjvubqX5nlb1cdh6AYAHTAoWmrPQqvmdok+haE1g813dzfa9XuV/0i4ZAMr/cRMkBAeynPqSeauzNsB2kooP8AvL+XVf5Cr6KUXYNu09EY5U/7p6j/ADxVS6YMw4IfsrHDfgeh+lN6mcFbRFYOoO9125/iU5B/H/EV1vhJlNnIqY+9kkd81yAXDnbnd3xwfxHQ/Wu58IWqLYmVD87n5uMfpV0fiObHteyKFrpCprsiBcQA+fH+J5A/HPHuKd4rivZ9Kuba0DN58fllgM7eQc1t6rCY1S5RC0sJ3Db/ABD+Ifl+oFZeu3ROnXIs8yO0TPhDjAxkn6U8SuSm7HDQqyq1YuXQ53w1uszJLJeyXEFvlhuA2+ma6/QtVi1T7SkeGaAqGZenzDOPrXEaH5J0QmSVUjkZF3E9csM16dHFEgYwoihzuJQAbvevIwvNJttnpY7li7W1Kkq4NRirE681A3Fdh55DOflrPlbmr054rOm+8allIrXDYU1i3bcmtS7OFNYt23BqGWigsDXt/bWifenkWMfia+gbaFYLeKFBhI1CAewGK8e+HFkL7xckjDKWsbS/j0H869lrvwcbRcjkxUtVEKKKK7DlCgU1zjBpwoAKKK5Xx/qfirT7S0j8F6Fbare3DlHkurkRRWoAyHcdWB5GAQaAOqoryOH4Wa14mmS6+J/iu81MBg40rS2NpZIQcgHbhnwejHBr1ygDz7xt4c8beI9bNtp3iqHQPDXlqWaxgJvZH53LvJwg6EMvPtVrwT8LvCvg+5+26dYNc6sSS+pXzme5YkYJ3t93I/ugV29FABRRRQBz3iDw6L2Y3unutvf4+Yn7s2BwG9D/ALQ/EHisCzu3aV7W8ieC8jxvifrz0PHBHuOK7i/vINPtJLm7kEcMYyWP6AepJ4xXl+oz32p+ILXU5FeNTlFizxHHg8HHU55Pv7AV5uNhCPvLdno4OU5rleyOjIrO1vT01GyaKQfSm2SXWsatPBDctb21uoMjoASSegGc+mTx3FT3Gm3UTEW2qlk/6bQhiPoQV/XNcPI2r9Dq5lGVr6nFH+0tMXyRmaLse4/D/D8qk0X7Yt+955TKduwZ7gnn+QrqDAkUSRDLKgCgt1NQPx0rhjg6NOq6sY2bOlTurFmPU3x86c1KurAeo/GqS8ipo4VbtXWmzNxj1RcXWBn/AFjCn/2yo/5bNVX7Iv8AdpPsa+gquaXcjkplh9ZQ9ZHNQvrEfoxpv2RfSqN7CEBpOUupUYUyxLrgH3E59zVCfVZ5cjcAPQVlzfepqZzWLmzqjRitUTXiNLCSxJLMq/mwFdHZDZcQluqamgP4lf8ACsaRMWIY9njP/j4rWmcK14QcFLyKbHscn+le1li9yTPEzN3nFHpdFFFdxwhRRRQAUUUUAFFFFABRRRQAUUUUAFFFYcvi/wANxX5sZfEOjpeiUwG3a9iEgkHVNu7O7260AeW/tNrbufAS30unw2p16MSyajEJLZV2nJlUsoZPUFhx3FcR4V8Vv4P8K6lp2m3U8FrceKJYbTWbGWG2011cZOGmimSGFcDhQ3I4bGc/Rdv4r8O3MNtNb69pMsNzcfZIHS8jZZZv+eSkH5n5Hyjmll8VeHobG5vZtd0mOztZzazzteRiOKYdY2bOFfkfKeaAPA/DvxR8Vaj4c8KnWdYi02wudXu7HU/EMcEX7lYlUxAl08pC5YruKAfKOBzWF488U6n4e+LF/q3hXVG1eNvDkCT62qwXBgtzdLvuAiKsblcBcBcc5PQ19K3HjHwzbaZa6jc+ItGh0+6LLb3Ul9EsUxU4YI5bDYIIODxWH4e+IlhqviHxhY3ItbLTvD32VjqUl2pinSaMuHyQAgGBzuIOe1AHXaRPFdaVZz2939thlhR0ufl/fAqCH+UAc9eABz0FW6xB4t8NnRzq48QaQdKEnlG9F7H5Af8Au7923PtmtDTdSsdU0+O+0y9tryxkBKXFvKskbAEg4ZSQcEEfhQBadQ6MjDKsMEV8pa9c3NzPeaRpB2CzuWjub7GVhIJGxM8M/wCi98nivcp7++8dTyWmgzzWXhhGKXOqxHbJeEHBjtjjhOxmHuE5+YeWatp1tptzrWn6dBHb2lrcskUUYwqKH4ArkxVlys7sB/ES9DM0Cxg061WC0QqudxOcs7d2YnkseuT1rqLZ92xuQ/Zl6n6Dv7iuesj9Px/z/n8K6G1B2A43AnoeNx/o3+fpgtT36qS0RoQOMADYA3rzG/8Ah9P59ahu0BG3GOMmOTn8j/8ArH0p0bY3SRsCufnDDj6MO31/Oopn3ZRQRgcxOeR9D/n6iqOdLUrrkHC84H3H6j6Gu88MMBpURQEE5JU/XtXDrhmIHJB+63BH+f8AOa9C0SDy9MhQrhwuSK1oL3jjzF/u0vMs3NwBHj8CD1rjdWjv7Sa6XToi4eMxLhd2Fbt+ByK6vUBujX1B4PpWT4glNtp0043BlQ52/Ss8bJqLOPB2515nKabolpotpZyXAEk1q0XnHqEOeePbNd7oOoJPZ28TK0crISob+IA9vwxXCafI76Nds43HKMfp3ru9C0pLSJbqY77yVBlj0Reu1R2H868vDSlOo5LY9TGxjGFpbl6cVXcVckGagZeK7meamZ84qhMvNatwmRVGROtQy0Yl70NYV62Aa6HUEIU1zWonANZs0R3vwetALPUb0j5pJRED7KM/+zfpXodc/wCA7EWHhTT0x80sfnN9W5/kRXQE4GT0r16MeWmkebVlzTbCivKNQ+M1lf3kmnfDzRtQ8X6kp2s1ovlWkZ/252GB25AIPrXW+Af+Ewks7ufx1/ZMVxNIGt7bTtxECY5V2b7zZ7jjr+Gpma3ifWYfD2g3mq3Ntd3UNsoZobSLzZXyQMKvc815p/anxS8b8aRptt4H0d+PtWojz75l9Vh+6h9m5969fooAzPDOm3Gj6DZ2F7qdzqtzAm17y5x5kpyTk4474HsB161p0UUAFFFFABRWFq3iKO0uzZ2Vu97eLjeiNtWPv8zc847AE+uKoY8RX5LS3cVjEeiQoM492bJz7jFZSrRTstWaxoyau9EdTNLHDG0k0ixxqMlnOAPqawrrxZpyArYl9Ql6Bbdcqf8AgZ+XH0JrNXw5p6P52o3Ml3N/elcufzJNWzNawALZwKuOAcVhPESXZfibQoRfd/gUpoLnUbhbzW2VUQkw2iHKp7k/xH3P4Ac02QDY20ADsKlkdpGy5yaaeRivOqT53c7IR5VYyvB9x5Wq6zbsQrSBJF9+MH+Q/OtR+9c5qtvc2OoR6lYxmSRMq8YON6nqP0B/Cmt4uth/rbS8Ru4KD+hqXK8Uuxq4Ny5o9TUueCaoymoIdctL4Ep5iMOquuDT1kSUZQgisZG8E1uTwrkVft15qnbnBrSgAIqooibJlUEU7YKFGKkFaJHO2QsnBxWPqakA1vYrK1NcqaUo6F05e8cLrGqR6fMiyW19MWGc29s8oH1Kg4qgniW3Df8AIP1j/wAF83/xNdJcL85qNF+audW7Hf73cpXHii2/suUf2drYwAcnTZscEHrtqze+LLZob5xpuuDdDG3OmTcEDqTt6c1r3CGXRruMfeaFwPrtNWkK3NjKAMiWxGPwI/wr28uatJLyPAzFPmTfmdN/wm9p/wBAfxJ/4Jrj/wCIqtqPxF0nTbOS7v8AT/EFvbR43SSaRcKoyQBzt7kgD3NdZYS+fYW0v/PSNW/MA1x0B/4TLxd9ozu8O6DOVhwflu75eGb3SHkD1kyf4BXachxHxK+JWq/D/wAYax/al0W0a/0NrvRonhQeVeJhTGTgMckhjuJxnA9KbB8Vdf0C3sNAvNEvvE3ii30uK/1JoYpEbfIciJEggcbgGAy2xePvZr0/xd4K8PeMG08+JNNS+NhL51tukdNjcZ+6RkHA4OQcdKZr3gfQNd1Uanf2kyaj5JtzdWl5NayvEf4GaJ1LL7HIoA4VvirruqeItb0Tw94Nld9OtoJ5rq7v1tzbCa380GSJkLBlJClQG6HOOhwPBnxh1q1+G/hG88Q2K6vrevTzw2jws4MyxyMHeRIYGKbRtAWNJC3U45x6/ong7QdE1LUL/S9PWC61CKGC5bzHcSJEmyNdrEgALxwBnvmsmH4XeEYNIg0uLTJksraf7TbIL643WsmSd0LeZuiySSQhUE9aAPNdb8c+JNX8bfDCa00vU9FubuXUo7jR72eW1iuGjjTYXJQFk5yGMeRzxmtDT/jlf6xLolp4f8GS6jqmpQ3Lm1/tOOLy5IXKsu91CsuBndx9K7y7+Gfha7aweezvWnsXmlt7gandLOrygCRjKJN7FgoGSTwKs6N8PvC+i3uk3el6THbXGlQyW9mySyfu0ckuCN2GJJJJbJ560Acfd/GSG08bWOiHT7a7s7vVBpQvLG6ml8mYnAEm6BY92SMqsrEe9HhH4wTeKdes4tM8KanLoV1dSWq6lHHO3lbeBJIPJEaqTxxKxHcDpXSL8LfB66tHqK6VItzHqH9qoq3k4iS6yD5oiD7ATgZwuDgZ6Vcsfh94asNTN9Y2E1vIbn7Z5MV5Otv53/PTyA/lbvfbQB1VFFFABXhOv/B/XdRfXTFdaUPt/iiDW498knECKwKt8n3/AJugyPevdqKAPBr/AOEHiM6ze6rZ3ekvOvi1PENrbyzSKjxDOUdhGSjnjkBhSQfB/WhoepQ3kenzanP4iuNbtLi01ea0az8xVClX+zvlgQeCuOBz1Fe9UUAeN6J4A8a6R4j0DxPe6ppfiPW7TS5NNu0vZXtk+aVpFkjkWJzuAIQ5QZA96zvFHwf17xBfeMb1r+wtJdWvtO1C1ijnlKlreN1eOVwqsFJfIZcngHANe60UAeHah8JLu6spnh0aws9Sa+W+juLfxNemaOYIR5xnlgcsxJ6bB0GSa7bT/Bmqal8NLfw542165vb9hi7vLJhGZRvJCElfmXGFOR8wHPU13dFAHIweDJ7eGOGDxX4iihjUIiI1sqqoGAABDwAK8Y1Tw7O2oeJHOu6u4jnlO4tFl8E8n937dsV9K143Z2purbVyPvTmbB+ua5MW7cp14S3Ndnmltos27A1vVB3GGj6f98e+fxrWh0O5jyv9uasAwAI3xYI9P9X+R/CprQFgGUgEfMD6f/W7fStSFxs2sMLnGD/Af7p9qxUmfQVIIpLoU7Zki8Q610xkNFlfqPL5/wA/WootHkW4idtZ1OQo28Ru8WyTvgEICP0/rWqzNGx+YqR/F1x/veo96ecSfK4COex+63+fUU+YyVNLUkt1Z5kjZdxJwDjkV6VbgiJeMgDqO1cR4ZhY6pGsqb0UEjPUfQ9670RlFBTpXTQWlzysxneSj2KWoSlE3hd+OoHeuQ8SaxcG0vLe3gH76Ex/Ofu7u9dhdgP06Z5HpWLqtvaLvkuotx2n1/p2rmxsnHUnBcrklJHK6FdQzaRcW8sNwlzIgiKhcgH1z6c16haMzWqb9u9RtO3pkcf0rzyHUWvdPn+zRRw+QF8pEHUA/rUugaj4gslka9tLk+bK0ro8Z4yeg9K8qhUjTk2tj1MVQlVW9n5/I756iY0M5aNWwVyAcHtUbNXonlEUvQ1Sk71dkICkk4A5JNef6n8SvDcOtQaTYXMurahLIqGLTYjceWCcFmZeAB1PJIA6VPK3sUmludFfrmM153418QaVoUJOqX0NuxGVjLZdvoo5P5V6TcgMprg9T8LaOmsXGsDTrc6lMVZ52Xc2VAAIzwpwB0xWen2jTXoegfDfxvqnia7tYLTwjqdj4bitgo1S/ZYWkcAAbITyVOD82fTpXpFR2zrJbxOpBVlDAjuCKkr2VseWyGztbeygEFnBFbwgkiOJAijPJ4FTUUUwCiiigAooooAKKKKAPOfDd/KYZ5DjzJpnkdsc5LEmtVp3c/M7H8a5K3u49O1fUbKZtvl3MgGfTcSP0IrZjv7cjPmL+deDKUr2bPa5Fo0i9L8w6msy9vnshuMTSL6LjP60+bVLeMZ3Z+lUpdThnUqVGD61BSizV0y/hv4PMgbODhgeCp9CO1XkRn4UE1w+jXIt/EcYjP7qbKOPXAJB/DB/Ouw1DxLZ2ERCbEwOSTVxSe7JnGSdoovHT5ZI8lMiua8QwJFEFRQGY4JqC48X3bA/Z7e4kT1A2j9SKyLzxA9zH/pdvJCP7zDI/EilJx+yXShNO8ivoulDVC0kkjxxZ+VAcfnWmdCu9MlEttK0kP8AEjnOR7Gs3RtQW1uzYuQpVh5MmeHBAIU+/P413+lXsVzH5FwBnoCa+HxGLxtHGuMp27J7P/hzrm+WPPFXXUw4HDAMOBWnav0BqLVtNktWLwjcvXArETV0V9pO1hwQe1fT4HGxxMdrSW67f8DzMXFTV47HXKwqQYxXKjWkXq6/mKU+IoR1ljH1cV6SmjB0mdQxArPvhvBxWDJ4lt8f8fEQ/wC2gqnL4it2zi5h/wC/gpOVxxptO5Yurdi5xTFt2XkkVmy60jZ2yqfoc0i6hJIOFlI9RGx/pWaptvRHS6iS1aN2KQIu0kc1JpjKbWxjQ/8ALq8P1K7h/wCy1z3n3RBMdvJkDhpBtUfh1P6Vfv8AU7bQ9G0zUZ2fyYk+cIu5nYsy7QB1Ys2AB1Jr1cBTnFtyVkePmFSEklF3Z12taldPpmieGtCmaPV9StVLXCcmytlUCSf/AHuQqZ6uw7A11ujaZaaNpVpp2nQiGztYxFEg7ADue59T3PNcr8LNJmttEOraod+s6kFM/ORBGmVjgU/3UGfqxZu9dtXccSCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK2pXC2mn3M7HAjjZvyFeTzTf2f4ZuZFOJCm1T7txn9c123xKuzbeHRGpw08yR/UdT/ACry/wAR3DG1tbYZw7FyPoMAfqa4MTK9RRPSwFPmkvX8jI0eQRS+VLhT2J/z07VsSwFfmjGW+6VPcf3T/MGs65s2ZVMIzJGOo7//AKzn8jV6yu/Ot1DfMQNuM/eH93PqOoNSj256+8gjZSFyx2dFcjlfY/5/WnhWjJQLlT1j7fVf8/lULZDl0G8MPmXH3x6/Uf57V1HhnTFZUuZ8SW5+aIdcj1pwi5OyOetVjSjzM1vC9i1tBubkuc7T1UfWuoCLgMhzmqKQjcHj5B9Ktoe4P1HrXfGPKrI+dqVHUk5MoXibW3AgViahcQK8ySuuHt5QMnvtJrob4B3VeCp61xvijQ5Ltg9usboVxtZ9pVv8K4sY9DpwaTmuZ2MLwoEl01isqAlD1OCDivStM1OLUbUNGx3qAHHoa43TNM00pawSxpc3G1jLInQHso9cVia9H4jttFjl8N3MWmQzIVS6jhE+wGQliyHjOOhrycNL2c326nq4qKr7b9P6+R3/AIg1nTdCsmu9Zv7axth/y0nkCA+wz1PsOaZp+oWup6dbX1hMs9pcxrLFIvRlIyDXA+E/hr4duDHrWty3niXVCSDc6tJ5oUjqEj+6B6A5x616A+2JFSNVVFACqowAB2FejeLV4nl8sou0jm/Gvguw8YvaLq93qIsYA3mWVvcGOK4JxjzAOTjBxjHWrej6FpOgWn2XRdPtrKDusMYXcfUnqT7mtIy+9QyPwalydrFqOtyCU8msjUUyprTlbms68OVNYs1R6H4FvjfeHLfd9+D9w3/Aen6YroK8++FdyfO1S1J4GyVR9cg/yFeg16tCXNTTPOrR5ZtBRRRWxmFFFFABRRRQAUUUUAed/EXS7SbUo7goY5zGu50ONw3Y59Tg9aw20K3jigZJ7j52dTyvYn2+ldR4/Ba8jA7QZ/8AHxWTN8sNqv8AEZJP54pewpy1cUP6xUjopOxUGhWYvL1JDcSJE6BQZSODj0xmpLGws0iiH2WA4EuSYwSeD1q+R/pV+f706L+QFVY322bydliY/ixwP51UaUI7JESqzl8TZgassWnaZbXVvbxrOJGAZUAONmOT6ZIrS8N+H45IlvNQcyzPzk84+npVmW3SV7O2lUMpjYup9GP+AqGxuX0a7NnOzPZ7sRSt2z0De/8AOvPxtBp+0itD0MFiLw9k3qdRFDaRLtWBSPcVR1DTre6idRGq56YFXEdXUMhBB6EUjyKjxqxw0h2qPU4J/kDXnuV9DrV07nm2oaP5ErxBQELAEemeAR+g/KrOjarLDcrZ3zETD/VyH+P2PvW/4jtWaUuq5bG5R6sOR+oFYPiWyW4torq3IZXUMGH86+dzelTlONOqtJ3s+z/4J2U5tO6PQdI1JbhBDc4PbJqpqug2iXBnkto5I36ttBI964/wrf3FzA6y586Egbv7w/xrv9I1FLiPyLg+3NeRhsTVweI9lUdpx+GXR+T7xZliKCs5wXuvdGfaeH9Hkb54YQOxCirw8NaOPuiIfgKoa/pdxB+8sZQgJzypYY+gIrBKap2u4D/wBv8A4qv0DBZvRxMbTXLNbrt/mn0Z5TwtR6w1R2Mfh7Sgf4Km/sLSl/uVxITVe13B/wB8N/8AFUeVq+P+PyH/AL8n/wCLru+uUu4vqlXsdqdL0dPvBDTmh0hVARUBrgJk1TveJ/wGPH9TUIhvT/rL2TPsFH9Kl46kilgar7HW6yLTyHWMpjHFeeaEkniLXtOuZQP7E0q9eO07i5ud/wA0n+6mSo/2ix/hBqv4l+0XNzbaJYX1yt/eAvNMrD/RrcHDSdOGP3V9zn+E11Hhq3hs9M0OztEWOC3lEKqBgDDAf0rehXjWehhiKEqK1PR/BzbvD1uf9uUflIwrarC8F8aGqf3JpR/5EY/1rdrZ7mK2CiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzz4wyMlto4H3TcNn/vnivO76TztUTP3YkAx743f1r0z4uWzT6RpzoOUuxn6FWryqc7L255+7z+RxXnVl++Z7WWK6ubtisYtQzEgPyT7Y/ntwPq1Yl1P5WoswyqyYMgH8B7Y9xWxOyrFtXuNv4FgD+gFU7XTru4SZntJ8SsTnyz+BFKTR6MGlds0LKwu7xN0MLspOSVHQ+o9v8+tdTpdvNo0ax3bZt5Gy+DxCx6MPY9/fn1qDwLcXENk1tdxSRvbNtG5SMofr6c/hXWSxpNGUZVZWBAB6H1FddGCtzI8THV5uTpPZD4E8tNyng9R6e9SEAHcv4j0rK0qdre5axnYtsG6FmOS6eh9x0/KtVvlz1KkfmK3PPKdywVyW4Q81ku0F8mpKzBhFDlfY1pnLbg3OK5HxSssck4hd4UkRVypxuHORXDjWlHU7MFHmnZbmZ4J1K03rJLdRI69Vc4z+ddl4fu7ebTClrJ5kcLuise67jg/T/CsjQ9Pt7exsIrq2T7S0R4KjIxnBP4YrHh8RLbaj/Z1gIl+zxFZsjq+84AH0/nXj0ZRozZ6tem8Q3y7/wDDnbSOqDCgAegGKoTuTk1HZzzXFssk8Zjds/KRg49asCEv2r0E+ZXR5zXK7MoEnNLgkVoizJ7VILLFLlDmRjSocVk35wDXWSWgxjFc3rtv5YOBWclY0i7l/wCFRzr+oen2cf8AoVeoV5n8JWC6nqiH77RoR9AT/iK9Mr0sJ/CRxYj+IwooorpMAooooAKKKKACiiuW1rxasWpPo/h60Osa4uPMhjfbDa56NPLgiMf7OC57KaAMn4kX9rp8zz31xFb28dspeSRtqqC5/wAK4mGTV/Fk8C232jRdFAZvtLLtu7hSScop/wBUvuw3egXg1evdCu7vxW95rMn9u65AVCeVHstrH5c4iUnAI3H5mJc+wOK6iDRNVkDLut7WNhtJGZGx7E4A/I1Mq0Y6AqUpambZQx2GnQxQ7/KhQsu92dsdFBZiST05JzToka5torXTomu2d18xoz8iBexbpnPbk+1b8Ph7TYDv1CV7x/7krZX/AL4GF/Srr34jjEVnGsUYGBgY4rCpi7Lt+ZtDDX8zlrnS9Ytrt7o/Zd7dIsM2BjAG7I/lWXere3dtNbmyAaTh3Z8oPp34+grsHkdySzEk1XusiByvXFcMsZU1s9Dsjhqel0VdFgvLyz22bQQwRExmebLbiDg7VBHfIySOnStOKxtrSUzyTyXV3t2qzgBUB67QOmfxPvWT4SvA2ly22fnjlfP4sWH6EVpGslKMYqy1NZxk5O7KupRiaM7uvrXOSabOEeOGYLExztIyB649K6i5HyGs1jiuStRhWXLUV0dFNtLQz7LTY7OILGzbs7ixPJNXSrA+ZHw46gd6N3NPQ81wZjllPG07bSWz/T0NY1HEmv8AxZZ6Vpo/tFZJXkOyKCIbpJW9FFcRJ4iu5b63eXTY7e1nmWDatxukRmOBkYx+FT+ItK1J/ESX9rZfbYPs4jjVXUGJ92SfmI6+o5rQ0Pw1cPqEWo60Y/Mh5t7aM7liOMZZsDcf0HNZ5dl0qMYSrazS3v07ab/MyuoSbhpc0BbSf3jTTbS9y2K6ARj0qKdQFPAr1+Qftmc66MvUmszWtUt9H02a9utzJGAFRRlpHJwqKO7MSAB6mtW9fDGuMtN3iDxD9ukB/svTZGjtUI4mnGVeX6Lyq++4+lSkt3sjbmdrLdnQ+C9Gkt0mvtTCtq18wluSpyseB8sSn+6g4HqcnvWjEPJtEccGHUJePbzAR+lXNM5AqtfDZb364+7d7h+MaH+ea9HL5Xq+qPLzFWp27M7zwgf9Cu1/u3Un9D/Wt2sPwn/qdRHpdt/6Albleq9zzFsFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHGfEm5UW1jadWeUy/QKMf+zV5oulvcahePOwt7UMd0j98nPHrXV+P9QEviWRT/q7OIKfr94/zH5Vw0l7PqMuZ2wudqoDwO5ry6rlKq+U93LoNQujpItRtrYhLCDe3J82Tk/h6Cn/23qDkhZiuCRgDA4//AFVl2a4+bHBbp7D/ACfyojynlAnJwQf++TUqlFavU6nGL6G5b+I7lGH2oLMmduSOenrXRabq0dxGNjZIOSufmFcBL/qj/wBdQf8A0GiO4a3klkR8MnI59qGpw1psxqYaFRbHoer/AL0RXFsB58Lbkzxn1B+oyKv2t2s8AdTlSN6/Tv8A59q5fT/EcE0flX2A4HDr1rS0qfMgVOYnYlD0z2OPx/nXZQxKqPlaszx6+GlR1exfYHe3PI4PvWRc3c097Nb2JiaWJDIdwyFwP51rDPAOcgbT+FYUkE2ki9nttsryq2AxwQW9ajGxTSuVhLc3mYvhLUJNT1E3Tyl8uc5OcdsVu+HtPtIo7toooWuFuZVklCjc3zEgk/p+FYHhvwzapaIpvJI72QkssMmFH19zU+k2V/a6zcx6KspWEqsm7lWBJb5s9+TXjUbU5t73PYxEVVuou1vkjsUtcnpVqK1xjIxVqF4pE3RSJIAcEowIzTiQK9SyPFcnsMESgdKZIAOlPZ6gkagEV7ggA1yWvMXJrqLhjtNctqwJc5rCZ0Uyr4JvTYeLrQZ+S4zAw9c9P1Ar1mPU7CXVJdNjvrV9RhjEslqsymVEPRimcgH1IrwySdrO/t7pRloZVkH4HNbMNzJo3x+17W73TdZfSbzRreGC6tNLubqN3BBIBijbtXZgpe64mGKWqZ63ZanYX811DY3trcy2knlXCQyq7Qv/AHXAPyn2NW6+ctYfx29/rpH/AAlS6G/iyEym3W4E403ad32cD5wmcZ8sZ/Wsvw7r3iG+8Oa0tgniLVNPbxdPaxXjXOozS2FqqjaSkMizuoDfc3devOK7TlPqGivmfwjD4+1FvAtlrsni5bQahqkN/ITc2zm3EaGEzODuA3FtrMxPUA8Uvgc/EiH/AIV7dzjxNJf3MOp2+pJqHnmFNin7MZkb5UOcYcgFu5NAH0vUN5dQWVpNdXk8VvbQoZJZpXCJGoGSzMeAAOSTXzPoNv4+GgX1xeav4wGvtpOoJcaedMvNpm8uQxutw0piD7tmzyFBPA29TT5NE8a39mNLnXxTcW2p+BWa7S6muWQ6kN21CWOEkO1QU43AkMCGOQD6D1K3i8S6LCNP1eaGyudsn2rTpVzNEecLIM4DcfMuDjoR1qzomkafoenpZaRaRWlqhJCRjGWPVierMe5OSe9fODWviLTvh54OGgt4pSWwsz9u0KW01eI3M4RQVWeJQ0YHO1dyxZ9s19FeFnuZPDOkvfWktldNaxGW2mnad4W2jKtIxJcjoWJyepoA43w3dSyWqzu376dRNI3qzcn9TWw08rDl2x9axLNVtdRu7dBhIriSMD0G47R+RFa2QO9eA3JNps9qUU7NIUknrRUE1zFEuXcD8ax9Q14RMI7dC8jfdUDLN9BU76Iai7XN+msNykHoa52FNXuppBJcRWmzGVK+YeVz2IA/M1a0a+uXn+zXm1pNiuHTgEHPbsePetZUKkI80lZGcalOT5YyuzNlZ9B1hrhwfsc2N7f3SOh/ofwrcn1e0hh82SVUTsWOBV6SzF0hSSLep7EVQ/4RaztmEv2RFx0O3pWfLK2hs6kJfFuZ8esy30pS1tpPKH/LVxtB+nf9KmlOOpqLWL+OxhYJhUUgYUcsT0A96wLRdQ1Kc7WEMZPAzkj8T/hXJiMTSw6vVla5rGN1dI3t3NWYOTVRdE1W1ZZC8c8PfsR9KtwZHUYPeqpV6dVtQd2ibprQ0YV6VbRMiq0Bq4ldcUc82II6qXq4Q1og1Xu1BjNW46ERlqchfD5zVH+KtbUYwCay2HzVxzR6dN3Rs6Z0FN1UD7NqA7+Yj/nGR/7LTdNPSmatkSagAeGt4nH1BkB/pXfl7tVR5mYL92zufB+TaXjHq1xu/ONK3qw/CIxp8ue7of8AyFHW5Xsvc8lbBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUN4/lWk8mcbUZvyFAHhHia8N3e6lOp/wBdcMB/u5/wFZVkOUPsT+Zp14x8iLPVmLH8j/jUVnvl2iPhcYJxyfpXk03dX7n1OFjy0jVN9HDGi5LSDI2qMk8n/GovtNxKQYogm3+/yeRjoM/rUttbIhwqlmJ52/8Aszf0/Sr0duwT52WJB2Xt+J/wFajbijLFncyZMkrjnOOFH9f5U0WKOW3Tbz3Abd/LFbiWiMBtiaXHOW5H4Fv6UsoaPh2giHYsc5/DijlF7V9DGW0iXlVlLfQj/wBCrq/ChItZURH3wuJEHHfr0/zmsS4HQiSQ/wDXNMg/of51Y0S7eyv42VJdrHa25uo/OrpvllcwxUXWpNHfkqwWVDlJB+RrJMMV9qk9rN8yLC0jL24HFakQVCYgoEUn3QOx9Kw9V1BdHvvtMwYo8bROFGTz3HrWmLS9ndnjYW/PaO5xWh6gmn+IrixM372OYMiFvmZSM4Hriuj8dSoohi0u9Ntc3syC4jifBljAOS2OmOOe9cPp9i/iLxB5skDqktx5jMRjyo14HPqQKu6X4w8BQazdWI1KKxvoZWiZL5GgzgkAhnGCD25rw405L3o38z3K04KcZTdn+Z3Pw/3QXOq2yf6hTGyj3wQf6V2Bya5HwPJFJd3TwyxyxTDKsjBgcEdCPrXZ7cCvQofw0eXjP4zZXYYqJxViSoGq2YIp3A4Nc1qi8k101z0Nc3qfQ1lI3gclqo4avafBtz9r8LaXLuDHyFUkeqjaf5V4xqeOa9I+EM/meF5Iic+TcOoHoDg/1Na4OVp27k4lXhc6rWdI03W7P7JrWnWeo2u4P5N3Asqbh0O1gRnk81JpmnWOlWUdnpdnbWVpH9yC2iWNF+iqABVqivTOAKKKKACiiigCtqaXcmn3CabNDBeshEMs0ZkRG7FlBBI9sisHw74oa61D+xtftRpfiBFL/Zy+6K5UdZIHwN6+owGX+IDjPTmsvxFoOn+IbD7JqcJdVYSRSI5SWGQdJI3HKMOxBoA5Dxdp1zBrs8unsmJojcukjFcMMKcEA9cA49c1lw2urXcKObiCJGYLxubqCfaofEGqal4V1axtfFtylzpzwyw2+tbQm4HbhbkDhGyQN4wjZ6KeK3rRxHpdoRg/K0nHfC4/rWDwlKT5mjZYytFcqexgrps0lm8lzdksCmPKTbncR/eLdvTFXP7OgthZNFGFdvMLOeWbBGNxPJ/Gp2YrbqnrJEv5DNT3ODc2sY6iHcfxNbU6FOn8KsYVK9Sr8buMR2NxdMeuf5JVfQbu3gvLm+uMPGcRQ/7q8Z/E7j9MU66ZhBeNGfmIkCn3+6P51z/huwk1ieOCQSQ2VuoVlOVZiO30HT3+nXmx05JRijrwMIvmlLodHdeMoUd1tlZ3BwVjUsR9cdKqS+M7nBW6s7pEPcpn9Ac10dtYabZKqwW0YC9BjinagYrqFkaCLGMZ2157btrI7U4X0ieaeIHXUYYnVg8TyHGDnnGQf0apvD2qM8i2d0dl0g+Rjx5o/wAacbFYvEFvCCfKd2cp2BGBn9f85qfxdo4z51upVhyCvBB9a+RzirQqV1hK2l1dPs/63O+m3F3idro+o8eXNyOhBqbUtPB/fQcg+leeeG9ea4kFtdMBdp0Y8eYP8a9E0fUFYeXL0PrXk4epVwNdUK7s18L/AK3i/wCtTKtTt+9p/NFKBsHmrqyLjqKreILGcKZrBVZ89GYqCPwB5rCGna/KAVWBAfVWb+or7jAVpYqL5Fqt12/4D6M5Z1Kas5Ox1AmT+8PzqKe4j2/eFYKaD4gbkyW2P+uTf/F1MPDWtuPnmhX/AHUP9Sa9H6vW7GftaP8AN+BHetCxOWFZxa3VuTWsfBupS/evmT6Kv9Vpt14NisrWS61XVzBbxjLyyyrEi845OABUfUaj7GqxtKK6lOG7iXAQGo57hbv+0nQ/JHbrFkH+LcSR+HH51WmHhG3XH/CU6ZN7NqaMP1as+HxF4et7XUoI9Z0kJ5SlALuPk5IwOfQCuvC4R05qUmceKxcakHGKPWvCgxp757sv/opK2q4jwz4y8Mx2DCXxHoyncuA19ED/AKtB/erY/wCE18K/9DLon/gfF/8AFV3M4lsb9FcL498dXHhzWvCul6Vpltqdx4gmkhhklvTBHHtVWBLLG5IIbsKy4vizbLp97/aNnBpmrafqkWl3tpc3MjIjyZ2MkkUTlwwBxlV6HJWkM9OormbHxzoF/ql1YWV1cXElrK8FxPFZTtbQyIMur3ATylIHXLCpvDPjDR/E7H+w5by5h2s63JsLiO3kAbadkzoI35/useh9DQB0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZviWYW/h/UZD2gfH1IwK0qwPHhx4R1Ij+4B/wCPCoqO0WyoK8kjwzU1zHCoPJbGPbFXLCILECTsjx16Z+noKo3mHvUB6IvP4np/KtaHjaWG5/4UHb3P+NebTVon09O8aSRo26gRjAWKIdS3B/Lt+P5Vcgh5BVQCDw8vJ+oHb9Kp27HI2ASSDufuofb3/X6VZUB3w5MzdweEH4fX6mtkYyJ3aNiChlnP+wcKPXkYH4EmoJQI2Lbba3BOM45b+X9atMV24lkOeuyPI4/Dk/UYqvMRGQVjjiYj7z/M5/Acn86bIRSmUsSP9Icf98Afyz+tUWIVznZlfTLkfX0rQmR3yzZ29/NPGP8AdHH51QkVMHbhlH8T/dH0HT/PWoZvE7vw/fDUNPTn94vBx6joan1Ly3tpZ2jjYpGXIcZAx1rjNCvntL5CGbY5+YN6ep9K6LxR5n9kXRtpChZCMgZyD1rWpPmou55U6HssSktmZmm35u4z5YSFATnauBxWf9ltfEMdwmu6TaXFtuZY47mJZOPXkcH6Unh/EGmzTOWwgJPrUlrdP9gExjETSAsFJzt+tfPNvc9mVOMm42Ivhr4V0Lwz4pmn0S1No10uxoxKxT8FJIHbpXq85KxMVUswBIUHGT6V5b4RkmvfFNrHED5cLF3YdgB3r1OU16uGlKULyPIx8IwqJR7HkjfFqXSQV8ceEdd0Db965WL7Var6/vU/oDXZeGPFOieKrN7nw9qdvfxIQH8tvmQnpuU4K556jtW/J1rNtdNsdPa4exsra2echpWhiVDIR0LEDk/Wt5NdjlimFy3ymuc1ZsZrT1wXcmnXcemyxw3rRMIJJF3Kj4+UkdwD2ryXUdb8faPldc8PWOrwr1uNJnKtj18t+SfYYrLl5tjZOxs6gcsa7n4LTExavAeivG4/EEf0rzDStYXXLBrpLO9siHMbQ3kXlyAjGePTmvRvgyxXUdWTHDRxt+Rb/GjD3VVJjra0mz1WiiivWPOCiiigAooooADRRRQByXjeJJr7To5UV42huFZWGQykJkEd686ez1Dwkv8AxJY5tR0OO3/eacWzLa7u9uT95en7on/dPRT6N4vf/iZ2g/uQSn/voqB/KsIHzY3ccedMMZ/uJ/8AXAq1sZvcoWGqWmrW1ndabOlxbyMzBl7EDbgjqCD1B5FaYkDahdzMMRwKEH4D/GsnT9Fso/Elzq1sjQyNHtmEbYScjB3svQsMY3dccVoyMILZUf78hMsg9Tngf59Kokhl+WydScsWRPqeWP64qjYzyabqciyDCSMzqc/eUtz+R/mPWp7m5iilgjmkVSgLMCcFnPYfhiqOqmW7t0+zQS5h5SaRdg3dScHkj8OfWuPGqEqdm7NbHZgZSjU0V09Gdgjh0DKcg81UvNRt7VSZpERRwWZgAPxrI0vVC2mh2G1j8pHXawOD+tafh3Tori3XVb5N7v8ANErc7FPTHoSME/l0Arxorm0PVmlDVnM3l1CdVtL2ORJIQxUsjAgE49PpXRakY54RtZWVh1Bq3qWm6dfBjPYwsx43FeR+PUVgXOipESLa5njUdELbgPz5/Wvns4yV42rGtTlZo2pVdU2ji9XshbXpkQ7SpyCDgg+ua6/RtUFwBGZENyq5yhGJB6j39RUKaNGJPMuHadx0DD5R+H+NWJYdyhCCpByrrwyn1BrXEZX9awqpVn762fby9GWn7/Mnp2Ox0jUUnj8mf9at3E0lkvGXiHI9q4qzuZPM2yAJcoMkDgOP7y/1Hb8ia+q+Orp9+n6HZRXU8R2y3M7EQxnjgY5Y88gdK8nK6+LoV/ZWtOHV7W7PyfR/cc+Jw0X70dmdb/wmFovH2iH8XH+NRP41sl63dsP+2i/41w3h7U5r3Uby01K0sGkiRZBLaKQvJIwQ2SDxn6VtTGAA4ix+FfexzFuKbjb5nLHAJ9TYk8bwkfupkf8A3Du/lWZeeMPtCNGY5ZVbqhhbB/MYrLkZM/KgpqnLcKPypPMZdEbLLY9WycXf2oZXTVX13og/kTUSW1rLZ6m5s4lkAVNrRrlceuOOc547EVfsYpHYc4FREbbbXcdmHP4KK6MHiZ1Z2kcmNw8KULxO48KWFk+mHNpbkgqOYl/55p7Vtf2bY/8APlbf9+l/wrK8GDGnSjOfnQ/+Qo63673ucK2OG+IHge68Ta54W1bTdVt9OutAnkniWezNxHKXVRggSIQBt7HvXP33wcS+0i5judcZ9ZvtYg1e+vzaDErRZ2xpGGGxQDgfMxHOc16zRSGeRz/BmG88Y3GtXGo29lBci4F1baRay2huxKGX98zTurEBm5CLkn6Cut+HfhjVfCOk2ujT6xZ6ho9lCYbZRYNDcAbsrvk81lbAyOEXPB9c9fRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVznxDk8vwle56uUUfi610dcd8UZAvh+CPPMlyox6gAn+lZVnanL0NKSvNHjfJ1CQ4yd2FH4CtaEDbksdh6t3c+3tWVCQ9zKx+7uPT0z0/GtaLII4zJjgdlFcEdj6h6RS8jSgwFUP8q9o17/AJfyFWTwAGIjToFXqfYY/kKqW/U+X97u7fy/+tVyIKh4DPIR16sf8B+QrVHNIniVyCFxCp5OMFif5fz/AAqNtodvs8e9jwWzxx6sf/r05eAWmYbRnK5+UD3Pf+X1pTI8wAi/dx9NxHP4D/H8qogpzxjdiUmWQ/wAcD3x/j+FZ9wG8wBsNJ1Cj7q+5rUc9Y7cDr8znnB/qaoXC+WdkfMjcljz+JqGawZWVfmKg5A5dvU+lda12JvC00hVpHMLRYHJzjArkyBkRJ90csf89zWtot3str5CvmqUJVPUgEfzpJ2TRniIcyUuzMvTJJY9ElSECWcsFUZ4J9/ard7lLFF6tjBx61V0W3mEVuIiWO7LKvO7ium0jQLuXUobq+2R28TBxHnLMR0z6V40KbqSsjrq1Y0tWzf8HaMmkaYu9ALuYb5W7j0X8K23qPzKUuK9mKUVZHztSUpycpbsjkHNV5RwandsmoJDUsaMq64Jrn9V5BrobusDURnNYyN4nL3i9a0/BWjnX11nSRqWoaW1xbowutPm8qeMrIGG1sHHTB9iRVK8XrWr8M7gW/jCNCeJ4nj/AB6/0p0Xaoh1Vemy4PD3xX8N86J4r0rxNar0t9atTDKB6CWPlj7tXo3ha61a90G0uPEOnRaZqrhvPtYpxMsZDEDDjg5AB9s47Vq0V7B5hDdXdvaLGbqeKASOI0MjhdzHooz1PB49qmrF8W+FtF8X6T/ZniSwjv7LeJRG7Mu1wCAwKkEHBIyD3rz7/hT95oh3+AfHGv6Fj7trcOL21H0jfp9cmgD1uiqmkRXkGlWcWp3K3V+kKLcTogRZZABuYKOgJycdqxvGHjjw54NksF8TanHp/wBuZ0t2kRirFcZyVB2/eHJwKAOkorP0XW9L1y2+06LqVnqEH/PS1mWUD6lScVoUAcFqxXV/Etx57SrbWwECojFd5ByzHHPUkY6cVZXSNBwN1hExAx8yA1SgGNWv8HP+kzf+jGq/XjVK0ud3PUjSioqwJpWhJnZZIoP90YpZdO0YtuMErt6GV8flnFJRSWIktgdFPcWGKytd32Gxt4C33nVBuP1NQ3EQljZSOSKkz7iispSctzSK5djjLnTri2sr8qD8zFkA/wB0f1Fdjb3MMtjAtsymIKCpU8EY4pJY1kQqw4Nc9d6LcWxaTTbiWDvsU/L/AN8nIH4Uk7bGjfPudG/Ssy74JpNG1F7uzkF0oS5hO2QDofQj2I/XNc/q+oyz3Qt7b77/AHQD0Hqf89qzqTjBc0nZFU4u9jULg0inLdKyZ4NT0wrLdR77Y43MByue/wBK2LbDxhh3qKdWFVXg7mnS6JJbZbmIAko6ncki/eQ+o/zzXI6T4W16zgWyjexESs5+0tIxJySQ2wAc8/3scCu3h9Kuw1Xs4t3a/r+mZyZm6Po0GlWrRozTTSHfNO+N0jep/kB2FF3EoBwK12X5apXUeVrRx0JjLU5+YAHpUaD5qsXaYbioIuWFZM609Da00VmuT9l130Mh/mK1dOHFc7quoJp2m6u8sFzMJLgxgW8LSsDuJyQoOBx1+lell38T5Hk5h8HzPSPBf/HndD0lUf8AkJK6GvOPCXjK0itLoHSvELZmA+TSZ2HEaDsvtW7/AMJvaf8AQH8Sf+Ca4/8AiK9V7nmx2Oqorz74r+N77wp4Y0PVNItoWfUNStbRo76JwUjlDE/KCpVxgcHpzkVf8ZeMYvDnizwtplxMIodVN0XJtfMG2GMOT5nmr5eAf7kmeny9aQzsqK828P8Axf0jXNY0OwtdI1uIa3HcS6fcTxwrHOkIYs3+tLKDtONyjOR0HNRWXxo8OXF/qtjJb3sN5p1hNqMkSy2txvjiBLqGgmkUONp+VitAHp1FeVD43aIYJJP7E8QbhpK64kflQbpLM53SD97gbcHIJB44BpNe+O/g7RzBukuboPZw3z+S0KmKOUAoCskis7YYErGGIHUUAerUV5bqfxu8OWDay5sNYnsdIlto7u8hiiMSC4GY3AMgYr64XPtVnwl491bWfi14u8L3OjlNN0nyPJuY9gZA8ZbdKfNOQ/8ABsXIBG4Kc0Aek0UUUAFFFFABRRRQAUUUUAFed/Fa4IuNMg/gAklP4YH+NeiV5R8U7gSa75YPEFpz9SSf5YrnxTtTZ0YZXqI8/wBPJwCOWPTP6mti3+YYUnbn5m7sax7PJGAcZ6n0Fa1ud4x0iA6ev/1q5UfTVC/BJkgJjYOM44+g/wA/4VaEwT5EBZzyQO/uT/n2rPV2fiM7U/vf4VNFKACsC7jnkk8Z9z3qkzncS4MD95cODjkDoqn/ABp4Z5uuY4/yZv8AD+f0qBAqnzJW3MOhPAX6U7e0v+qyif3yOT9B/U/rTIsSSSBQIoFXcB07KPf/AAqncARDavzSv3Pf3PtUzSLEPLhG5+pGenuTVd8LlmbLH7zH/PSkxxRVlPkxHby57nuadpEpGoLGsjRhlMYZeoyKrzvkGQjgcIPX3qOwZE1CAMRhWGSe5PX/AD71Js43i7m9oaiwuyqztJ2O7tXb2VyGAzXl2lXgkmdwFXLnCjoOa7PTrzgDPNclL3VY82s/aScmdVvFG+s1LoYHNSCYHvXRzHNylxnFRSPxUJk96hll460rhykF0/J5rEvTnJrRuJOtZN4/BqGzRIxbzrTPDE32fxXpUgOP9IVT9GO0/wA6S8b5jWfHIYruGVTgpIrD8DmoTtJMtq6aPo2imwuJIkcdGUN+dOr3DyQooooAKhvLS3vbd7e9giuIHGGjlQOrfUHg1NRQB5rrPwS8Eahd/bLLTZdE1AHK3Wjztaun0C/IP++a9JRQiKozgDAyST+ZpaKAPNL+eTS/EF9DcIRvleVCf41Y7sj164+oqRdZgPUYrv72ytb6IR3ttBcRg5CzRhxn6Gs1vCuhsf8AkF2y/wC6u3+VedUwTcm4s74YyKilKJybaxAOnNVLrXAMBCqZOASev0rtl8KaED/yDLc/7wz/ADq7ZaRpti++y0+0t3/vRQqp/MCpWAl1kX9dpraJxuleH9V1ACeeb7FCwyolQtI3/AcjaPrz7Co9Ne4S6ns7kq8sEjRll6Ng9fx4OK9ErzjRL2L7Hd6pcH5p5GlUd8MxIH6gUV8PCmoxjuxUsRKpzOWx0ZghtoDLcyKvfk9KzL3XbV18u3gkkA/iROv54rNEc+pSCS6Y+XnKx54FasFkiAYFdEMMre8c0q7voYUctt/pTxBklcDcjjBwM/4muY0W4jl1i7bAEqtmP/aUcZH5frXU+Ko44IRIjBJh93HX8q8/mSW0aKaHKyxHKk/lj6Y4r57PcPBw+rxlZy2/rserga0ppya2PX9Pki1KxMEoVmxjB5yPSsSS0NlKYudn8Of5VnaDqoaOK7gJCN95e6nuDXZXcMeoWQmjxuxn6Gvl8sxM6M3zLWOkl3S6+sfyNKsPZSuvhZhQ/erRhXpWdGCshVuCDzWpB0FfZU2paoymTbMiqN4pArTQCq95GGU4rdx0MYyszlr0daqRffrUu4M5yaqxwIrZLVzSWp3QkrGpp/asll/0fWPUXA/Vx/jWmlxHCoCHJrHgkM1pfzfwS3AYe4DYB/TNehl38R+h5mYfBr3PRPCQC298B2uj/wCgJW7WJ4V/1F9/19N/6Ctbdeq9zzY7HMfEHwZY+ONItdP1K6vbVLa7jvYpbRkDiRM7fvqwI+bpis+++HVpquqaLqGvazq+rXOkvcmA3H2eMMs8YjdHEUSZXAyMYOSeSMAdvRSGeFeGvgzqUXiPSZNZuYovD+lWN3Z21kl+bqQLcK6Mof7PCVUBzgne2cc46dFp3wS0GyCL/autzpFpM+jRLLJABHbyhtwG2IZYb2IJzyec16nRQB5uPg9oA2/6Zqvy+Hj4aH72P/j2Ofn+5/rOevT/AGafp3wn0vR54LjQNZ1zSbpNPi02ae1khLXMUahUMgeJgHAAG5Apr0WigDzPVfg14f1Sy8UW11f6wV8RPayXb+ehdTb/AHChKHr/ABbt2faui0/wTZad461HxTY3t/DdajHFHeWoMZgn8tNiMQULggf3WGcc5rqqKACiiigAooooAKKKKACgDFFFABXinxDk3+Jtawc7EVf/ACGP8a9rrwjxWTPrmuydczSKPwGP6Vx4x+6l5nZgv4lznrUjbyfk6n3NaKNuI35x2Qd/rWVaN09e3fH0FaMTbSQpwT6csawPpZrUvnlczMFX+6Dx+J71IrscCNdq+rDH6f8A6qrxA5yAqnpub5j/APWp52DiSQsT2ZsfpTMLFhJEVgXYySDoOuD9O1Tl5HBBPlr7H5j/AIVSWeNRtjBI7BRx+fShpZDkDCD1PJp3JcSxJIkK4HA9BySf61Wcl+ZOFHRfX60xnSP5icse55JqrcTbh83C9l7n60FRiNu5tx3f98D196zGmEe6QthUBbP05z+dS3EpYnJ57+w9K53xbe/ZdJZF/wBbOduB2XvUmsmqcHJmr4cvcoNx5JzXZWd7tI5ryTQ71ljBzXZWV9uQc1ytWZ46d0ehW19nHNaEd2D3rhrO+6c1qQXpyOapMlo60TZHBpryZFY8F2COTUr3agdaq5NiSeTk1k3cvBp9xdA55rLuZ855qWykitctljVKTrU8jZNQSc1BZ9CaLIJdGsZAfvQIf/HRV2sbwdJ5vhXS2/6YKv5DH9K2a9yDvFM8iSs2FFFFUIKKKKACiiigAooooAKKKKACvKrjTp9KvbbTrlSIIifKf+GVRwp+oHUevtg16rWfrWkwatAsc5ZHQ7kkT7ymolBSak+hSm4pxXU5+3iRIwzEBQKytW14R5hsV8yXpxVjxFoU9tHaJDezyK5YSbsAdsYwPrUVjp0NoPlXLepr5TP+J45dJ4elG8/wVzsw+FU0pyehlQadNPm51Bi0h6A9qp6hZxSxsNtdTc/6o1z8+SxFfnP16viarrVJXZ7uFguWyOV0m4XStVMVwdtpOdrk9Fbs39DXoug3htLo20pzG3TNcXqulvdphImYnjAFbtpa3dpZWsV5uM6xB45GGC6jgg+6ng+xB717df2koRzCktY6S/K/6P5ET5eZ0ZPRm54oi+xxteRglFGWCjPHr+FUFbVVAxp17/35JrbtL2G50pzeSJGI1+ZpGAAHuTSeB/EVhfvNpVtfwXb2w3RNHKrkx5xg4/unj6Y6nNfSZJWhXl7J35WrxfbvF+nTy9DzalSdKNrXtuZCya2eF0y8/wC/eP5mnPZ+IJx8unTAf7UkY/m1eiUV9SsFDuzl+uy6RR5hL4e8RzH5bVE/66TqP5ZqzZ+CNXkYG8vbSAekYaU/rtr0aimsFS66g8dV2Whymn+CrSGTffXEt4P+eRASM/UDk/QnHtXM61Ht/tUKMf6YFAH/AF0b/CvUa5q+0czSzYxh5/M6fU/1rqpQjT0irHJVnOprJ3LHhI5g1D2u2H/jq1u1Q0e0+yJcjj95MZP0A/pV+qZK2CiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvB5v9Iurh2582V2P4k17tKwWN2PAAJNeGWEZd4x681w43aKOvC7tnL+WbaaSFz8yEg44/HNWY5cKByB6LwPzrf1/Q2uphPalVnxhlbgN+PrWWNA1PGfs/PqGXP6msIyTPooV4Tim3qQCZCfmEbf7z5/pU6TYHyiJR7Gqt1Z3lr/AK+GZB67Mj8xxVcSt/eH5Yqrl2UldGobjH3pIx/n61G027+N29gMD/P41QEjH+MU0uc8uB9KLjUC20u3JGEz36k1WabcSI889WNMwG7M31pkjhVOPm9l6fnSbsN8sdWBwBlvuj9a5TUopNTuzK3+p3hEz6etdG8Ml0cSZWPv2z7VXuoxGyYHAkQY/GsnU10PNxVb2vurY457e40l8SqTDn7w7Vv2N6hjBDCuiudOSeNwy+ormLnw5MkxNo21SfunpS5lLc5OVx2Ni31AA9a1rbUOmDXKrp91Ag8xSD+Yq/awy4HWoasUnc6yPUsAc059TJHWsJIpumKmEMncUDsaLXjN3phmLHvUUNuxxxVlbcgdKQDFOaVl4qXyiBQV+Q0AexfDiYTeEbMDrGXjP/fRP9a6auM+FDbvDDj+7cOP0Fdn3r2qLvTR5dVWmwooorQzCiiigAooooAKKKKACiiigAooooAiniWUAMM4qs1jEx5QVeorjxGBoYh3qRT9S41JR2ZmNpcLZyOKg/sO1DbtgrawKMD0rmhk2Eh8NNfcaLE1FsyhBp0EeNsY/Kotd0sahYbIti3MR3wOw4VvQ+xGQfY+talFdv1Wk6bpOK5WrNGftJc3NfU+eLp/7d1S9a++S2tZmt0s5MYjYcF2GRlsg/QVc+FjyQ+O7efVgI7OZJodKv8AyfLW7Y7SYCRgZQBtpx84BI5Vq9bvvBnhy/1Q6jeaPaTXhIZpHTO4+pHQ/iKva7otjrmkS6ZqEO61cLjYSjRspBVkI5VlIBBHQgVxYLK4YRpR+FbI6a2LdSNuppUVyPhXWL201E+GvE8gfVokL2t5t2pqUK4zIB0Ei5AdOx+YfKRjrq9U4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK2qNs0y7fONsLnPp8pryDQ4t00fsK9T8Vts8Naoc4/0Zx+akV5v4eTPzegrgxnxJHZhtmaEyAzir8ESsoyKgZcyitC1TpXKkbtkZskPPNUL7w/aXeTLEhf8AvbcN+fWuiVRxSlBV2JU3F3TOGk8HwsfllkjHsc/zzVZ/CcCEZuJm/wC+R/Su7lCgVnXIzSdzaOIqdziLrQreL+Atj+8SapvaxoOEAx7V118gI+tc/dJjNZMbm5bsw7hOtY2orhkPrIn/AKEK6C5HNYerLiNT6On/AKEKlbh0OiEQweOtENmrtg9asheMVatYsuM0CGLpG9OACKdHoRP/ACxH5V0mmW5dh6V0MFqiL0Ga1jC5nKdjg4/Dpcj5StLJoDJ0INd5IigcCs26Xmm4pCU2zkv7K8scsBVaWBUNdDdisa6HzGs2aIy5gAeKgA+RqszjrUC/dNSM9K+Ehz4fuh6XTf8AoK13HeuG+EYxoV7/ANfZ/wDQFrua9jD/AMNHm1vjYUUUVsZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGP4p0C38Q6cLeaSS3uYXE1rdw4EttKPuuhPfqCOhBIOQTXkP7QOlahr3g3wHo/iGWCDUL3xJa2dxNZElAWWVPMQNyOCGweh4ycZr3aigD5N8P+JvGui6j8T7+awM/jDStOsrSTCGTzNjlPtAX+LMZ8z0PXpxWrq3xF8ZWPhO+vLHxloupeZcWP2ea0aO8lthISrpKRbRR84ztKh16H1r6dooA8A+I/irx58OLixtLjWjr0ms2MtnZTCwhgCaiZh5bBFB4EbqAGJBKZ9RVDxJ428d6d4q1TRZ/EukaNNpcNqbeXVWSJNT+UGWQILd2lLNkbYmjK5Awxzj6OooARCSilgAxHIHaloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDA8fSeV4P1Rs4/dY/MgVwfhw5izXa/EvjwPqpHZF/9CFcT4b/AOPbNedi/jR24b4GbI5etS0HArMTl617QcVhE1kWAMCkfpT8cU1+laGVynMetUZuRV2UdapzdKzZrEzrsfLWBeDk1v3fSsO8Gc1my0YtwKxNXX/Rz/vL/wChCt24HBrC1rItGI6gqf8Ax4VK3L6HTw8oD7VpWX3hWba8oPpWlZfeFCEzqtJUDFbQ6Vj6X0Fa4PFdEDnmRTfdrNuO9ac33TWdMMk0SHAyLoVj3Y61uXK8Gsi7Xg1izVGPOKqr/FVy4FUh1apKPT/hN/yLdx/19v8A+gpXa1xXwmbPh24HpdP/AOgrXa17ND+GjzK3xsKKKK1MwooooAKKKKACiiigAooooAKKKKACiiuA+K9jc65Bp+jaXqVpFqBl+1nTrl2RL+JPvRkjkjkcd/bGR0YWiq9VU5Oye77f1/w5FSXJG6Vzt768tdPtJLq/uYbW2jwXmmkCIvOOWPA5IpZbu3hs3u5riGO0RPMaZnAQJjO4t0xjnNeCx6pb3envY6bolrpGoahrVto15aosdzZERlmeSNGUp6Z4OMKevNP8YeItU8R+GfECW199ktJNWXQbHTY4owHGVyzkqXyR0AKge9exHIZucYuVtdW+2i6X8+trLoczxas3Y96t5ormCOe3kSWGVQ6SRsGV1IyCCOCCO9SV4nJ4l8V3I1+HwzHNBDod0unWsINokBEZCsZ2mYSDcPu7MDtk847r4qaxqWheCZdV0ycW89tNA0p2q+YzIqsvzAj+Lr1riqZXUhVhSUlebstdVe1r9t1+JpHEJxcrPT+tDrLu5gs7aS4u54oLeJd0ksrhVQepJ4Ap1vNFcwRz28iSwyqHSSNgyupGQQRwQR3rxbXvFGuav4V1XVIp410zWNRh0vRrWa0jkUoXw0rKyndu2tgHIHPHSnz+J/FV43iKPwxDLbQ6Jdrp9rAgs47fbGwVjMZWDjcPu7AAOBzzjoWSVHHWUU72d3ZL4dHpvd27aP5y8VG+z/q/+R7VRXh/i7x14osdU8YaRptxi/syl1A5hjYWtqsPmSH7vzZJVRuz972ruPhtrOqeJZNT1i4uSdGZ1t7GARqASigSS7gMnL5A5wMH2rCvlFahQ+sTa5bJ790munW/4PyvUMTGcuRLX+v6+Z3FFFFeWdAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc98QoTP4M1WNepiz+RBrh/DsZW0Ga9N1qEXGlXcJ5DxkfpXJ6fp4jhAAxXFiafNJM6qE7RaK0Q+eti0GFqJbMg5xV63hIFYRptGsppigUxx1qyIjTXjOKvldjK+plzdTVKc8VpzxHmqcsBx0rJxZtFoxrrpWLd966O6t2I6VkXNqxzxWbizRSRzk461h60v+hyfh/MV1k1i/PFZGr6c7WkoC9qnlZXMi7ZcqK1bLiQVBZWT+WvHatG3tHDrxQosTkjo9M6CtQVn6dGygZFagjOK3jF2MZMgm+6az5etacyHFZ8kR3dKHFhFmXc9DWRdjg10M1uzDpVCewdgeKzcGaKSOWnU4qkVO88V1baS7dqYmiNvyVoVKTH7RI6T4TKV8P3YP/P23/oK121c/4Js/sWkyJjG6Zm/QV0FerRVoJHn1XebYUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFUdU0jTdWjWPVdPs72NeQtzCsgH4MDV6iqjJwfNF2Ymk9GZ8ei6VEtmsWmWKLZkm2CwIBAT1KcfL+GKhPhvQzqH286LphvvME32j7LH5m8cht2M7vfrWtRVKtUW0n94uWPYzJ9A0e41JdRn0nT5dQUgrdPbIZQR0IcjPH1q5fWdtf2slrfW8NzbSDDxTIHRu/IPBqeik6k3ZtvTby9B8q7FFtI01obOFtPszFZMr2yGFdsDL90oMfKR2xjFRT6Bo9xqS6jPpOny6gpBW6e2QygjoQ5GePrWnRTVWotpP7xcq7FB9H0x7m7uH06za4u4/JuZTApaZMY2ucZZcADB4xViytLawtY7axt4ba2jGEihQIij2A4FT0VLnKSs3oOyWoUUUVIwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbKN0bD1BFUIrUBcYrRPSmquBUtXGnYqfZhTlgxVvFGBS5EPmZW8qmtDkVbxRijkQcxnPbZ7VE1oD2rU20baXs0PnZhy2APaqkmlg9q6Yxg9qaYh6VPskNVGcm+kA/w1Vu9DDwuNvUV2hgHpSG3z2FHsUP2jOXg0kKoGO1WU0wAjiugEOOwp4iAo9ig9ozMgtNoHFWhBVsIBS4pqmiedlFrbNRmyB7Vp4FGKfs0HOzL+wg9qT+z19K1cUYFP2aFzsyvsCelIbFQela2BTSoo5EHMyGxjEUO0epNWKRRgYpatEsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low back pain can be caused by problems with the muscles, ligaments, discs, bones (vertebrae), or nerves. Often back pain is caused by strains or sprains involving the muscles or ligaments. These problems cannot always be seen on imaging tests, such as MRIs or CAT scans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4917=[""].join("\n");
var outline_f4_51_4917=null;
var title_f4_51_4918="Spinal nerves thoracic vertebra";
var content_f4_51_4918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Spinal nerves section through thoracic vertebra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4918=[""].join("\n");
var outline_f4_51_4918=null;
var title_f4_51_4919="Posthemorrhagic hydrocephalus Grade III IVH";
var content_f4_51_4919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging (MRI) of posthemorrhagic hydrocephalus in a patient with grade III IVH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a followup MRI obtained 1 year following initial presentation, axial FLAIR images (A, B, C, D) demonstrate marked bilateral hydrocephalus with colpocephalic features, hypoplasia/atrophy of the cerebellum (arrowhead), and dysmorphia of the pons (short arrow). Coronal CISS image (E) demonstrates disproportionate dilation of the atrium and occipital horn of the lateral ventricle (dashed arrow) reflecting the colpocephalic features.",
"    <div class=\"footnotes\">",
"     CISS: constructive interference in steady state (a gradient-echo MRI sequence); MRI: magnetic resonance imaging; IVH: intraventricular hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4919=[""].join("\n");
var outline_f4_51_4919=null;
var title_f4_51_4920="Pathogenesis of hantavirus infections";
var content_f4_51_4920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of hantavirus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Brian Hjelle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4920/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/51/4920/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Hantavirus is comprised of a group of more than 20 distinct species of rodent-borne viruses of the family Bunyaviridae. Two major forms of hantavirus disease are recognized, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS, also called HPS).",
"   </p>",
"   <p>",
"    Among the agents of HCPS, the most severe forms are associated with Sin Nombre virus (SNV) and the southern (prototypical) form of Andes virus; slightly milder forms are caused by the northern form of Andes virus (Andes-Nort), Laguna Negra virus (LNV), and Choclo virus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The known etiologic agents for the more serious forms of HFRS are Hantaan virus (HTNV) and Dobrava virus (DOBV); a form of intermediate severity is caused by Seoul virus (SEOV); and a milder form of HFRS is caused by a vole-borne hantavirus, Puumala virus (PUUV) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology and pathogenesis of hantavirus infections, with a special emphasis on HCPS, will be reviewed here. The composition of these enveloped viruses and their epidemiology, clinical manifestations, and prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25544?source=see_link\">",
"     \"Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantaviruses appear to exhibit similar replicative kinetics and to elicit similar immune responses in both rodents and humans, but rodent infection leads to a persistent state of infection with no overt clinical or pathologic consequence. By contrast, human infection often leads to overt signs and symptoms, subsequent resolution of disease and viremia, and probable immunity to future infection with the same viral strain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Levels of plasma viral RNA appear to be higher in patients with severe clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/5\">",
"     5",
"    </a>",
"    ]; titers decline during convalescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/6\">",
"     6",
"    </a>",
"    ]. The possibility of a persistent state in humans has been raised by a study of immune responses in 78 patients with Andes-Nort virus infections in which both T cell and neutralizing antibody responses failed to decline during years of convalescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/7\">",
"     7",
"    </a>",
"    ]. Viremia was not present in these subjects, so the location of any long-term reservoir of Andes virus replication within the host, if present, is not known. Further study is necessary to elucidate whether the persistence of these responses is due to ongoing infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tissue tropism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hantaviruses show very similar tissue tropism in both human and rodent hosts, with consistent involvement of the vascular endothelium of the heart, kidney, lung, and lymphoid organs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/8\">",
"     8",
"    </a>",
"    ]. Involvement of the central nervous system (CNS) is rare.",
"   </p>",
"   <p>",
"    Neither rodent nor human infection leads to overt cytopathic damage by direct viral involvement, consistent with the pattern observed in most in vitro studies. However, the possibility that hantavirus replication might stimulate apoptosis has emerged in some, but not all studies of virus infection in cultured cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Thus far, there is no evidence for increased apoptotic activity in human or animal tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cell entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantaviruses use beta-3 integrins to enter endothelial cells, which leads to dysregulation of endothelial cell migration. Since beta-3 integrins are associated with changes in vascular permeability and maintenance of vascular integrity, hantavirus infection of endothelial cells may play a central role in the disease process of hantavirus cardiopulmonary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Entry of pathogenic hantaviruses into cells appears to require the presence of the beta-3 integrin polypeptide, which in endothelial cells is complexed with alpha-v to make",
"    <span class=\"nowrap\">",
"     alpha-v/beta-3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The entry of pathogenic hantaviruses can be blocked both by vitronectin, the natural ligand for",
"    <span class=\"nowrap\">",
"     alpha-v/beta-3,",
"    </span>",
"    and by anti-beta-3 monoclonal antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infected endothelial cells are also rendered dysfunctional by direct toxicities of the virus, such as immune tyrosine activation motifs (ITAMs) in the viral Gn glycoprotein, or other virally-induced processes that directly inhibit the function of endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Hantaviruses can enhance the permeability of endothelial cells by sensitizing them to the effects of vascular endothelial growth factor, suggesting a possible in vitro correlate of the observed permeability of vascular endothelial cells during infection in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EARLY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have demonstrated that many hantavirus infections are contracted through the airborne route. After they reach the lung parenchyma, they are taken up in phagocytes and transported to draining lymph nodes. The viruses establish infection in the regional nodes and disseminate primarily to distant organs. The viruses replicate principally in vascular endothelial cells and then establish a secondary viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By the time symptoms occur in hantavirus cardiopulmonary syndrome, both viral RNA and antiviral antibodies can be detected in the blood. Patients who succumb quickly to infection display widespread involvement of tissues by viral antigens and RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/4,6,20-23\">",
"     4,6,20-23",
"    </a>",
"    ]. Similar patterns of viral involvement are likely to occur in hemorrhagic fever with renal syndrome, although perhaps involving lower quantities of virus and resulting in lower case-fatality ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY (SHOCK) STAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock has long been recognized as a key development in the pathogenesis of fatal hantavirus cardiopulmonary syndrome (HCPS) and hemorrhagic fever with renal syndrome (HFRS), with deaths from shock reported from the earliest known outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. Hemodynamic measurements in severe cases have demonstrated severe myocardial depression with worsening cardiac indices over time in association with lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/26,32\">",
"     26,32",
"    </a>",
"    ]. In patients with HCPS, the cause of hypoxemia is related to increased permeability and is differentiated from cardiac pulmonary edema by its association with low pulmonary artery occlusion pressures and increased protein content of edema fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it has been recognized that pulmonary edema occurs in HFRS, it has been suspected that such cases can be partially traced to iatrogenic volume overload [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/29,33-35\">",
"     29,33-35",
"    </a>",
"    ]. However, it is clear that the agents of HFRS can cause pulmonary edema and that the agents of HCPS can cause renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INFLAMMATORY MEDIATORS AND THE IMMUNE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is no morphologic evidence for inflammatory involvement of the heart in most cases of hantavirus cardiopulmonary syndrome (HCPS) or hemorrhagic fever with renal syndrome (HFRS), cardiogenic shock must occur through an indirect and strictly functional mechanism, most likely through the action of soluble mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/36\">",
"     36",
"    </a>",
"    ]. Cardiogenic depression in HCPS patients from Brazil has been linked to myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/36\">",
"     36",
"    </a>",
"    ]. Such mediators, including the proinflammatory cytokines TNF-alpha and IL-1 beta, have long been implicated in septic shock due to bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/37\">",
"     37",
"    </a>",
"    ]. It seems likely that at least part of the myocardial depressant effect of hantavirus infection of the lungs or kidneys is due to the release of soluble inflammatory mediators from the involved organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HCPS, it is suspected that various proinflammatory and antiviral cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1)-beta, and interferon (IFN)-gamma, are agents of a reversible increase in vascular permeability that leads to severe, noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/30\">",
"     30",
"    </a>",
"    ]. One study detected high numbers of cytokine-producing cells in the lungs of patients with HCPS compared with modest increases in patients with non-HCPS acute respiratory distress syndrome, suggesting a role of T cells and local cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/38\">",
"     38",
"    </a>",
"    ]. However, studies in an Andes virus HCPS hamster model indicate that the disease occurs even when T cells are depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other more subtle findings also argue for the central role of an immunologic process mediated by TNF-alpha and related inflammatory molecules. Both conventional and electron microscopic studies fail to show lytic attack of endothelium by the hantaviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/40\">",
"     40",
"    </a>",
"    ]. Pleural fluid and tracheal aspirates in HCPS resemble plasma in appearance and in the content and composition of protein in these fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/41\">",
"     41",
"    </a>",
"    ]. The observation that at least for HCPS caused by Sin Nombre virus there is virtually no loss of red blood cells into the pleural fluid demonstrates that the capillary leak allows only proteins to exit the vascular space, which is not consistent with gross lysis of the endothelial layer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     T cell responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both hantavirus cardiopulmonary syndrome (HCPS) and hemorrhagic fever with renal syndrome (HFRS), investigations support a role for CD8+ and CD4+ cytotoxic T cells in the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. By extension from other acute viral infections, it is possible that many of these T cells are directed against antigenic epitopes in the virus; however, only a very small number of specific antiviral T cell clones have been identified from patients with hantavirus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/42-44,47\">",
"     42-44,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The T cell response may be protective, at least in HFRS. This was suggested in a study of 18 patients with HFRS in which the combined frequencies of hantavirus-specific T cells five to eight days following fever onset were significantly higher in patients with mild or moderate HFRS compared with those with severe HFRS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dendritic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dendritic cells (DCs) play an important role as antigen-presenting cells in viral infections. In vitro studies demonstrate that DCs activated by hantavirus (HTNV) upregulate major histocompatibility complex, costimulatory, and adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, infection of DCs with HTNV leads to the release of proinflammatory cytokines (tumor necrosis factor alpha and alpha interferon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reactive oxygen species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive oxygen and nitrogen species (RONS) are abundant in the lungs of patients with hantavirus cardiopulmonary syndrome (HCPS) and in animal disease models of HCPS, but absent in the non-pathogenic infection of deer mice [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/50\">",
"     50",
"    </a>",
"    ]. Evidence for increased production of nitric oxide (NO) has been presented for PUUV infection in both humans and in a nonhuman primate model [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Together, these observations seem to put T cells, macrophages, and their cytokine and chemokine products at the center of the pathogenic process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other mediators of tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although investigations have concentrated on cytokine abnormalities and have demonstrated that hantavirus infections in vitro can elicit expression of cytokines, the exact nature of the mediators of tissue injury remain to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/2\">",
"     2",
"    </a>",
"    ]. Other investigations have examined the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/11,13,49,54-63\">",
"     11,13,49,54-63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The role of the kinin system and deposition of immune complexes",
"     </li>",
"     <li>",
"      Viral induction of interferon-stimulated genes (ISG)",
"     </li>",
"     <li>",
"      Viral depression of endothelial cell migration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing evidence supports the role of dysregulated innate immune responses in hantavirus pathogenesis. Steady amplification of hantavirus particles in vivo could contribute to ISG responses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    production of mediators that stimulate vascular leak in endothelial cells. Even replication-incompetent hantavirus particles elicit strong ISG responses for prolonged periods of time (Hjelle, B, unpublished data) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/11,57,62,64-66\">",
"     11,57,62,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC CORRELATES OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantavirus infections elicit both antibody and T cell responses. Specific antiviral IgM, IgG, and IgA are usually detectable by the time the patient complains of respiratory difficulty in hantavirus cardiopulmonary syndrome (HCPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cell responses have been less well studied. CD8 T cells are present in peripheral blood during the acute phase of illness that recognize SNV specific epitopes on the virus nucleocapsid protein, suggesting a role for the immune response and pulmonary capillary leak syndrome via production of IFN-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Host genetic susceptibility may also play a role in disease manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/45,67,68\">",
"     45,67,68",
"    </a>",
"    ]. Individuals with HLA-B*3501 have an increased risk of developing severe HCPS, suggesting that CD8 T cell responses to SNV contribute to pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/45\">",
"     45",
"    </a>",
"    ]. In contrast, the presence of HLA-B27, which has been associated with slower HIV progression, may convey some degree of protection from severe disease caused by PUUV and SNV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of hemorrhagic fever with renal syndrome (HFRS), capillary leak is manifest in the retroperitoneum; the kidneys are heavy, edematous, and congested, weighing 50 to 100 percent more than expected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/69\">",
"     69",
"    </a>",
"    ]. Pathologic examination demonstrates perirenal hemorrhage, tubular degeneration, and an assortment of casts; the swollen and hemorrhagic medulla is generally most heavily involved. Inflammatory cells have been identified in the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hantavirus cardiopulmonary syndrome (HCPS), capillary leak is overwhelmingly centered in the lungs. Autopsy studies demonstrate that the lungs are heavy and edematous, and tracheal and pleural fluid are abundant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/72\">",
"     72",
"    </a>",
"    ]. Histologic abnormalities include interstitial pneumonitis with mononuclear cell infiltrate, hyaline deposition in the alveoli, and sometimes diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/40,72\">",
"     40,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mononuclear inflammatory cell infiltrates can be seen as well in lymphoid organs, including the spleen, lymph nodes, and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Many of the abnormal mononuclear cells are enlarged, activated cells of the lymphoid lineage that are commonly termed \"immunoblasts\".",
"   </p>",
"   <p>",
"    In contrast to HFRS, the kidneys are usually uninvolved pathologically in HCPS. There have been reports of HCPS patients with renal failure, but the detection of viral antigens in the kidney may not necessarily indicate the presence of replicating virus in these tissues. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Immunohistochemistry'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25544?source=see_link\">",
"     \"Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry studies have shown that hantaviruses have strong tropism for endothelial cells, especially the endothelium of small blood vessels, in both humans and reservoir rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/8,40,74,75\">",
"     8,40,74,75",
"    </a>",
"    ]. The cardinal feature of both hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS) is capillary leak [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/23,30,31,41,76,77\">",
"     23,30,31,41,76,77",
"    </a>",
"    ]. The localization of viral antigens in the endothelium by IHC is important because it places the virus in the small vessels of the lung or the kidney, the site of the lesion of clinical significance. Platelet consumption may be linked to the exposure to the blood of normally subcellular layers of matrix and basement membrane that lie beneath the dysfunctional microvascular endothelium.",
"   </p>",
"   <p>",
"    IHC also shows viral antigens to be disseminated widely throughout the body, including clinically uninvolved tissues such as glomerular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/8,40\">",
"     8,40",
"    </a>",
"    ]. Deposition in renal tissues may occur during viremia and does not necessarily imply ongoing viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/78\">",
"     78",
"    </a>",
"    ]. Hantaviral antigens have also been found within follicular dendritic cells, macrophages, and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in HFRS, there are more data supporting the presence of replicating virus in the kidneys. It is sometimes possible, for example, to visualize inclusions and virions directly by electron microscopic examination in the renal tubular epithelium of patients with HFRS due to HTNV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/79\">",
"     79",
"    </a>",
"    ]. Similar involvement of endothelium is observed with the agents of HFRS, although some reports have demonstrated involvement of renal tubular epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/70,80\">",
"     70,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less is known about other related hantaviruses. Involvement of macrophages has been observed, but is exceedingly rare during infection by the New World North American forms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/81\">",
"     81",
"    </a>",
"    ]. Pituitary hemorrhage has been observed in necropsy examinations of patients with HTNV and PUUV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4920/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genus Hantavirus is comprised of a group of more than 20 distinct species of rodent-borne viruses of the family Bunyaviridae. Two major forms of hantavirus disease are recognized, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS, also called HPS). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human infection with a hantavirus often leads to overt signs and symptoms, subsequent resolution of disease and viremia, and probable immunity to future infection with the same viral strain. The hantaviruses show similar tissue tropism in both human and rodent hosts, with consistent involvement of the vascular endothelium of the heart, kidney, lung, and lymphoid organs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hantaviruses use beta-3 integrins to enter endothelial cells, leading to dysregulation of endothelial cell migration. Since beta-3 integrins are associated with changes in vascular permeability and maintenance of vascular integrity, hantavirus infection of endothelial cells may play a central role in the disease process of HCPS. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cell entry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hantavirus infections are contracted through the airborne route. After they reach the lung parenchyma, they are taken up in phagocytes and transported to draining lymph nodes. The viruses establish infection in the regional nodes and disseminate to distant organs. The viruses replicate principally in vascular endothelial cells and then establish a secondary viremia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiogenic shock has long been recognized as a key development in the pathogenesis of fatal HCPS and HFRS, and deaths from shock may occur. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cardiopulmonary (shock) stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hantavirus infections, the immune system, both innate and acquired, is suspected to be a determinant of the magnitude of the capillary leak and its associated morbidity. Infected microvascular endothelial cells appear to represent a target of attack by virus-specific T cells. These antiviral T cells sustain functional damage through viral induction of interferon response genes as well as through direct cytotoxicity. Antiviral T cells collaborate with tissue macrophages to establish a milieu of proinflammatory cytokines as well as chemokines that potentiate direct viral toxicity through the formation of intercellular gaps between endothelial cells. The gaps, in turn, permit the passage of plasma proteins into the interstitium. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Inflammatory mediators and the immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor necrosis factor-alpha and interleukin-1-beta are likely to be important factors in the pathogenesis of HCPS, given their abundant expression in HCPS and their known abilities to promote vascular leakage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cytokines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/1\">",
"      Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/2\">",
"      Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines 2002; 1:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/3\">",
"      Lee HW, van der Groen G. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/4\">",
"      Terajima M, Hendershot JD 3rd, Kariwa H, et al. High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis 1999; 180:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/5\">",
"      Xiao R, Yang S, Koster F, et al. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis 2006; 194:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/6\">",
"      Hjelle B, Spiropoulou CF, Torrez-Martinez N, et al. Detection of Muerto Canyon virus RNA in peripheral blood mononuclear cells from patients with hantavirus pulmonary syndrome. J Infect Dis 1994; 170:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/7\">",
"      Manigold T, Mori A, Graumann R, et al. Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus. PLoS Pathog 2010; 6:e1000779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/8\">",
"      Green W, Feddersen R, Yousef O, et al. Tissue distribution of hantavirus antigen in naturally infected humans and deer mice. J Infect Dis 1998; 177:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/9\">",
"      Kang JI, Park SH, Lee PW, Ahn BY. Apoptosis is induced by hantaviruses in cultured cells. Virology 1999; 264:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/10\">",
"      Li XD, M&auml;kel&auml; TP, Guo D, et al. Hantavirus nucleocapsid protein interacts with the Fas-mediated apoptosis enhancer Daxx. J Gen Virol 2002; 83:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/11\">",
"      Khaiboullina SF, Rizvanov AA, Otteson E, et al. Regulation of cellular gene expression in endothelial cells by sin nombre and prospect hill viruses. Viral Immunol 2004; 17:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/12\">",
"      Markotic A, Hensley L, Geisbert T, et al. Hantaviruses induce cytopathic effects and apoptosis in continuous human embryonic kidney cells. J Gen Virol 2003; 84:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/13\">",
"      Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. Arch Virol 2002; 147:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/14\">",
"      Gavrilovskaya IN, Shepley M, Shaw R, et al. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 1998; 95:7074.",
"     </a>",
"    </li>",
"    <li>",
"     Mackow, ER, Ginsberg, MH, Gavrilovskaya, IN. Beta3 integrins mediate the cellular entry of pathogenic hantaviruses. In: Saluzzo JF, Dobet B, editors. Factors in the emegence and control of rodent-borne viral diseases (Hantaviral and Arenal Diseases). Paris: Elsevier, 1999: 113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/16\">",
"      Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol 1999; 73:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/17\">",
"      Larson RS, Brown DC, Ye C, Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol 2005; 79:7319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/18\">",
"      Geimonen E, LaMonica R, Springer K, et al. Hantavirus pulmonary syndrome-associated hantaviruses contain conserved and functional ITAM signaling elements. J Virol 2003; 77:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/19\">",
"      Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. J Virol 2008; 82:5797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/20\">",
"      Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/21\">",
"      Hjelle B, Jenison S, Torrez-Martinez N, et al. A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J Virol 1994; 68:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/22\">",
"      Jenison S, Hjelle B, Simpson S, et al. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect 1995; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/23\">",
"      Mertz GJ, Hjelle BL, Bryan RT. Hantavirus infection. Adv Intern Med 1997; 42:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/24\">",
"      Schilling S, Emmerich P, Klempa B, et al. Hantavirus disease outbreak in Germany: limitations of routine serological diagnostics and clustering of virus sequences of human and rodent origin. J Clin Microbiol 2007; 45:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/25\">",
"      Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med 1994; 149:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/26\">",
"      Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med 1996; 24:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/27\">",
"      SHEEDY JA, FROEB HF, BATSON HA, et al. The clinical course of epidemic hemorrhagic fever. Am J Med 1954; 16:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/28\">",
"      EARLE DP. Analysis of sequential physiologic derangements in epidemic hemorrhagic fever; with a commentary on management. Am J Med 1954; 16:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/29\">",
"      GILES RB, SHEEDY JA, EKMAN CN, et al. The sequelae of epidemic hemorrhagic fever; with a note on causes of death. Am J Med 1954; 16:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/30\">",
"      Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999; 50:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/31\">",
"      Kanerva M, Mustonen J, Vaheri A. Pathogenesis of puumala and other hantavirus infections. Rev Med Virol 1998; 8:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/32\">",
"      ENTWISLE G, HALE E. Hemodynamic alterations in hemorrhagic fever. Circulation 1957; 15:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/33\">",
"      Clement J, Heyman P, McKenna P, et al. The hantaviruses of Europe: from the bedside to the bench. Emerg Infect Dis 1997; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/34\">",
"      POWELL GM. Hemorrhagic fever: a study of 300 cases. Medicine (Baltimore) 1954; 33:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/35\">",
"      Cohen MS. Epidemic hemorrhagic fever revisited. Rev Infect Dis 1982; 4:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/36\">",
"      Saggioro FP, Rossi MA, Duarte MI, et al. Hantavirus infection induces a typical myocarditis that may be responsible for myocardial depression and shock in hantavirus pulmonary syndrome. J Infect Dis 2007; 195:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/37\">",
"      Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/38\">",
"      Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999; 179:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/39\">",
"      Hammerbeck CD, Hooper JW. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J Virol 2011; 85:9929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/40\">",
"      Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/41\">",
"      Bustamante EA, Levy H, Simpson SQ. Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest 1997; 112:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/42\">",
"      Ennis FA, Cruz J, Spiropoulou CF, et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 1997; 238:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/43\">",
"      Van Epps HL, Schmaljohn CS, Ennis FA. Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. J Virol 1999; 73:5301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/44\">",
"      Terajima M, Van Epps HL, Li D, et al. Generation of recombinant vaccinia viruses expressing Puumala virus proteins and use in isolating cytotoxic T cells specific for Puumala virus. Virus Res 2002; 84:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/45\">",
"      Kilpatrick ED, Terajima M, Koster FT, et al. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004; 172:3297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/46\">",
"      Hayasaka D, Maeda K, Ennis FA, Terajima M. Increased permeability of human endothelial cell line EA.hy926 induced by hantavirus-specific cytotoxic T lymphocytes. Virus Res 2007; 123:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/47\">",
"      Van Epps HL, Terajima M, Mustonen J, et al. Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med 2002; 196:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/48\">",
"      Wang M, Wang J, Zhu Y, et al. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009; 199:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/49\">",
"      Raftery MJ, Kraus AA, Ulrich R, et al. Hantavirus infection of dendritic cells. J Virol 2002; 76:10724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/50\">",
"      Davis IC, Zajac AJ, Nolte KB, et al. Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome. J Virol 2002; 76:8347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/51\">",
"      Groeneveld PH, Colson P, Kwappenberg KM, Clement J. Increased production of nitric oxide in patients infected with the European variant of hantavirus. Scand J Infect Dis 1995; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/52\">",
"      Linderholm M, Groeneveld PH, T&auml;rnvik A. Increased production of nitric oxide in patients with hemorrhagic fever with renal syndrome--relation to arterial hypotension and tumor necrosis factor. Infection 1996; 24:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/53\">",
"      Klingstr&ouml;m J, Plyusnin A, Vaheri A, Lundkvist A. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J Virol 2002; 76:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/54\">",
"      Collan Y, L&auml;hdevirta J, Jokinen EJ. Electron Microscopy of Nephropathia Epidemica. Glomerular changes. Virchows Arch A Pathol Anat Histol 1978; 377:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/55\">",
"      Jokinen EJ, Collan Y, L&auml;hdevirta J. Renal immune complexes in epidemic nephropathy. Lancet 1977; 1:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/56\">",
"      Lee M. Coagulopathy in patients with hemorrhagic fever with renal syndrome. J Korean Med Sci 1987; 2:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/57\">",
"      Geimonen E, Neff S, Raymond T, et al. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc Natl Acad Sci U S A 2002; 99:13837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/58\">",
"      Song JS, Min CH, Kang E, Yu SH. Expression of ICAM-1 on the Hantaan virus-infected human umbilical vein endothelial cells. Korean J Intern Med 1999; 14:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/59\">",
"      Sundstrom JB, McMullan LK, Spiropoulou CF, et al. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J Virol 2001; 75:6070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/60\">",
"      Chen LB, Yang WS. Abnormalities of T cell immunoregulation in hemorrhagic fever with renal syndrome. J Infect Dis 1990; 161:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/61\">",
"      Lee M, Kim BK, Kim S, et al. Coagulopathy in hemorrhagic fever with renal syndrome (Korean hemorrhagic fever). Rev Infect Dis 1989; 11 Suppl 4:S877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/62\">",
"      Khaiboullina SF, Rizvanov AA, Deyde VM, St Jeor SC. Andes virus stimulates interferon-inducible MxA protein expression in endothelial cells. J Med Virol 2005; 75:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/63\">",
"      Geimonen E, Fernandez I, Gavrilovskaya IN, Mackow ER. Tyrosine residues direct the ubiquitination and degradation of the NY-1 hantavirus G1 cytoplasmic tail. J Virol 2003; 77:10760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/64\">",
"      Sinclair JR, Carroll DS, Montgomery JM, et al. Two cases of hantavirus pulmonary syndrome in Randolph County, West Virginia: a coincidence of time and place? Am J Trop Med Hyg 2007; 76:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/65\">",
"      Prescott J, Ye C, Sen G, Hjelle B. Induction of innate immune response genes by Sin Nombre hantavirus does not require viral replication. J Virol 2005; 79:15007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/66\">",
"      Kraus AA, Raftery MJ, Giese T, et al. Differential antiviral response of endothelial cells after infection with pathogenic and nonpathogenic hantaviruses. J Virol 2004; 78:6143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/67\">",
"      Mustonen J, Partanen J, Kanerva M, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/68\">",
"      Vapalahti O, Lundkvist A, Vaheri A. Human immune response, host genetics, and severity of disease. Curr Top Microbiol Immunol 2001; 256:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/69\">",
"      Tsai TF. Hemorrhagic fever with renal syndrome: clinical aspects. Lab Anim Sci 1987; 37:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/70\">",
"      Poljak M, Avsic Zupanc T. Immunohistochemical detection of Hantaan virus antigen in renal tissue from patient with hemorrhagic fever with renal syndrome. Nephron 1994; 67:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/71\">",
"      Cizman B, Ferluga D, Kaplan-Pavlovcic S, et al. Renal involvement in Hantavirus disease. Adv Exp Med Biol 1989; 252:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/72\">",
"      Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 1995; 26:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/73\">",
"      Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 1994; 330:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/74\">",
"      Kurata T, Tsai TF, Bauer SP, McCormick JB. Immunofluorescence studies of disseminated Hantaan virus infection of suckling mice. Infect Immun 1983; 41:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/75\">",
"      Botten J, Mirowsky K, Kusewitt D, et al. Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc Natl Acad Sci U S A 2000; 97:10578.",
"     </a>",
"    </li>",
"    <li>",
"     Mertz, GJ, Hjelle, B, Williams, TM, Koster, FT. Host responses in the hantavirus cardiopulmonary syndrome. In: Saluzzo JF, Dodet B, editors. Emergence and Control of Rodent-Borne Viral Diseases (Hantaviral and Arenal Diseases). Paris: Elsevier, 1999: 133.",
"    </li>",
"    <li>",
"     Hjelle, B, Gonzalez-Scarano, F. Bunyaviruses and Disease. In: Cunningham MW, Fujinami RS, editors. Effects of Microbes on the Immune System. Philadelphia: Lippincott Williams &amp; Wilkins, 1999: 521.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/78\">",
"      Botten J, Mirowsky K, Kusewitt D, et al. Persistent Sin Nombre virus infection in the deer mouse (Peromyscus maniculatus) model: sites of replication and strand-specific expression. J Virol 2003; 77:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/79\">",
"      Hung T, Zhou JY, Tang YM, et al. Identification of Hantaan virus-related structures in kidneys of cadavers with haemorrhagic fever with renal syndrome. Arch Virol 1992; 122:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/80\">",
"      Kim S, Kang ET, Kim YG, et al. Localization of Hantaan viral envelope glycoproteins by monoclonal antibodies in renal tissues from patients with Korean hemorrhagic fever H. Am J Clin Pathol 1993; 100:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/81\">",
"      Toro J, Vega JD, Khan AS, et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis 1998; 4:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/82\">",
"      HULLINGHORST RL, STEER A. Pathology of epidemic hemorrhagic fever. Ann Intern Med 1953; 38:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/83\">",
"      Hautala T, Sironen T, Vapalahti O, et al. Hypophyseal hemorrhage and panhypopituitarism during Puumala Virus Infection: Magnetic Resonance Imaging and detection of viral antigen in the hypophysis. Clin Infect Dis 2002; 35:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4920/abstract/84\">",
"      Suh DC, Park JS, Park SK, et al. Pituitary hemorrhage as a complication of hantaviral disease. AJNR Am J Neuroradiol 1995; 16:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8315 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4920=[""].join("\n");
var outline_f4_51_4920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tissue tropism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cell entry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EARLY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CARDIOPULMONARY (SHOCK) STAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INFLAMMATORY MEDIATORS AND THE IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      T cell responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dendritic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reactive oxygen species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other mediators of tissue injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMMUNOLOGIC CORRELATES OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=related_link\">",
"      Hantavirus cardiopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25544?source=related_link\">",
"      Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_51_4921="Tacrolimus (systemic): Pediatric drug information";
var content_f4_51_4921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tacrolimus (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=see_link\">",
"    see \"Tacrolimus (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=see_link\">",
"    see \"Tacrolimus (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9559505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9559510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hecoria&trade;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9559511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advagraf&reg;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10527287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10527364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=see_link\">",
"      see \"Tacrolimus (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"     <b>",
"      Note:",
"     </b>",
"     Younger children generally require higher maintenance doses on a mg/kg basis than older children, adolescents, or adults (Kim, 2005; Montini, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liver transplant: Initial: 0.15-0.2 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart transplant: Initial: 0.1-0.3 mg/kg/day divided every 12 hours (Pollock-Barziv, 2005; Swenson, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Kidney transplant: Initial: 0.2-0.3 mg/kg/day divided every 12 hours (Filler, 2005; Kim, 2005; Montini, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prevention of graft-vs-host disease (unlabeled use): Convert from I.V. to oral dose (1:4 ratio): Multiply total daily I.V. dose times 4 and administer in 2 divided oral doses per day, every 12 hours (Yanik, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liver transplant: 0.03-0.05 mg/kg/day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart transplant: 0.01-0.03 mg/kg/day as a continuous infusion (Groetzner, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Kidney transplant: 0.06 mg/kg/day as a continuous infusion (Trompeter, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prevention of graft-vs-host disease (unlabeled use): Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion. Treatment should begin at least 24 hours prior to stem cell infusion and continued only until oral medication can be tolerated (Yanik, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 0.075-0.2 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liver transplant: Initial: 0.1-0.15 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart transplant: Initial: 0.075 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Kidney transplant: Initial: 0.2 mg/kg/day in combination with azathioprine or 0.1 mg/kg/day in combination with mycophenolate mofetil. Administer in 2 divided doses every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prevention of graft-vs-host disease (unlabeled use): Convert from I.V. to oral dose (1:4 ratio): Multiply total daily I.V. dose times 4 and administer in 2 divided oral doses per day, every 12 hours (Uberti, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. continuous infusion: 0.01-0.05 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liver or kidney transplant: Initial: 0.03-0.05 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart transplant: Initial: 0.01 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Graft-vs-host disease (unlabeled use):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prevention: 0.03 mg/kg/day (based on lean body weight) as continuous infusion. Treatment should begin at least 24 hours prior to stem cell infusion and continued only until oral medication can be tolerated (Przepiorka, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment: Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion (Furlong, 2000; Przepiorka, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal or hepatic impairment:",
"     </b>",
"     Patients with renal or hepatic impairment should receive the lowest dose in the recommended dosage range; further reductions in dose below these ranges may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemodialysis:",
"     </b>",
"     Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9564277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hecoria&trade;: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prograf&reg;: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prograf&reg;: 5 mg/mL (1 mL) [contains dehydrated ethanol 80%, polyoxyl 60 hydrogenated castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9559517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9559509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10527365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer on an empty stomach; use oral syringe or glass container (not plastic or foam cup) when administering this medication; do not administer with grapefruit juice; do not administer within 2 hours before or after antacids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: May administer by I.V. continuous infusion; I.V. concentrate for injection must be diluted to 0.004-0.02 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to administration; polyvinyl chloride-free administration tubing should be used to minimize the potential for significant drug absorption onto the tubing; begin no sooner than 6 hours post-transplant; continue only until oral medication can be tolerated",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9564188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS (only in glass or polyethylene containers).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, anidulafungin, benztropine, calcium gluconate, caspofungin, cefazolin, cefotetan, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, digoxin, diphenhydramine, dobutamine, dopamine, doripenem, doxycycline, erythromycin lactobionate, esmolol, fluconazole, furosemide, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, insulin (regular), isoproterenol, leucovorin calcium, lorazepam, methylprednisolone sodium succinate, metoclopramide, metronidazole, micafungin, morphine, multivitamins, mycophenolate, nitroglycerin, nitroprusside, oxacillin, penicillin G potassium, phenytoin, piperacillin, potassium chloride, propranolol, ranitidine, sodium bicarbonate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, ganciclovir, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10527311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable for 24 hours when mixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS in glass or polyolefin containers; 24-hour stability in plastic syringes stored at 24&deg;C; no need to protect from light; do not store in polyvinyl chloride containers since the polyoxyl 60 hydrogenated castor oil injectable vehicle may leach phthalates from polyvinyl chloride containers; polyvinyl-containing administration sets adsorb drug and may lead to a lower dose being delivered to the patient; tacrolimus is unstable in alkaline media; do not mix with acyclovir or ganciclovir",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10527303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of organ rejection in solid organ transplantation patients (FDA approved in children and adults) or prevention and treatment of graft-versus-host disease (GVHD) in allogeneic stem cell transplantation patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9559508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prograf&reg; may be confused with Gengraf&reg;, PROzac&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9559544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported for kidney, liver, and heart transplantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal ECG (QRS or ST segment abnormal), angina pectoris, arrhythmia, atrial fibrillation, atrial flutter, bradycardia, cardiopulmonary failure, deep thrombophlebitis, edema (including peripheral), heart failure, heart rate decreased, hemorrhage, hemorrhagic stroke, hyper-/hypotension, hypervolemia, orthostatic hypotension, pericardial effusion (heart transplant), peripheral vascular disorder, phlebitis, postprocedural pain, syncope, tachycardia, thrombosis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, chills, confusion, depression, dizziness, encephalopathy, fever, flaccid paralysis, hallucinations, headache, insomnia, mood elevated, pain, psychosis, quadriparesis, somnolence, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, bruising, cellulitis, exfoliative dermatitis, fungal dermatitis, hirsutism, photosensitivity reaction, skin discoloration, skin disorder, skin neoplasm, skin ulcer, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, alkalosis, Cushing's syndrome, bicarbonate decreased, dehydration, diabetes mellitus, gout, hypercholesterolemia, hyper-/hypocalcemia, hyperglycemia, hyper-/hypokalemia, hyperlipemia, hyperuricemia, hypomagnesemia, hyponatremia, hypophosphatemia, new-onset diabetes after transplant, post-transplant diabetes mellitus, serum iron decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, abdominal pain, appetite increased, constipation, cramps, diarrhea, duodenitis, dyspepsia, dysphagia, esophagitis (including ulcerative), flatulence, gastritis, gastroesophagitis, GI perforation/hemorrhage, ileus, nausea, oral moniliasis, pancreatic pseudocyst, rectal disorder, stomatitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder spasm, cystitis, dysuria, nocturia, oliguria, urge incontinence, urinary frequency, urinary incontinence, urinary retention, urinary tract infection, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, coagulation disorder, leukocytosis, leukopenia, prothrombin decreased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubinemia, cholangitis, cholestatic jaundice, GGT increased, hepatitis (including granulomatous), jaundice, LDH increased, liver damage, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Incision site complication, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, hypertonia, incoordination, joint disorder, leg cramps, monoparesis, myasthenia, nerve compression, neuropathy, osteoporosis, paresthesia, quadriparesis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Abnormal kidney function, acute renal failure, albuminuria, BK nephropathy, BUN/creatinine increased, hematuria, hydronephrosis, renal tubular necrosis, toxic nephropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, atelectasis, bronchitis, cough increased, dyspnea, emphysema, lung disorder, lung function decreased, pleural effusion, pneumothorax, pulmonary edema, respiratory disorder, rhinitis, sinusitis, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abscess, allergic reaction, CMV infection, crying, diaphoresis, flu-like syndrome, graft dysfunction, healing abnormal, hernia, herpes simplex, hiccups, infection, peritonitis, sepsis, writing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylaxis, anaphylactoid reaction, angioedema, ARDS, atrial flutter, basal cell carcinoma, bile duct stenosis, blindness, cardiac arrest, cerebral infarction, cerebrovascular accident, deafness, delirium, DIC, hemiparesis, hemolytic anemia, hemolytic-uremic syndrome, hemorrhagic cystitis, hepatic necrosis, hepatotoxicity, interstitial lung disease, leukoencephalopathy, lymphoproliferative disorder (related to EBV), malignant melanoma, myocardial hypertrophy (associated with ventricular dysfunction; reversible upon discontinuation), MI, neutropenia, osteomyelitis, pancreatitis (hemorrhagic and necrotizing), pancytopenia, posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML), quadriplegia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, respiratory failure, septicemia, squamous cell carcinoma, Stevens-Johnson syndrome, toxic epidermal necrolysis, thrombocytopenic purpura, torsade de pointes, TTP, veno-occlusive hepatic disease, venous thrombosis, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) have been reported (with concurrent sirolimus).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10527304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tacrolimus, polyoxyl 60 hydrogenated castor oil, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10527307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with hepatic or renal impairment. Systemic therapy should be administered under the supervision of a physician experienced in immunosuppressive therapy in a facility appropriate for monitoring and managing therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10527305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Immunosuppression with tacrolimus may result in increased susceptibility to infection and the possible development of lymphoma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Increased risk of other malignancies, including skin malignancies; risk is related to intensity and duration of immunosuppression. Lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk highest in young children; use combination immunosuppressant therapy with caution. Insulin-dependent post-transplant diabetes mellitus has been reported with use; risk increases in African-American and Hispanic kidney transplant patients. Neurotoxicity and nephrotoxicity have been reported especially when used in high doses. To avoid excess nephrotoxicity, do not administer simultaneously with cyclosporine; 24 hours should elapse before one is given after the other. Monitor serum potassium levels during therapy; hyperkalemia and hypokalemia have been reported. May cause hypertension; antihypertensive therapy may be required. Myocardial hypertrophy has been reported; ECG evaluation should be considered in any patient who develops renal failure or clinical manifestations of ventricular dysfunction. Closely monitor tacrolimus levels to assist in dose adjustment, monitor compliance, prevent organ rejection, and reduce drug-related toxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Each mL of injection contains polyoxyl 60 hydrogenated castor oil (HCO-60) (200 mg) and dehydrated alcohol USP 80% v/v. Anaphylaxis has been reported with the injection; use should be reserved for those patients not able to take oral medication. Adequate airway, supportive measures, and agents for treating anaphylaxis should be available when tacrolimus is administered I.V.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9564168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9564169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): May decrease the metabolism of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     TraZODone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent boceprevir. Follow tacrolimus concentrations closely and monitor patients for evidence of tacrolimus toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clotrimazole (Oral): May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Tacrolimus (Systemic). Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ertapenem: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibrate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibric Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with fluconazole.  Reduced doses of fluconazole will likely be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Tacrolimus (Systemic). Mifepristone may increase the serum concentration of Tacrolimus (Systemic). Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pantoprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Sirolimus may decrease the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus and sirolimus should only be used concomitantly as part of a protocol with a known risk:benefit profile and an established safety record.  Several regimens combining these agents have been associated with excess morbidity and/or mortality.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Significant tacrolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both tacrolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10527310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food reduces the rate and extent of absorption by ~27%; grapefruit juice may increase tacrolimus blood concentration",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9559521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9559522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum. Tacrolimus concentrations in the placenta may be higher than the maternal serum. No consistent pattern of congenital anomalies has been observed. Transient neonatal hyperkalemia and renal dysfunction have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10527366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes, BUN, serum creatinine, glucose, potassium, magnesium, phosphorus, blood tacrolimus concentrations, CBC with differential; blood pressure, neurologic status, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10527367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited data correlating serum concentration to therapeutic efficacy/toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough (whole blood ELISA): 5-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough (HPLC): 0.5-1.5 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart transplant: Typical whole blood trough concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Months 1-3: 10-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Months &ge;4: 6-18 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kidney transplant: Whole blood trough concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with azathioprine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 1-3: 7-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 4-12: 5-15 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with mycophenolate mofetil/IL-2 receptor antagonist (eg, daclizumab): Months 1-12: 4-11 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liver transplant: Whole blood trough concentrations: Months 1-12: 5-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of graft-vs-host disease: 10-20 ng/mL (Uberti, 1999); although some institutions use a lower limit of 5 ng/mL and an upper limit of 15 ng/mL (Przepiorka, 1999; Yanik, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10527312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to an intracellular protein forming a complex which inhibits phosphatase activity of calcineurin resulting in the inhibition of T-cell activation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10527313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Erratic and incomplete oral absorption (5% to 67%); food within 15 minutes of administration decreases absorption (27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes to erythrocytes, breast milk, lung, kidneys, pancreas, liver, placenta, heart, and spleen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 2.6 L/kg (mean)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 0.85-1.41 L/kg (mean) in liver and renal transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99% to alpha-acid glycoprotein (some binding to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic metabolism through the cytochrome P450 system (CYP3A) to eight possible metabolites (major metabolite: 31-demethyl tacrolimus has same activity as tacrolimus",
"     <i>",
"      in vitro",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 7% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 7% to 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 7.7-15.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 23-46 hours (in healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in bile; &lt;1% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: 7-103 mL/minute/kg (average: 30 mL/minute/kg); clearance higher in children",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10527368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=see_link\">",
"      see \"Tacrolimus (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose at the same time each day; you will be susceptible to infection (avoid crowds and people with infections); notify physician if you develop increased urination, thirst, chest pain, acute headache or dizziness, symptoms of respiratory infection, rash, unusual bruising or bleeding. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10527370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tacrolimus should be initiated no sooner than 6 hours after transplant; convert I.V. tacrolimus to oral form as soon as possible or within 2-3 days (the oral formulation should be started 8-12 hours after stopping the I.V. infusion); when switching a patient from cyclosporine to tacrolimus, allow at least 24 hours after discontinuing cyclosporine before initiating tacrolimus therapy to minimize the risk of nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional dosing considerations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Switch from I.V. to oral therapy: Approximately threefold increase in dose compared to I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients: Approximately two times higher dose compared to adults",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F9564281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.5 mg/mL tacrolimus oral suspension may be made with capsules and a 1:1 mixture of Ora-Plus&reg; and Simple Syrup, N.F. Mix the contents of six 5 mg tacrolimus capsules with quantity of vehicle sufficient to make 60 mL. Store in glass or plastic amber prescription bottles; label \"shake well\". Stable for 56 days at room temperature (Esquivel, 1996; Foster, 1996).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL  tacrolimus oral suspension may be made with capsules, sterile water, Ora-Plus&reg;, and Ora-Sweet&reg;. Pour the contents of six 5 mg capsules into a plastic amber prescription bottle. Add ~5 mL of sterile water and agitate bottle until drug disperses into a slurry. Add equal parts Ora-Plus&reg; and Ora-Sweet&reg; in sufficient quantity to make 30 mL. Store in plastic amber prescription bottles; label \"shake well\". Stable for 4 months at room temperature (Elefante, 2006).",
"    </p>",
"    <div class=\"reference\">",
"     Elefante A, Muindi J, West K, et al, &ldquo;Long-Term Stability of a Patient-Convenient 1 mg/mL Suspension of Tacrolimus for Accurate Maintenance of Stable Therapeutic Levels,&rdquo;",
"     <i>",
"      Bone Marrow Transplant",
"     </i>",
"     , 2006, 37(8):781-4.",
"     <span class=\"pubmed-id\">",
"      16518428",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Esquivel C, So S, McDiarmid S, Andrews W, and Colombani PM, &ldquo;Suggested Guidelines for the Use of Tacrolimus in Pediatric Liver Transplant Patients,&rdquo;",
"     <i>",
"      Transplantation",
"     </i>",
"     , 1996, 61(5):847-8.",
"     <span class=\"pubmed-id\">",
"      8607198",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Foster JA, Jacobson PA, Johnson CE, et al, &ldquo;Stability of Tacrolimus in an Extemporaneously Compounded Oral Liquid (Abstract of Meeting Presentation),&rdquo;",
"     <i>",
"      American Society of Health-System Pharmacists Annual Meeting",
"     </i>",
"     , 1996, 53:P-52(E).",
"     <span class=\"pubmed-id\">",
"      9117806",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Asante-Korang A, Boyle GJ, Webber SA, et al, &ldquo;Experience of FK506 Immune Suppression in Pediatric Heart Transplantation: A Study of Long-Term Adverse Effects,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 1996, 15(4):415-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/8732602/pubmed\" id=\"8732602\" target=\"_blank\">",
"        8732602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filler G, Webb NJ, Milford DV, et al, \"Four-Year Data After Pediatric Renal Transplantation: A Randomized Trial of Tacrolimus Vs Cyclosporin Microemulsion,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2005, 9(4):498-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/16048603/pubmed\" id=\"16048603\" target=\"_blank\">",
"        16048603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong T, Storb R, Anasetti C, et al, \"Clinical Outcome After Conversion to FK 506 (Tacrolimus) Therapy for Acute Graft-Versus-Host Disease Resistant to Cyclosporine or for Cyclosporine-Associated Toxicities,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(9):985-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/11100278/pubmed\" id=\"11100278\" target=\"_blank\">",
"        11100278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Groetzner J, Reichart B, Roemer U, et al, \"Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2005, 79(1):53-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/15620914/pubmed\" id=\"15620914\" target=\"_blank\">",
"        15620914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim JS, Aviles DH, Silverstein DM, et al, \"Effect of Age, Ethnicity, and Glucocorticoid Use on Tacrolimus Pharmacokinetics in Pediatric Renal Transplant Patients,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2005, 9(2):162-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/15787787/pubmed\" id=\"15787787\" target=\"_blank\">",
"        15787787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDiarmid SV, Colonna JO, Shaked A, et al, &ldquo;Differences in Oral FK506 Dose Requirements Between Adults and Pediatric Liver Transplant Patients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1993, 55(6):1328-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/7685933/pubmed\" id=\"7685933\" target=\"_blank\">",
"        7685933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menegaux F, Keeffe EB, Andrews BT, et al, &ldquo;Neurological Complications of Liver Transplantation in Adult Versus Pediatric Patients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1994, 58(4):447-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/8073514/pubmed\" id=\"8073514\" target=\"_blank\">",
"        8073514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montini G, Ujka F, Varagnolo C, et al, \"The Pharmacokinetics and Immunosuppressive Response of Tacrolimus in Paediatric Renal Transplant Recipients,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2006, 21(5):719-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/16550361/pubmed\" id=\"16550361\" target=\"_blank\">",
"        16550361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollock-Barziv SM, Dipchand AI, McCrindle BW, et al, \"Randomized Clinical Trial of Tacrolimus- Vs Cyclosporine-Based Immunosuppression in Pediatric Heart Transplantation: Preliminary Results at 15-Month Follow-Up,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2005, 24(2):190-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/15701436/pubmed\" id=\"15701436\" target=\"_blank\">",
"        15701436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Przepiorka D, Devine S, Fay J, et al, \"Practical Considerations in the Use of Tacrolimus for Allogeneic Marrow Transplantation,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1999, 24(10):1053-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/10578154/pubmed\" id=\"10578154\" target=\"_blank\">",
"        10578154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swenson JM, Fricker FJ, and Armitage JM, \"Immunosuppression Switch in Pediatric Heart Transplant Recipients: Cyclosporine to FK 506,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 25(5):1183-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/7534779/pubmed\" id=\"7534779\" target=\"_blank\">",
"        7534779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taormina D, Abdallah HY, Venkataramanan R, et al, \"Stability and Sorption of FK 506 in 5% Dextrose Injection and 0.9% Sodium Chloride Injection in Glass, Polyvinyl Chloride, and Polyolefin Containers,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(1):119-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/1373936/pubmed\" id=\"1373936\" target=\"_blank\">",
"        1373936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trompeter R, Filler G, Webb NJ, et al, \"Randomized Trial of Tacrolimus Versus Cyclosporin Microemulsion in Renal Transplantation,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2002, 17(3):141-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/11956848/pubmed\" id=\"11956848\" target=\"_blank\">",
"        11956848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uberti JP, Cronin S, and Ratanatharathorn V, \"Optimum Use of Tacrolimus in the Prophylaxis of Graft Versus Host Disease,\"",
"      <i>",
"       BioDrugs",
"      </i>",
"      , 1999, 11(5):343-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/18031144/pubmed\" id=\"18031144\" target=\"_blank\">",
"        18031144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yanik G, Levine JE, Ratanatharathorn V, et al, \"Tacrolimus (FK506) and Methotrexate as Prophylaxis for Acute Graft-Versus-Host Disease in Pediatric Allogeneic Stem Cell Transplantation,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(2):161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/51/4921/abstract-text/10918426/pubmed\" id=\"10918426\" target=\"_blank\">",
"        10918426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16051 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4921=[""].join("\n");
var outline_f4_51_4921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559505\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559511\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527287\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527364\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564277\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559517\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559509\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564188\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527311\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527303\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559508\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559544\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527304\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527307\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527305\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564168\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527310\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559521\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559522\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527366\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527367\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527312\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527313\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527368\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527370\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564281\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=related_link\">",
"      Tacrolimus (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=related_link\">",
"      Tacrolimus (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/30/6630?source=related_link\">",
"      Tacrolimus (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/21/341?source=related_link\">",
"      Tacrolimus (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/9/26772?source=related_link\">",
"      Tacrolimus (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_51_4922="Adjuvant therapy for resected rectal cancer";
var content_f4_51_4922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant therapy for resected rectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4922/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/51/4922/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/51/4922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the cornerstone of curative therapy for rectal cancer. However, surgery alone provides a high cure rate only for patients with early stage disease. Following potentially curative resection, five-year survival rates are 80 and 90 percent for patients with stage I disease, while they are 70 percent or lower for those with stage II or III disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many randomized trials have attempted to improve upon the results of surgery alone through the addition of adjuvant therapy. While adjuvant strategies for resected colon cancer have focused on chemotherapy alone, radiation therapy (RT) has emerged as an important component of adjuvant therapy for rectal cancer because of the distinct patterns of failure following resection. In contrast to colon cancer, in which the failure pattern is predominantly distant metastases, the site of first failure in patients undergoing surgery for rectal cancer is equally distributed locally (ie, pelvis) and in distant sites (eg, liver, lung) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/1\">",
"     1",
"    </a>",
"    ]. Local recurrence is mainly related to difficulties in obtaining optimal surgical clearance of the radial margin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of early trials evaluated postoperative RT with or without chemotherapy. More recently, focus has shifted to preoperative (neoadjuvant) application of combined chemoradiotherapy in an attempt to preserve the anal sphincter. Adjuvant therapy for resectable rectal cancer will be reviewed here. Preoperative staging evaluation, neoadjuvant chemoradiotherapy, surgical management of rectal cancer, treatment of locally advanced rectal cancer, and posttreatment follow-up after definitive treatment are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUVANT RT ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for postoperative RT is based upon patterns of failure following potentially curative surgery. After surgery alone, local failure is a component of first failure in less than 10 percent of patients with T1-2 disease, 15 to 35 percent of those with stage T3N0 disease, and 45 to 65 percent with stage T3-4, node positive disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Significantly fewer local recurrences (generally, &lt;10 percent) are reported in series utilizing total mesorectal excision (TME, (",
"    <a class=\"graphic graphic_figure graphicRef65765 \" href=\"UTD.htm?35/11/36020\">",
"     figure 1",
"    </a>",
"    )) (4 to 12 percent). The morbidity associated with local failure is substantial, and salvage procedures are usually of limited success. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=see_link\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials consistently show significantly better local control [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] and longer time to local failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/8\">",
"     8",
"    </a>",
"    ] using conventional fractionation adjuvant RT in patients with resected stage II or III disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). However, a survival benefit has not been demonstrated in any trial. In a meta-analysis, which included 2157 patients treated on eight randomized trials of surgery with or without adjuvant RT (mostly without chemotherapy), RT significantly reduced the five-year risk of local recurrence (17 versus 28 percent) compared to surgery alone, but survival was similar (58 versus 59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMBINED CHEMOTHERAPY PLUS RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to RT alone, there appears to be a survival advantage when postoperative RT is combined with 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU)-based chemotherapy following resection of transmural or node-positive rectal cancer. The efficacy of this combined modality approach was established by a series of prospective randomized trials during the 1980s and 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/5-7,10-12\">",
"     5-7,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early trials",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     GITSG trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal Tumor Study Group (GITSG) protocol 7175 randomly assigned 227 patients with completely resected Dukes' B2 and C rectal cancer (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) to one of four arms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Observation",
"     </li>",
"     <li>",
"      Postoperative RT only (40 or 48 Gy)",
"     </li>",
"     <li>",
"      Chemotherapy only [semustine (methyl-CCNU) plus (5-FU)]",
"     </li>",
"     <li>",
"      Postoperative RT (40 or 44 Gy) with concurrent 5-FU followed by maintenance chemotherapy using 5-FU and semustine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trial was terminated early after 227 of a planned 500 patients were entered because of observed outcome differences. Patients treated with chemoradiotherapy had a significantly lower recurrence rate than those undergoing surgery alone (33 versus 55 percent), and after eight-years of follow-up, significantly longer survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/6\">",
"     6",
"    </a>",
"    ]. Eighteen percent of patients in the chemoradiotherapy group had acute severe or life-threatening events, and there were three late deaths; two due to enteritis in the combined therapy group and one due to acute leukemia in the chemotherapy alone group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     NCCTG trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second major trial by the Mayo",
"    <span class=\"nowrap\">",
"     Clinic/North",
"    </span>",
"    Central Cancer Treatment Group (NCCTG) randomly assigned 204 patients with completely resected Dukes' B2 and C rectal cancer to postoperative RT alone (45 to 50.4 Gy) or with concurrent 5-FU, which was both preceded and followed by one cycle of 5-FU and methyl-CCNU [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no surgery alone control arm.",
"   </p>",
"   <p>",
"    At a median follow-up of over seven years, chemoradiotherapy was associated with a significant 47 percent reduction in the risk of relapse, and a 36 percent reduction in the risk of cancer-related death. Local recurrence rates were diminished by 46 percent, and the likelihood of developing distant metastases by 37 percent. In contrast to the GITSG trial, chemoradiotherapy was generally well tolerated and long-term toxicity was not observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     NSABP trial R-01",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest randomized trial, performed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), randomly assigned 555 patients with resected Dukes' B and C rectal cancer to one of three arms: observation only, adjuvant chemotherapy only (methyl-CCNU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and 5-FU; MOF), or postoperative RT only (46 to 47 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/7\">",
"     7",
"    </a>",
"    ]. No group received postoperative chemoradiotherapy.",
"   </p>",
"   <p>",
"    There was a significant disease-free survival (DFS) advantage to MOF chemotherapy compared to surgery alone or with RT, but no overall survival benefit. Patients receiving postoperative RT had a reduction in local recurrence, but no improvement in survival compared with surgery alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23407468\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit for the addition of adjuvant chemotherapy after potentially curative resection of a rectal cancer was also shown in a meta-analysis of 21 trials comparing outcomes between 4367 patients who did not receive adjuvant chemotherapy and 4854 who did [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/13\">",
"     13",
"    </a>",
"    ]. All of the trials used fluoropyrimidine-based chemotherapy. The use of adjuvant chemotherapy was associated with a significant reduction in the risk of disease relapse (HR for relapse 0.75, 95% CI 0.68-0.83) and death (HR for death 0.83, 95% CI 0.76-0.91).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Refinements in chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the chemotherapy regimens utilized by the GITSG, the NSABP and the NCCTG contain methyl-CCNU (semustine), a known risk factor for acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two subsequent randomized trials showed that methyl-CCNU does not produce an additive benefit to RT plus 5-FU in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One of these trials, which evaluated the use of continuous infusion 5-FU as well as the value of methyl-CCNU as a component of the adjuvant regimen, was also the first to suggest that patients receiving protracted infusion 5-FU during RT had significantly better outcomes compared to those receiving bolus 5-FU (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/12\">",
"     12",
"    </a>",
"    ]. Methyl-CCNU is no longer utilized in adjuvant chemotherapy regimens in patients with colorectal cancer.",
"   </p>",
"   <p>",
"    A major focus of clinical study has been how best to optimize the proven combination of RT and 5-FU during chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Infusional versus bolus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key contribution was the finding that the radiation sensitizing effects of 5-FU in vitro are maximal when exposure to 5-FU occurs for at least 24 hours and up to 48 hours after RT exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/15\">",
"     15",
"    </a>",
"    ]. These data lent support to the use of continuous administration schedules of 5-FU concurrent with fractionated RT in a variety of gastrointestinal cancers, including rectal cancer.",
"   </p>",
"   <p>",
"    Two large randomized trials have compared infusional versus bolus 5-FU as adjuvant treatment of rectal cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first NCCTG-led Intergroup study tested the value of prolonged venous infusion (PVI) 5-FU (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for five weeks) versus bolus 5-FU alone (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 1 to 3 and 36 to 39) during RT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/12\">",
"       12",
"      </a>",
"      ]. PVI 5-FU was associated with a significant reduction in distant metastases (31 versus 40 percent), and improvements in four-year relapse-free survival (RFS) as well as overall survival (70 versus 60 percent), but there was no difference in local recurrence. Patients receiving PVI 5-FU during RT were at higher risk of severe diarrhea, but the effect did not persist after completion of RT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      United States Intergroup study (INT 0144) was designed to investigate the benefit of PVI versus bolus 5-FU not only during but also before and after RT. The study randomly assigned 1917 patients to the following groups [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/17\">",
"       17",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Group 1: Bolus 5-FU before (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily days 1 through 5, and 29 through 34) and after (450",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) RT, with PVI during RT (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      Group 2: PVI before (300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 42 days), after (300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 56 days), and during RT (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      Group 3: Bolus 5-FU with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      and levamisole before RT (5-FU 425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, LV 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, both on days 1 through 5, and 29 through 34), after RT (5-FU 380",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, LV 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, days 29 to 34 and 57 to 62), and during RT (5-FU 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus LV 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, days 1 to 4, during weeks 1 and 5 of RT). Levamisole (150 mg daily on days 1 to 3 and 14 to 16) was administered with each cycle before and after RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a median 5.7 years of follow-up, there were no differences among the groups in three-year DFS (67 to 69 percent) or overall survival (81 to 83 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/17\">",
"     17",
"    </a>",
"    ]. Locoregional failure rates were also similar in all groups (4.6 to 8 percent). Toxicity (including gastrointestinal toxicity) was similar among all groups except that the PVI arm had significantly lower rates of grade 3 to 4 hematologic toxicity (4 versus 49 to 55 percent in the bolus arms, respectively).",
"   </p>",
"   <p>",
"    These data can be interpreted as showing that both bolus and infusional 5-FU alone represent appropriate choices for adjuvant 5-FU-based chemotherapy in conjunction with postoperative RT. However, many institutions favor infusional 5-FU based upon the results of the first Intergroup study and the lower rate of hematologic toxicity using this approach as compared to bolus treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. A major problem with PVI 5-FU is the cost, inconvenience, and the risk of maintaining a central line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     5-FU plus leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    enhances 5-FU cytotoxicity by interacting with thymidylate synthase to form a stable ternary complex, prolonging inhibition of the enzyme by 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of modulating the effect of 5-FU with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    during chemoradiotherapy was tested in United States Intergroup trial 0114 (INT-0114) that randomly assigned 1696 patients with completely resected rectal cancer to postoperative pelvic RT plus one of the following chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bolus 5-FU alone (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days for two monthly courses prior to chemoradiotherapy, 450",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days monthly for two courses after chemoradiotherapy, and 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for three days during weeks 1 and 5 of RT)",
"     </li>",
"     <li>",
"      5-FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (5-FU 425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus leucovorin 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days on days 1 to 5 and 29 to 33 prior to chemoradiotherapy, followed by chemoradiotherapy with 5-FU 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus leucovorin 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days during weeks 1 and 5 of RT, and two additional courses of 5-FU 380",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus leucovorin 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days once per month)",
"     </li>",
"     <li>",
"      5-FU plus levamisole (two courses of chemotherapy alone before and after chemoradiotherapy using bolus 5-FU alone during RT as outlined in the bolus 5-FU alone arm); levamisole is a nonspecific immune stimulant that was mainly studied in combination with 5-FU as adjuvant treatment for patients with resected node-positive colon carcinoma; its use fell out of favor because of toxicity and the drug is no longer available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H2#H2\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Historical perspective'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      5-FU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      and levamisole, with the same doses and schedule as the",
"      <span class=\"nowrap\">",
"       5-FU/leucovorin",
"      </span>",
"      arm described above, in conjunction with oral levamisole",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With extended follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/19\">",
"     19",
"    </a>",
"    ], there was no significant advantage to any of the regimens compared to bolus 5-FU alone (the three drug regimen was more toxic) and there was no obvious benefit for levamisole in resected rectal cancer. Results from this trial that address the impact of 5-FU dosing on outcome for obese patients are discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Chemotherapy dosing for obese patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Orally active fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is an orally active fluoropyrimidine prodrug that was designed to mimic continuous infusion 5-FU while avoiding the cost, inconvenience, and risk of maintaining a central line for PVI 5-FU. The conversion of capecitabine to active 5-FU requires three different enzymes, one of which (thymidine phosphorylase) is present in higher concentrations in tumors (particularly colorectal cancers) than in normal tissue. As a result of this tumor selectivity, significantly higher tumor to plasma ratios of 5-FU are achievable with capecitabine than with intravenous 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III German trial directly compared chemoradiotherapy (50.4 Gy) with concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1650",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily in two divided doses on days 1 to 38) versus infusional 5-FU (225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion daily) in patients with stage II or III rectal cancer undergoing adjuvant (n = 213) or neoadjuvant (n = 161) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/22\">",
"     22",
"    </a>",
"    ]. All patients in the capecitabine arm treated in the adjuvant setting received two postoperative cycles of capecitabine (2500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily days 1 to 14 of each 21-day cycle) before chemoradiotherapy, and three additional cycles after afterward, while those treated neoadjuvantly received chemoradiotherapy followed by surgery and then five courses of capecitabine at the same dose and schedule. In the adjuvant setting, the 5-FU group received two cycles of bolus 5-FU (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, days 1 to 5, every 28 days) both before and after chemoradiotherapy, while those treated in the neoadjuvant setting received chemoradiotherapy followed by surgery and four courses of the same dose and schedule of postoperative bolus 5-FU.",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    had significantly more hand foot syndrome overall, but less neutropenia. Within the neoadjuvant therapy stratum, early secondary efficacy endpoints favored capecitabine (higher rate of T-stage downstaging and pN0 status), although the primary endpoint, overall survival, was not reported. Efficacy results for patients treated in the adjuvant setting were not reported.",
"   </p>",
"   <p>",
"    Taken together, these results support the view that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is an appropriate substitute for infusional 5-FU when given concurrently with RT for treatment of rectal cancer in either the preoperative or postoperative setting. Oral capecitabine is considered an acceptable option during RT (as well as monotherapy after chemoradiotherapy in guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    ). However, in our view, infusional 5-FU is still the preferred approach, largely because no study has yet demonstrated the long-term therapeutic equivalence of this approach compared to concomitant IV 5-FU during RT for either preoperative or postoperative therapy. One other ongoing trial, NSABP trial 04, is addressing the equivalence of these two approaches directly in the neoadjuvant setting.",
"   </p>",
"   <p>",
"    An additional concern is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    metabolism is difficult to follow, and systemic exposure correlates poorly with efficacy and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/23\">",
"     23",
"    </a>",
"    ]. The likely variable bioavailability of oral fluoropyrimidines in individual patients raises concerns as to adequate dosing of these agents.",
"   </p>",
"   <p>",
"    For all of these reasons, we continue to recommend infusional 5-FU during adjuvant RT. If placement of a port is not an option,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is a reasonable approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oxaliplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with resected node-positive colon cancer data from the randomized MOSAIC and NSABP C-07 trials indicate the superiority of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to a 5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    backbone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is beneficial for adjuvant treatment of rectal cancer is not yet established. The only available data come from a United States Intergroup trial (E3201) in which FOLFOX was compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    and an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimen (FOLFIRI, (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"UTD.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    )) following either preoperative or postoperative 5-FU-based chemoradiotherapy for rectal cancer. Unfortunately, the trial was terminated after only 225 of the planned 3150 patients were enrolled, due to a competing trial evaluating the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) (E5204). The safety of combining FOLFOX after 5-FU-based chemoradiotherapy was shown in a preliminary toxicity report from the 225 enrolled patients, but no efficacy data were provided [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    FOLFOX caused more grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    neutropenia (31 versus 4 percent), but less grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    diarrhea (13 versus 3 percent, respectively).",
"   </p>",
"   <p>",
"    Despite the lack of data, guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    include FOLFOX (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    using a regimen such as that outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 3",
"    </a>",
"    )) as an acceptable regimen for the chemotherapy component of adjuvant therapy in rectal cancer. Although this is a popular approach based upon results from the MOSAIC and NSABP C07 adjuvant studies in colon cancer, physicians should be aware that there is no evidence that FOLFOX is better that fluoropyrimidine therapy alone in the adjuvant setting for rectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the lack of benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    as a component of neoadjuvant concomitant chemoradiotherapy, it should not be used concurrently with RT in the adjuvant setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H20#H20\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on '5-FU/capecitabine plus other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Irinotecan-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimens, chemotherapy regimens that contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    have not been beneficial for adjuvant treatment of resected colon cancer, and regimens containing irinotecan cannot be routinely recommended for adjuvant treatment of rectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H19#H19\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one randomized trial has explored the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based adjuvant chemotherapy in conjunction with 5-FU-based chemoradiotherapy for resected rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/25\">",
"     25",
"    </a>",
"    ]. There were 321 patients who were randomly assigned to weekly bolus LV (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus 5-FU (450",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    without or with irinotecan (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly); both groups received four weekly infusions, followed by pelvic RT concurrent with 5-FU, and followed by five additional months of weekly chemotherapy. There were no differences between the groups in terms of three-year disease free, overall, relapse-free or local relapse-free survival; however, toxicity was higher in the irinotecan arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sequencing of chemotherapy and RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of the GITSG study, most trials demonstrating benefit for combined chemoradiotherapy have used a \"sandwich\" technique, in which one or two cycles of chemotherapy were followed by combined modality therapy and then additional chemotherapy. However, the optimal sequence of RT and chemotherapy is unknown. This issue was addressed in a Korean trial that randomly assigned 308 patients with resected stage II or III rectal cancer to begin RT (45 Gy in 25 fractions) with either the first or third planned course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/26\">",
"     26",
"    </a>",
"    ]. At 10 years, there was no significant benefit for early RT in terms of DFS (71 versus 63 percent), overall survival (66 versus 64 percent), or rate of recurrence (27 versus 35 percent), either locoregional or distant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chemotherapy dosing for obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most chemotherapy drugs are dosed on the basis of body surface area. Doses for obese patients are sometimes calculated based upon ideal rather than actual body weight, a practice for which there is no scientific basis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/27\">",
"     27",
"    </a>",
"    ]. Underdosing of chemotherapy may have adverse clinical consequences for obese patients with rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     '5-FU plus leucovorin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines from ASCO recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, the results of randomized trials suggest that several regimens are appropriate for adjuvant therapy after resection of rectal cancer. For concurrent chemoradiotherapy, the use of infusional 5-FU is generally preferred over bolus 5-FU because of its more favorable side effect profile. If placement of a port is not an option,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is a reasonable approach.",
"   </p>",
"   <p>",
"    For the chemotherapy component of adjuvant therapy, several regimens are acceptable, including bolus 5-FU alone (as was used in both US Intergroup trials 0144 and 0114),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU (either weekly bolus or short-term infusional), infusional 5-FU alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , and FOLFOX (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although improvements in local control and survival have been achieved by the use of adjuvant combined modality therapy, acute and late treatment related morbidities have also been observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 100 patients, compared with those treated with low anterior resection (LAR) alone, patients who received chemoradiotherapy after LAR had more bowel movements per day (median 7 versus 2) and a greater likelihood of nighttime bowel movements (46 versus 14 percent), occasional incontinence (39 versus 7 percent), and needing to wear a pad (41 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the intergroup trial described above, 24 percent of patients receiving concurrent pelvic RT and PVI 5-FU experienced severe or life-threatening diarrhea during treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/12,16\">",
"       12,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link&amp;anchor=H19#H19\">",
"       \"Gastrointestinal toxicity of radiation therapy\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to acute toxicity, there may be significant late effects as well. This was illustrated in an analysis of 306 rectal cancer patients treated with postoperative RT from 1981 to 1990, in which the ten-year probability of developing chronic bowel injury was 25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"       \"Diagnosis and management of chronic radiation enteritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the advantages of neoadjuvant compared to adjuvant therapy for rectal cancer is a decrease in the likelihood of chronic bowel toxicity. As an example, in the seminal German Rectal Cancer Study, which randomly assigned 823 patients with clinically staged",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    or node-positive rectal cancer to the same chemoradiotherapy regimen administered either preoperatively or postoperatively, the benefits of preoperative therapy included a significantly fewer pelvic relapses, a twofold higher chance of sphincter preservation, and a significantly lower rate of chronic anastomotic strictures (4 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H13#H13\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'German Rectal Cancer Study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Can adjuvant therapy be omitted in any patient with stage II or III rectal cancer?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Patients undergoing TME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity of adjuvant RT in patients undergoing optimal local resection (ie, total mesorectal excision [TME], (",
"    <a class=\"graphic graphic_figure graphicRef65765 \" href=\"UTD.htm?35/11/36020\">",
"     figure 1",
"    </a>",
"    )) is controversial. Proponents of eliminating RT quote series that demonstrate a very low local recurrence rate with TME [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one such report, the 10-year local recurrence rate was 4 percent in a group of patients who underwent TME without adjuvant therapy for Duke's B2 or C disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) over a 13-year period at a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opponents of this view quote other data that suggest a higher rate of local recurrence with TME alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In one of these studies, in which 95 patients with T3N0 rectal cancer underwent TME (79 LAR and 16 abdominoperineal resection [APR]) without postoperative adjuvant therapy, the five-year rate of actuarial local recurrence was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, a benefit for RT even among patients undergoing TME was suggested in a Dutch neoadjuvant trial that randomly assigned 1861 patients with resectable rectal cancer to TME alone or a short course of preoperative RT (5 Gy daily for five days, in the \"Swedish style\", followed by TME) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/37\">",
"     37",
"    </a>",
"    ]. The two-year rate of local recurrence was significantly less in the radiated group (2 versus 8 percent), although long-term bowel toxicity was prominent using this technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H24#H24\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Short-course, Swedish style RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other data support the benefit of adjuvant chemotherapy for patients undergoing TME, even if RT is not administered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/38\">",
"     38",
"    </a>",
"    ]. In a multicenter trial that randomly assigned 276 patients undergoing TME for node-positive rectal cancer to oral tegafur plus uracil (UFT) or no adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/38\">",
"     38",
"    </a>",
"    ]. The patients receiving UFT had significantly better three-year RFS (78 versus 60 percent) and overall survival (91 versus 81 percent, respectively).",
"   </p>",
"   <p>",
"    Taken together, these data suggest that there is potential benefit for adjuvant therapy, even after a TME.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Favorable risk rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be subsets of patients with resected stage IIA or IIIA (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) rectal cancer who do well without the routine use of postoperative adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88194366\">",
"    <span class=\"h4\">",
"     T3N0&nbsp;disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that a subset of patients with resected T3N0 rectal cancer do well without adjuvant therapy. A review of the experience at Massachusetts General Hospital included 117 patients with T3N0 rectal cancer who underwent resection with curative intent and received neither neoadjuvant nor adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/39\">",
"     39",
"    </a>",
"    ]. For the 25 patients with favorable histologic features (well or moderately differentiated histology, extending 2 mm or less into perirectal fat, and without vascular invasion), the 10-year actuarial local control rate and RFS were 95 and 87 percent, respectively. The 10-year actuarial local control and recurrence free survival rates were lower (71 and 55 percent, respectively) in the 88 patients with less favorable histologic features.",
"   </p>",
"   <p>",
"    Other data support the view that these patients do as well with adjuvant chemotherapy alone as with chemotherapy plus RT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/5,6,40,41\">",
"     5,6,40,41",
"    </a>",
"    ]. This issue was addressed in a pooled analysis of 3791 patients with rectal cancer enrolled in five randomized trials comparing a variety of adjuvant strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/41\">",
"     41",
"    </a>",
"    ]. For patients with T3N0 disease, five-year overall survival rates with surgery plus chemotherapy (84 percent) compared favorably to those of patients undergoing surgery with RT and bolus chemotherapy (74 and 76 percent). However, the five-year DFS rate was only 69 percent.",
"   </p>",
"   <p>",
"    We still recommended 5-FU-based chemoradiotherapy for all patients with T3N0 rectal cancer, even if a TME was performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88194388\">",
"    <span class=\"h4\">",
"     T1-2N1 disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III rectal cancer are a heterogeneous group with five-year survival rates that range from 30 to 74 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. The 2010 AJCC classification separates these patients into prognostically distinct A, B, and C categories depending upon depth of tumor invasion and the number of involved lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to the results reported for T3N0 disease, patients with resected T1-2N1 disease may do as well with adjuvant chemotherapy alone as with chemoradiotherapy. In the same pooled analysis described above, the five-year survival rates for patients with T1-2N1 (one to three positive lymph nodes) disease undergoing surgery with chemotherapy (85 percent) compared favorably to those of patients undergoing surgery plus RT and bolus chemotherapy (82 and 83 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/41\">",
"     41",
"    </a>",
"    ]. The five-year DFS rate was 78 percent.",
"   </p>",
"   <p>",
"    Nevertheless, we still recommended 5-FU-based chemoradiotherapy for all patients with node-positive rectal cancer, regardless of the number of involved nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Patients undergoing neoadjuvant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no trial has demonstrated conclusively that additional postoperative 5-FU-based chemotherapy improves outcomes in patients who had neoadjuvant chemoradiotherapy, most oncologists recommend it and guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend that all such patients receive chemotherapy even if they have no residual tumor in the surgical specimen. This topic is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H27#H27\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Benefit of postoperative chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6323794\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMORADIOTHERAPY FOR T2-3 RECTAL CANCER AFTER LOCAL EXCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early rectal cancers who have nonaggressive features can be treated by local excision, including the transanal, transsphincteric, and posterior parasacral approaches. Local excision permits removal of both the tumor and adjoining rectal tissue in one specimen without tumor fragmentation, and allows assessment of inked margins, histologic differentiation, vascular involvement, and depth of invasion.",
"   </p>",
"   <p>",
"    This approach is usually reserved for patients with well-differentiated T1 lesions that are less than 3 cm in diameter, located in the middle to distal rectum, and lack lymphovascular invasion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87589066#H87589066\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although more radical surgery is preferred, select patients (ie, those with comorbid illness, refusal of major resection) with completely resected early rectal cancers deeper than T1 may be treated with a local excision if used in conjunction with radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early prospective study of 26 patients with",
"      <span class=\"nowrap\">",
"       T2/T3",
"      </span>",
"      rectal cancer less than 4 cm in diameter and within 10 cm from the dentate line treated with a local excision (TAE, transsphincteric, or transcoccygeal approach) and adjuvant chemoradiation therapy identified a local recurrence in two patients (8 percent) with a mean follow-up of 40.5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/43\">",
"       43",
"      </a>",
"      ]. This is comparable to the rate of local recurrence in 22 patients (9 percent) with",
"      <span class=\"nowrap\">",
"       T0/T1",
"      </span>",
"      rectal cancer treated with local excision alone.",
"     </li>",
"     <li>",
"      However, these data could not be replicated using neoadjuvant chemoradiotherapy followed by local excision in a later multi-institutional prospective study conducted by the American College of Surgeons Oncology Group (ACSOG &ndash; Z6041) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/44\">",
"       44",
"      </a>",
"      ]. In this study, 77 patients with clinically staged T2N0 rectal cancer were treated with neoadjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , and radiation therapy followed by a local excision. Although the complete pathologic response was 44 percent and downstaging to ypT0-T1 occurred in 49 patients (64 percent), it also identified four patients with residual T3 cancer, one of whom had a positive lymph node in the surgical specimen. Furthermore, of the cohort receiving neoadjuvant therapy, 33 of 84 (39 percent) had &ge;grade 3 adverse events, including gastrointestinal, metabolic, and hematologic complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treating T2 or T3 disease without radical surgery should only be done in those patients refusing standard surgery. If this approach is chosen, close posttreatment surveillance is mandatory. Furthermore, all patients undergoing a local excision must be closely followed indefinitely, as almost one-third of local recurrences occur more than five years after resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link&amp;anchor=H87594804#H87594804\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY: DIET, EXERCISE, AND ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that dietary factors and obesity may influence outcomes in some patients with colorectal cancer. However, whether weight reduction or changes in diet would improve outcomes after treatment for rectal cancer is not known. Higher levels of physical activity may reduce the risk of colorectal cancer-specific and overall mortality, in addition to having a beneficial impact on fatigue, quality of life, and functional status. The roles of diet, physical activity, and body weight in cancer survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332277876\">",
"    <span class=\"h2\">",
"     Aspirin and other NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous observational studies and randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    against the development of colorectal adenomas and cancer through its actions as an inhibitor of the cyclooxygenase 2 (COX-2) pathway. This pathway is overexpressed in 80 to 85 percent of CRCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest that use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs may also improve survival among patients receiving treatment for early colorectal cancer. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H41#H41\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Aspirin and other NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2949556\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE AND SURVIVOR ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for posttreatment cancer surveillance and issues that arise in long-term survivors of rectal cancer (genitourinary problems, bowel and anorectal dysfunction) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28202?source=see_link\">",
"     \"Approach to the long-term survivor of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS OF POSTOPERATIVE RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the treatment of abdominopelvic tumors, careful attention must be paid to RT technique. It is generally",
"    <strong>",
"     not",
"    </strong>",
"    appropriate to treat rectal tumors with anteroposterior-posteroanterior (AP-PA) fields alone. Since the anterior structures, which receive high dose, are not substantially at risk for local failure, the two-field technique results in increased treatment-related toxicity without significant improvement in local control. At our institution, we generally treat patients with a four-field box technique, although a three-field with right and left lateral fields and a posterior field is also reasonable. The use of lateral fields permits sparing of a portion of the bladder and some anteriorly placed small bowel.",
"   </p>",
"   <p>",
"    The AP-PA fields extend from approximately the lower level of the L5 vertebral body to 4 to 5 cm below the anastomosis (or below the tumor when treating preoperatively) in patients with a low anterior resection (LAR). For patients with an abdominoperineal resection (APR), the fields always extend to include the perineum. There are a substantial number of local recurrences in the perineum, and this area needs to be in the high dose volume. Laterally, the fields extend approximately 1.0 to 1.5 cm beyond the bony pelvis so that the lateral pelvic soft tissue receives the full radiation dose. The lateral fields have the same cephalad and caudad extent as the AP-PA fields.",
"   </p>",
"   <p>",
"    Patients are treated in a prone position. The posterior border of the lateral field extends beyond the bony sacrum so that the full dose is delivered to the presacral space, a common site of local failure. Anteriorly, the fields extend to adequately cover the original tumor with at least a 2 cm margin. Blocks can often be used to spare a portion of the femoral neck on the lateral fields.",
"   </p>",
"   <p>",
"    The bladder should be full during treatment so as to push some of the small intestine out of the radiation treatment volume. When the perineum needs to be treated, a bolus is placed on it so that a full dose will be delivered to the scar in this region. A bolus is a material with similar density to tissue that is placed directly on the skin surface. The beam then strikes the absorbing surface at the bolus, whose thickness is calculated so that the maximum dose to the target volume occurs closer to the skin surface. If the reaction becomes marked, the bolus can be removed. Perineal reactions do not typically produce major symptoms.",
"   </p>",
"   <p>",
"    Patients are treated at 1.8 Gy, five fractions per week, to a total dose of 45 Gy to these fields. The field size is then reduced and a boost dose is delivered to the tumor bed. Prior to designing the boost field, a special small bowel radiographic series is obtained to define the exact location of the small bowel with respect to the boost area. Only by knowing the exact bowel position can one design the treatment volumes to minimize excess irradiation of the small intestine.",
"   </p>",
"   <p>",
"    Great effort is made to avoid doses greater than 45 Gy to any small bowel that is fixed in the pelvis. In this regard, it is helpful to have the surgeon (at the time of the initial surgical procedure) try to move small intestine out of the pelvis. This can best be accomplished by reperitonealizing the pelvic floor. When this is not possible, a loop of omentum can be swung to cover the pelvic floor or the uterus can be retroverted to accomplish the same purpose. Some centers have investigated the use of prostheses or artificial mesh, but these are still being investigated. These approaches are most important when treating patients after an abdominoperineal resection; after an LAR, the remaining rectum and colon prevent some small bowel from being immobilized deep in the pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the cornerstone of therapy for rectal cancer, but surgery alone provides a high likelihood of cure only for patients with stage I disease. In contrast to colon cancer, in which the failure pattern is predominantly distant metastases, the site of first failure in patients undergoing surgery for rectal cancer is equally distributed locally (ie, pelvis) and in distant sites (eg, liver, lung). This provides the rationale for combined modality adjuvant therapy utilizing a combination of radiation therapy (RT) and chemotherapy. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with resected stage I disease have an excellent prognosis with surgery alone and they do not need adjuvant therapy. For patients with resected stage II or III rectal cancer (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ), data from the early randomized GITSG and NCCTG trials demonstrate a significant local control and survival benefit for postoperative combined modality therapy over surgery alone. Although both of these trials utilized inferior chemotherapy by modern standards, they established the benefit of adjuvant therapy, and no subsequent randomized trial exploring refinements in adjuvant therapy has included a control (surgery alone) arm. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Refinements in chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neoadjuvant rather than adjuvant chemoradiotherapy is a preferable approach for patients with transmural or node-positive tumors, particularly if they are low-lying within the rectum. Advantages of this approach include better local control, increased likelihood of sphincter saving surgery, and a lower risk of chronic anastomotic stricture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H12#H12\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Versus adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represents our approach to adjuvant therapy in patients with resected rectal cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend postoperative combined modality therapy over surgery alone for patients with resected stage II and III (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ) rectal cancer, even if a total mesorectal excision (TME) was performed (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Can adjuvant therapy be omitted in any patient with stage II or III rectal cancer?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the concurrent use of a fluoropyrimidine as a radiation sensitizer during postoperative RT rather than RT alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). There are no trials directly comparing RT with and without a radiation sensitizer in this setting. This recommendation is based upon the lack of a survival benefit with adjuvant RT alone in randomized trials, and the results of the GITSG and NCCTG trials which show a survival benefit with combined use of concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (FU)-based chemoradiotherapy plus chemotherapy (using regimens that are considered inferior by modern standards) over surgery alone. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adjuvant RT alone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Early trials'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For concurrent chemoradiotherapy, the use of infusional FU is generally preferred over bolus IV FU because of its more favorable side effect profile. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Infusional versus bolus 5-FU'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although definitive data showing equivalent survival in patients with rectal cancer are not yet available, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is an acceptable substitute for infusional 5-FU during chemoradiotherapy in patients for whom port placement is not an option. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Orally active fluoropyrimidines'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For the chemotherapy portion of adjuvant therapy, several regimens are acceptable, extrapolating from experience in adjuvant treatment of colon cancer. Options include weekly",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (the Roswell Park regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/45\">",
"       45",
"      </a>",
"      ]), the de Gramont regimen of short-term infusional FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/46\">",
"       46",
"      </a>",
"      ], or FOLFOX (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"       table 3",
"      </a>",
"      ), as used in the Mosaic trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/51/4922/abstract/47\">",
"       47",
"      </a>",
"      ]. Although FOLFOX is a reasonable choice in this setting, clinicians should be aware that there is no evidence that FOLFOX is better than non-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -containing chemotherapy in the adjuvant setting of rectal cancer. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Oxaliplatin-based regimens'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Chemotherapy dosing for obese patients should be based on actual and not ideal body weight, with subsequent dose modifications based upon toxicity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Chemotherapy dosing for obese patients'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal sequence of adjuvant radiation therapy and chemotherapy has not been established conclusively. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sequencing of chemotherapy and RT'",
"      </a>",
"      above.) In a non study setting, we typically administer two months of chemotherapy followed by six weeks of concomitant fluoropyrimidine-based chemoradiotherapy and followed by two months of chemotherapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sequencing of chemotherapy and RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/1\">",
"      Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988; 61:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/2\">",
"      Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/3\">",
"      Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/4\">",
"      Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following \"curative surgery\" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974; 34:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/5\">",
"      Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/6\">",
"      Douglass HO Jr, Moertel CG, Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 315:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/7\">",
"      Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/8\">",
"      Balslev I, Pedersen M, Teglbjaerg PS, et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer 1986; 58:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/9\">",
"      Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/10\">",
"      Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/11\">",
"      Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. J Clin Oncol 1992; 10:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/12\">",
"      O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/13\">",
"      Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3:CD004078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/14\">",
"      Boice JD Jr, Greene MH, Killen JY Jr, et al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983; 309:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/15\">",
"      Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982; 8:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/16\">",
"      Miller RC, Sargent DJ, Martenson JA, et al. Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. Int J Radiat Oncol Biol Phys 2002; 54:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/17\">",
"      Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/18\">",
"      Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997; 15:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/19\">",
"      Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol 2002; 20:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/20\">",
"      Sch&uuml;ller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/21\">",
"      Kovach JS, Beart RW Jr. Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 1989; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/22\">",
"      Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/23\">",
"      Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 2003; 55:252.",
"     </a>",
"    </li>",
"    <li>",
"     Benson AB, Catalan P, Meropol NJ, et al. ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs. oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients with stage II/III rectal cancer receiving either preoperative or postoperative radiation (RT)/FU (abstract). J Clin Oncol 2006; 24:152s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/25\">",
"      Kalofonos HP, Bamias A, Koutras A, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008; 44:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/26\">",
"      Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys 2011; 81:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/27\">",
"      Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/28\">",
"      Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004; 22:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/29\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/30\">",
"      Kollmorgen CF, Meagher AP, Wolff BG, et al. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994; 220:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/31\">",
"      Miller AR, Martenson JA, Nelson H, et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys 1999; 43:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/32\">",
"      Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/33\">",
"      MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/34\">",
"      Kariv Y, Kariv R, Hammel JP, Lavery IC. Postoperative radiotherapy for stage IIIA rectal cancer: is it justified? Dis Colon Rectum 2008; 51:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/35\">",
"      Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/36\">",
"      Bokey EL, Ojerskog B, Chapuis PH, et al. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 1999; 86:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/37\">",
"      Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/38\">",
"      Akasu T, Moriya Y, Ohashi Y, et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/39\">",
"      Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/40\">",
"      Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol 2004; 22:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/41\">",
"      Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004; 22:1785.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/43\">",
"      Bleday R, Breen E, Jessup JM, et al. Prospective evaluation of local excision for small rectal cancers. Dis Colon Rectum 1997; 40:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/44\">",
"      Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/45\">",
"      Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23:8671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/46\">",
"      Andr&eacute; T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25:3732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/51/4922/abstract/47\">",
"      Andr&eacute; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2529 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4922=[""].join("\n");
var outline_f4_51_4922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUVANT RT ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMBINED CHEMOTHERAPY PLUS RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - GITSG trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - NCCTG trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - NSABP trial R-01",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23407468\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Refinements in chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Infusional versus bolus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - 5-FU plus leucovorin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Orally active fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oxaliplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Irinotecan-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sequencing of chemotherapy and RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chemotherapy dosing for obese patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment-related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Can adjuvant therapy be omitted in any patient with stage II or III rectal cancer?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Patients undergoing TME",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Favorable risk rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88194366\">",
"      T3N0&nbsp;disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88194388\">",
"      T1-2N1 disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Patients undergoing neoadjuvant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6323794\">",
"      ADJUVANT CHEMORADIOTHERAPY FOR T2-3 RECTAL CANCER AFTER LOCAL EXCISION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADJUNCTIVE THERAPY: DIET, EXERCISE, AND ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332277876\">",
"      Aspirin and other NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2949556\">",
"      POSTTREATMENT SURVEILLANCE AND SURVIVOR ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TECHNICAL ASPECTS OF POSTOPERATIVE RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2529|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/11/36020\" title=\"figure 1\">",
"      Mesorectal excision rect CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5454\" title=\"table 2\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/53/17246\" title=\"table 3\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37149\" title=\"table 4\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=related_link\">",
"      Diagnosis and management of chronic radiation enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_51_4923="Topical combination acne";
var content_f4_51_4923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Topical combination products for acne vulgaris",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benzoyl peroxide and topical antibiotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide 5% and clindamycin 1% gel (Benzaclin&reg;, Duac&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide 5% and erythromycin 3% gel (Benzamycin&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide 2.5% and clindamycin 1.2% gel (Acanya&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Topical retinoid and topical antimicrobial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 1.2% and tretinoin 0.025% gel (Ziana&reg;, Veltin&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide 2.5% and adapalene 0.1% (Epiduo&reg;)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4923=[""].join("\n");
var outline_f4_51_4923=null;
var title_f4_51_4924="Strategy smoking cessation";
var content_f4_51_4924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Smoking cessation for the primary care clinician",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Strategy 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ask: systematically identify all tobacco users at every visit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Strategy 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Advise: strongly urge all smokers to quit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        In a clear, strong, and personalized manner, urge every smoker to quit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Strategy 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Identify smokers willing to make a quit attempt.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ask every smoker if he or she is willing to make a quit attempt at this time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Strategy 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Assist: aid the patient in quitting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Help the patient with a quit plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Encourage nicotine replacement therapy or bupropion except in special circumstances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give key advice on successful quitting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Provide supplementary materials.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Strategy 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrange: schedule follow-up contact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Schedule follow-up contact, either in person or via telephone.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Fiore MC, Bailey WC, Cohen JJ, et al. Smoking Cessation. Clinical Practice Guideline Number 18. AHCPR Publication No. 96-0692. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4924=[""].join("\n");
var outline_f4_51_4924=null;
var title_f4_51_4925="VO2 plateau";
var content_f4_51_4925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    VO",
"    <sub>",
"     2",
"    </sub>",
"    plateau",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 356px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oxygen consumption plateaus at approximately 45 mL/kg per minute as the workload increases from stage 5 to stage 6. Once VO",
"    <sub>",
"     2",
"    </sub>",
"    plateau has been reached, exercise continues primarily through anaerobic metabolism.",
"    <div class=\"footnotes\">",
"     VO",
"     <sub>",
"      2",
"     </sub>",
"     : volume of oxygen consumed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4925=[""].join("\n");
var outline_f4_51_4925=null;
var title_f4_51_4926="Endarterectomy severe stenosis";
var content_f4_51_4926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Carotid endarterectomy prevents stroke in symptomatic patients with a severe stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The European Carotid Surgery Trial included 778 patients with a history of a stroke, TIA, or retinal infarct who had a severe carotid stenosis (70 to 99 percent). Left panel: The percent of patients free of disabling or fatal stroke was higher with carotid endarterectomy than medical therapy, even when considering surgical death (94 versus 89 percent, p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from European Carotid Surgery Trialist Collaborative Group. Lancet 1991; 337:1235.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4926=[""].join("\n");
var outline_f4_51_4926=null;
var title_f4_51_4927="Acute gastric volvulus";
var content_f4_51_4927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Acute gastric volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 512px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If unsuccessful, the patient will need surgery for decompression.",
"     <br/>",
"     &Delta; Typically laparoscopic. If surgery is required to decompress the stomach, the findings at surgery will determine choice of repair + gastropexy versus gastropexy alone.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Open or laparoscopic.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_51_4927=[""].join("\n");
var outline_f4_51_4927=null;
 